Document:

Purchase Agreement

 EXHIBIT 4.3 
  

INVITROGEN CORPORATION 
  
 $450,000,000 
  
 Principal Amount 
  
 1.5% Convertible Senior Notes due 2024 
  
 Purchase
Agreement 
  
 February 12, 2004 
  
 UBS SECURITIES LLC 
 BEAR, STEARNS & CO. INC. 
  

 1.5% Convertible Senior Notes due 2024 
  
 INVITROGEN CORPORATION 
  
 PURCHASE AGREEMENT 
  
 February 12, 2004 
  
 UBS
SECURITIES LLC 
 BEAR, STEARNS & CO. INC. 
 c/o UBS
Securities LLC 
 299 Park Avenue 
 New York, N.Y. 10171 
  
 Dear Sirs: 
  
 Invitrogen Corporation, a Delaware corporation (the
“Company”), proposes to issue and sell to UBS SECURITIES LLC (“UBS”) and Bear, Stearns & Co. Inc. (each an “Initial Purchaser” and, collectively, the “Initial
Purchasers”) an aggregate of $450,000,000 in principal amount of its 1.5% Convertible Senior Notes due 2024 (the “Firm Notes”), subject to the terms and conditions set forth herein. The Company also proposes to
issue and sell to the Initial Purchasers not more than an additional $67,500,000 principal amount of its 1.5% Convertible Senior Notes due 2024 (the “Additional Notes”), if requested by the Initial Purchasers as provided in
Section 2 hereof. The Firm Notes and the Additional Notes are herein collectively referred to as the “Notes”. The Notes are to be issued pursuant to the provisions of an indenture (the “Indenture”), to
be dated as of the Closing Date (as defined below), between the Company, and U.S. Bank National Association, as trustee (the “Trustee”), pursuant to which the Notes, as provided therein, will be convertible at the option of
the holders thereof into shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The Notes and the Common Stock issuable upon conversion thereof are herein collectively referred to as the
“Securities”. The Securities and the Indenture are more fully described in the Offering Memorandum (as hereinafter defined). Capitalized terms used but not defined herein shall have the meanings given to such terms in the
Indenture. 
  
 1. Offering Memorandum. The Notes
will be offered and sold to the Initial Purchasers pursuant to one or more exemptions from the registration requirements under the Securities Act of 1933, as amended (the “Act”). The Company has prepared a preliminary
offering memorandum, dated February 12, 2004 (the “Preliminary Offering Memorandum”) and a final offering memorandum, dated February 12, 2004 (the “Offering Memorandum” and together with the
Preliminary Offering Memorandum and all other documents and reports incorporated therein by 

  

 1 

 
reference, the “Offering Document”), relating to the Notes. The Company’s Annual Report on Form 10-K most recently filed with
the Commission and all subsequent reports which have been filed by the Company with the Commission or sent to stockholders pursuant to the Exchange Act prior to the date hereof are collectively referred to as the “Exchange Act
Reports.” 
  
 Upon original issuance thereof, and
until such time as the same is no longer required pursuant to the Indenture, the Notes (and all securities issued in exchange therefor, in substitution thereof or upon conversion thereof) shall bear a legend substantially as follows: 
  
 “THIS SECURITY (OR ITS PREDECESSOR) WAS ORIGINALLY ISSUED IN A
TRANSACTION EXEMPT FROM REGISTRATION UNDER THE UNITED STATES SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AND THIS SECURITY AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED
IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THIS SECURITY IS HEREBY NOTIFIED THAT THE SELLER OF THIS SECURITY MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT
PROVIDED BY RULE 144A THEREUNDER. 
  
 THE HOLDER OF THIS SECURITY
AGREES FOR THE BENEFIT OF THE COMPANY THAT (A) THIS SECURITY AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION THEREOF MAY BE OFFERED, RESOLD, PLEDGED OR OTHERWISE TRANSFERRED, ONLY (I) IN THE UNITED STATES TO A PERSON WHOM THE SELLER
REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A, (II) OUTSIDE THE UNITED STATES IN AN OFFSHORE TRANSACTION IN ACCORDANCE WITH RULE 904
UNDER THE SECURITIES ACT, (III) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF AVAILABLE) OR (IV) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT, IN EACH OF CASES (I)
THROUGH (IV) IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES, AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THIS SECURITY FROM IT OF THE RESALE RESTRICTIONS REFERRED
TO IN (A) ABOVE. 
  
 THE HOLDER OF THIS SECURITY IS ENTITLED TO
THE BENEFITS OF A REGISTRATION RIGHTS AGREEMENT (AS SUCH TERM IS DEFINED IN THE INDENTURE REFERRED TO ON THE REVERSE HEREOF) AND, BY ITS ACCEPTANCE HEREOF, AGREES TO BE BOUND BY AND TO COMPLY WITH THE PROVISIONS OF SUCH REGISTRATION RIGHTS
AGREEMENT.” 
  

 2 

 2. Agreements to Sell and Purchase. 
  
 (a) On the basis of the representations, warranties and
covenants contained in this Agreement, and subject to the terms and conditions contained herein, the Company agrees to issue and sell to the Initial Purchasers, and the Initial Purchasers agree, severally and not jointly, to purchase from the
Company, the principal amount of Firm Notes set forth opposite its name as set forth on Schedule A hereto at a purchase price equal to 98% of the principal amount thereof (the “Purchase Price”). 
  
 (b) On the basis of the representations and warranties
contained in this Agreement, and subject to its terms and conditions, (i) the Company agrees to issue and sell the Additional Notes and (ii) the Initial Purchasers shall have a right, but not the obligation, to purchase, severally and not jointly,
the Additional Notes, from the Company at the Purchase Price. The Initial Purchasers may exercise their right to purchase Additional Notes in whole or in part from time to time by giving written notice of such election to exercise this option not
later than 11 days after the Closing Date. UBS shall give any such notice on behalf of the Initial Purchasers and such notice shall specify the aggregate principal amount of Additional Notes to be purchased pursuant to such exercise and the date for
payment and delivery thereof. The purchase date specified in any such notice shall be a business day (i) no earlier than the Closing Date (as hereinafter defined) and (ii) two (2) business days after such notice has been given. If any Additional
Notes are to be purchased, each Initial Purchaser, severally and not jointly, agrees to purchase from the Company the principal amount of Additional Notes which bears the same proportion to the total principal amount of Additional Notes to be
purchased from the Company as the principal amount of Firm Notes set forth opposite the name of such Initial Purchaser in Schedule A bears to the total principal amount of Firm Notes. 
  
 3. Terms of Offering. The Initial Purchasers have advised the Company that the Initial Purchasers will make
offers (the “Exempt Resales”) of the Notes purchased hereunder on the terms set forth in the Offering Memorandum, as amended or supplemented, solely to persons whom the Initial Purchasers reasonably believe to be
“qualified institutional buyers” as defined in Rule 144A under the Act (“QIBs”) (such persons being referred to herein as the “Eligible Purchasers”). The Initial Purchasers will offer the
Notes to Eligible Purchasers initially at a price equal to 100% of the principal amount thereof (plus accrued interest, if applicable). Such price may be changed at any time without notice. 
  
 Holders (including subsequent transferees) of the Securities will have the
registration rights set forth in the registration rights agreement (the “Registration Rights Agreement”), to be dated the Closing Date, in substantially the form of Exhibit A hereto, for so long as such Securities
constitute “Transfer Restricted Securities” (as defined in the Registration Rights Agreement). Pursuant to the Registration Rights Agreement, the Company will agree to file with the Securities and Exchange Commission (the
“Commission”) under the circumstances set forth therein, a shelf registration statement pursuant to Rule 415 under the Act (the “Registration Statement”) relating to the resale by certain holders of
the Securities and to use its best efforts to cause such Registration Statement to be declared and remain effective and usable for the periods specified in the Registration Rights Agreement. This Agreement, the Indenture, the Notes, and the
Registration Rights Agreement are hereinafter sometimes referred to collectively as the “Operative Documents.” 
  

 3 

 4. Delivery and Payment. 
  
 (a) Delivery of, and payment of the Purchase Price for, the Firm Notes shall be made at the offices of Gray
Cary Ware & Freidenrich LLP, 4365 Executive Drive, Suite 1100, San Diego, California 92121-2189 or such other location as may be mutually acceptable. Such delivery and payment shall be made at 9:00 a.m. New York City time, on February 19, 2004
or at such other time on the same date or such other date as shall be agreed upon by the Initial Purchasers and the Company in writing. The time and date of such delivery and the payment for the Firm Notes are herein called the “Closing
Date”. 
  
 (b) Delivery of, and
payment for, any Additional Notes to be purchased by the Initial Purchasers shall be made at the offices of Gray Cary Ware & Freidenrich LLP, 4365 Executive Drive, Suite 1100, San Diego, California 92121-2189 at 9:00 a.m. New York City time, on
the date specified in the exercise notice given by UBS pursuant to Section 2(b) or such other time on the same or such other date as the Initial Purchasers and the Company shall agree in writing. The time and date of delivery and payment for any
Additional Notes are hereinafter referred to as an “Option Closing Date.” 
  
 (c) One or more of the Notes in definitive global form, registered in the name of Cede & Co., as nominee of the Depository Trust
Company (“DTC”), having an aggregate principal amount corresponding to the aggregate principal amount of the Notes (collectively, the “Global Note”), shall be delivered by the Company to the Initial
Purchasers (or as the Initial Purchasers direct) in each case with any transfer taxes thereon duly paid by the Company against payment by the Initial Purchasers of the Purchase Price thereof by wire transfer in same day funds to the order of the
Company. The Global Note shall be made available to the Initial Purchasers for inspection not later than 9:30 a.m., New York City time, on the business day immediately preceding the Closing Date. 
  
 5. Agreements of the Company. The Company hereby agrees with
the Initial Purchasers as follows: 
  
 (a) To
advise the Initial Purchasers promptly and, if requested by the Initial Purchasers, confirm such advice in writing, (i) of the issuance by any state securities commission of any stop order suspending the qualification or exemption from qualification
of any Notes for offering or sale in any jurisdiction designated by the Initial Purchasers pursuant to Section 5(d) hereof, or the initiation of any proceeding by any state securities commission or any other federal or state regulatory authority for
such purpose and (ii) of any proposal to amend or supplement the Offering Document and the Company will not effect such amendment or supplementation without UBS’ consent, which consent shall not be unreasonably withheld or delayed. If, at any
time prior to the completion of the resale of the Notes by the Initial Purchasers, any event occurs as a result of which the Offering Document as then amended or supplemented would include an untrue statement of a material fact or omit to state any
material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, the Company promptly will notify UBS of such event and promptly will prepare, at its own expense, an
amendment or supplement which will correct such statement or omission. Neither UBS’ consent to, nor the Initial Purchasers’ delivery to offerees or investors of, any such amendment or supplement shall constitute a waiver of any of the
conditions set forth in Section 9. 

  

 4 

 
The Company shall use its best efforts to prevent the issuance of any stop order or order suspending the qualification or exemption of any Notes under any
state securities or Blue Sky laws and, if at any time any state securities commission or other federal or state regulatory authority shall issue an order suspending the qualification or exemption of any Notes under any state securities or Blue Sky
laws, the Company shall use its best efforts to obtain the withdrawal or lifting of such order at the earliest possible time. 
  
 (b) To furnish the Initial Purchasers and those persons identified by the Initial Purchasers to the Company as many copies of the
Preliminary Offering Memorandum and the Offering Memorandum, any documents incorporated by reference therein, and any amendments or supplements thereto, as the Initial Purchasers may reasonably request at any time prior to the completion of the
resale of the Notes by the Initial Purchasers. Subject to the Initial Purchasers’ compliance with its representations and warranties and agreements set forth in Section 7 hereof, the Company consents to the use of the Preliminary Offering
Memorandum and the Offering Memorandum, any documents incorporated by reference therein, and any amendments and supplements thereto required pursuant hereto, by the Initial Purchasers in connection with Exempt Resales. 
  
 (c) If, at any time prior to the completion of the resale of
the Notes by the Initial Purchasers, any event shall occur or condition shall exist as a result of which, in the opinion of counsel to the Initial Purchasers, it becomes necessary to amend or supplement the Offering Memorandum in order to make the
statements therein, in the light of the circumstances when such Offering Memorandum is delivered to an Eligible Purchaser, not misleading, or if, in the opinion of counsel to the Initial Purchasers, it is necessary to amend or supplement the
Offering Memorandum to comply with any applicable law, forthwith to prepare an appropriate amendment or supplement to such Offering Memorandum so that the statements therein, as so amended or supplemented, will not, in the light of the circumstances
when it is so delivered, be misleading, or so that such Offering Memorandum will comply with applicable law, and to furnish to the Initial Purchasers and such other persons as the Initial Purchasers may designate such number of copies thereof as the
Initial Purchasers may reasonably request. 
  
 (d) Prior to the sale of all Notes pursuant to Exempt Resales as contemplated hereby, to cooperate with the Initial Purchasers and counsel to the Initial Purchasers in connection with the registration or qualification of the Notes for offer
and sale to the Initial Purchasers and pursuant to Exempt Resales under the securities or Blue Sky laws of such jurisdictions as the Initial Purchasers may reasonably request and to continue such registration or qualification in effect so long as
required for Exempt Resales and to file such consents to service of process or other documents as may be necessary in order to effect such registration or qualification; provided, however, that the Company shall not be required in connection
therewith to qualify as a foreign corporation in any jurisdiction in which it is not now so qualified or to take any action that would subject it to general consent to service of process or taxation other than as to matters and transactions relating
to the Preliminary Offering Memorandum, the Offering Memorandum or Exempt Resales, in any jurisdiction in which it is not now so subject. 
  
 (e) So long as the Notes are outstanding, (i) to mail or make generally available as soon as practicable after the end of each fiscal year
to the record holders of the Notes a financial report of the Company and its subsidiaries on a consolidated basis (and a similar financial 

  

 5 

 
report of all unconsolidated subsidiaries, if any), all such financial reports to include a consolidated balance sheet, a consolidated statement of
operations, a consolidated statement of cash flows and a consolidated statement of shareholders’ equity as of the end of and for such fiscal year, together with comparable information as of the end of and for the preceding year, certified by
the Company’s independent public accountants and (ii) to mail or make generally available as soon as practicable after the end of each quarterly period (except for the last quarterly period of each fiscal year) to such holders, a consolidated
balance sheet, a consolidated statement of operations and a consolidated statement of cash flows (and similar financial reports of all unconsolidated subsidiaries, if any) as of the end of and for such period, and for the period from the beginning
of such year to the close of such quarterly period, together with comparable information for the corresponding periods of the preceding year. 
  
 (f) So long as the Notes are outstanding, to furnish to the Initial Purchasers as soon as available, copies of all reports or other
communications furnished by the Company to its security holders or furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed and such other publicly available information
concerning the Company and/or its subsidiaries as the Initial Purchasers may reasonably request. 
  
 (g) So long as any of the Notes remain outstanding and during any period in which the Company is not subject to Section 13 or 15(d) of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), to make available to any holder of Securities in connection with any sale thereof and any prospective purchaser of such Securities from such holder, the
information (“Rule 144A Information”) required by Rule 144A(d)(4) under the Act. 
  
 (h) Whether or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be
paid all reasonable expenses incident to the performance of the obligations of the Company under this Agreement, including: (i) the reasonable fees, disbursements and expenses of counsel to the Company and accountants of the Company in connection
with the sale and delivery of the Notes to the Initial Purchasers and pursuant to Exempt Resales, and all other fees and expenses in connection with the preparation, printing, filing and distribution of the Preliminary Offering Memorandum, the
Offering Memorandum and all amendments and supplements to any of the foregoing (including financial statements), including the mailing and delivering of copies thereof to the Initial Purchasers and persons designated by them in the quantities
specified herein, (ii) all costs and expenses related to the transfer and delivery of the Notes to the Initial Purchasers and pursuant to Exempt Resales, including any transfer or other taxes payable thereon, (iii) all costs of printing or producing
this Agreement, the other Operative Documents and any other agreements or documents in connection with the offering, purchase, sale or delivery of the Securities (other than the fees, disbursements and expenses of counsel to the Initial Purchasers,
except as provided in clause (iv) below), (iv) all expenses in connection with the registration or qualification of the Securities for offer and sale under the securities or Blue Sky laws of the several states and all costs of printing or producing
any preliminary and supplemental Blue Sky memoranda in connection therewith (including the filing fees and reasonable fees and disbursements of counsel for the Initial Purchasers in connection with such registration or qualification and memoranda
relating thereto), (v) the cost of printing certificates representing the Securities, (vi) all expenses and listing fees in connection with the application for quotation of the Notes in the National Association of Securities Dealers, Inc. 

  

 6 

 
(“NASD”) Automated Quotation System - PORTAL (“PORTAL”), (vii) the fees and expenses of the Trustee and the
Trustee’s counsel in connection with the Indenture and the Notes, (viii) the costs and charges of any transfer agent, registrar and/or depositary (including DTC), (ix) any fees charged by rating agencies for the rating of the Notes, (x) all
costs and expenses of the Registration Statement, as set forth in the Registration Rights Agreement, (xi) all expenses and listing fees in connection with the application for listing the Common Stock on the Nasdaq Stock Market’s National Market
(the “Nasdaq National Market”) and (xii) and all other costs and expenses incident to the performance of the obligations of the Company hereunder for which provision is not otherwise made in this Section. 
  
 (i) To use its best efforts to effect the inclusion of the
Notes in PORTAL and to maintain the listing of the Notes on PORTAL for so long as the Notes are outstanding. 
  
 (j) To obtain the approval of DTC for “book-entry” transfer of the Notes, and to comply with all of its agreements set forth in
the representation letters of the Company to DTC relating to the approval of the Notes by DTC for “book-entry” transfer. 
  
 (k) To cause the Common Stock issuable upon conversion of the Notes to be duly included for quotation on the Nasdaq National Market prior
to the Closing Date subject to notice of official issuance. The Company will ensure that such Common Stock remain included for quotation on the Nasdaq National Market or any other national securities exchange following the Closing Date for so long
as any shares of Common Stock remain registered under the Exchange Act. 
  
 (l) The Company shall not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, any shares of Common Stock or securities convertible into or exchangeable or exercisable for any shares of Common Stock, including options, warrants or other rights to purchase shares of Common Stock
or publicly disclose the intention to make any such offer, sale, pledge, disposition or filing, or (ii) enter into any swap or other arrangement that transfers, in whole or in part, any of the economic consequences associated with the ownership of
any Common Stock (regardless of whether any of the transactions described in clause (i) or (ii) is to be settled by the delivery of Common Stock, or such other securities, in cash or otherwise), except to the Initial Purchasers pursuant to this
Agreement, for a period of 90 days after the Closing Date without the prior written consent of UBS. Notwithstanding the foregoing, during such period (i) the Company may grant stock and stock options pursuant to the Company’s existing stock
option plans or other employee benefit plans and may issue shares of Common Stock upon the exercise of such options and make additional inducement grants of restricted stock to new employees, (ii) the Company may issue shares of Common Stock upon
the exercise of an option or warrant or the conversion of a security outstanding on the date hereof (including the Notes), and (iii) the Company may issue shares of Common Stock in connection with acquisitions of companies and businesses. Other than
pursuant to the Registration Rights Agreement, the Company also agrees not to file any registration statement with the Commission with respect to any shares of Common Stock, or any registration statement relating to any U. S. dollar-denominated debt
securities issued or guaranteed by the Company and having a maturity of more than one year from the date of issue, or any securities convertible into or exercisable or exchangeable for Common Stock for a period of 90 days after the 

  

 7 

 
Closing Date without the prior written consent of UBS. The Company shall, prior to or concurrently with the execution of this Agreement, deliver an agreement
in the form of Schedule C hereto executed by each of the directors and officers of the Company listed on Schedule D hereto. The Company agrees that with respect to the transfer of shares of Common Stock pursuant to the agreements in the form of
Schedule C by each of the persons listed on Schedule D, the Company shall not consent to the transfer of more than an aggregate of 500,000 shares of Common Stock with respect to all of the persons listed on Schedule D on or prior to 90 days after
the date of the Offering Memorandum. 
  
 (m) Not
to sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in the Act) that would be integrated with the sale of the Notes to the Initial Purchasers or pursuant to Exempt Resales in a manner that
would require the registration of any such sale of the Notes under the Act. 
  
 (n) Not to voluntarily claim, and to actively resist any attempts to claim, the benefit of any usury laws against the holders of any Notes. 
  
 (o) To comply with all of its agreements set forth in the Registration Rights Agreement. 
  
 (p) To use its best efforts to do and perform all things
required or necessary to be done and performed under this Agreement by it prior to the Closing Date and to satisfy all conditions precedent to the delivery of the Notes. 
  
 (q) Until the earlier of (i) the second anniversary of the last Option Closing Date and (ii) the first date
of effectiveness of the registration statement to be filed pursuant to the Registration Rights Agreement, the Company will not, and will not permit any of its “controlled” “affiliates” (as defined in Rule 405 under the Securities
Act) to, resell any of the Notes or the Common Stock underlying the Notes that constitute “restricted securities” under Rule 144 that have been reacquired by any of them. 
  
 6. Representations, Warranties and Agreements of the Company. As of the date hereof, the Company represents
and warrants to, and agrees with, the Initial Purchasers that: 
  
 (a) The Offering Document does not, and any supplement or amendment to it will not, contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make
the statements therein, in the light of the circumstances under which they were made, not misleading, except that the representations and warranties contained in this paragraph (a) shall not apply to statements in or omissions from the Offering
Document (or any supplement or amendment thereto) based upon information relating to the Initial Purchasers furnished to the Company in writing by the Initial Purchasers expressly for use therein as set forth in Section 8(b) hereof. The Initial
Purchasers shall not be deemed to have provided any other information (and therefore are not responsible for any statements or omissions related to such other information). No stop order preventing the use of the Preliminary Offering Memorandum or
the Offering Memorandum, or any amendment or supplement thereto, or any order asserting that any of the transactions contemplated by this Agreement are subject to the registration requirements of the Act, has been issued. 
  

 8 

 (b) Each of the Company and its subsidiaries has been duly incorporated, is validly
existing as a corporation in good standing under the laws of its jurisdiction of incorporation and has the corporate power and authority to carry on its business as described in the Offering Document and to own, lease and operate its properties, and
each is duly qualified and is in good standing as a foreign corporation authorized to do business in each jurisdiction in which the nature of its business or its ownership or leasing of property requires such qualification, except where the failure
to be so qualified would not have a material adverse effect on the business, prospects, financial condition or results of operations of the Company and its subsidiaries, taken as a whole (a “Material Adverse Effect”).

  
 (c) All outstanding shares of capital stock
of the Company have been duly authorized and validly issued and are fully paid, non-assessable and not subject to any preemptive or similar rights. 
  
 (d) The entities listed on Schedule B hereto are the only subsidiaries, direct or indirect, of the Company. All of the outstanding shares
of capital stock of each of the Company’s subsidiaries have been duly authorized and validly issued and are fully paid and non-assessable, and are owned by the Company, directly or indirectly through one or more subsidiaries (except to the
extent that the Company’s direct or indirect ownership is less than 100% as set forth on Schedule B hereto), free and clear of any security interest, claim, lien, encumbrance or adverse interest of any nature (each, a
“Lien”). 
  
 (e) This
Agreement has been duly authorized, executed and delivered by the Company. 
  
 (f) The Indenture has been duly authorized by the Company and, on the Closing Date, will have been validly executed and delivered by the Company. When the Indenture has been duly executed and delivered by the Company,
the Indenture will be a valid and binding agreement of the Company, enforceable against the Company in accordance with its terms except as (i) the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting
creditors’ rights generally and (ii) rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability. On the Closing Date, the Indenture will conform in all material respects to
the requirements of the Trust Indenture Act of 1939, as amended (the “TIA” or “Trust Indenture Act”), and the rules and regulations of the Commission applicable to an indenture which is qualified
thereunder. 
  
 (g) The Notes have been duly
authorized and, on the Closing Date, will have been validly executed and delivered by the Company. When the Notes have been issued, executed and authenticated in accordance with the provisions of the Indenture and delivered to and paid for by the
Initial Purchasers in accordance with the terms of this Agreement, the Notes will be entitled to the benefits of the Indenture and will be valid and binding obligations of the Company, enforceable in accordance with their terms except as (i) the
enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally and (ii) rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general
applicability. On the Closing Date, the Notes will conform as to legal matters to the description thereof contained in the Offering Memorandum. 
  

 9 

 (h) The Notes are convertible into Common Stock in accordance with the terms of the
Indenture; the shares of Common Stock initially issuable upon conversion of the Notes have been duly authorized and reserved for issuance upon such conversion and, when issued upon such conversion, will be validly issued, fully paid and
nonassessable, will conform to the description thereof contained in the Offering Memorandum and will be duly authorized for listing on the Nasdaq National Market, subject to notice of official issuance; the Company has the authorized and outstanding
capital stock as set forth in the Offering Memorandum; and the stockholders of the Company or other holders of the Company’s securities have no pre-emptive or similar rights with respect to the Notes or the Common Stock issuable upon the Notes.

  
 (i) The Registration Rights Agreement has
been duly authorized by the Company and, on the Closing Date, will have been duly executed and delivered by the Company. When the Registration Rights Agreement has been duly executed and delivered, the Registration Rights agreement will be a valid
and binding agreement of the Company, enforceable against the Company in accordance with its terms except as (i) the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally and (ii)
rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability. On the Closing Date, the Registration Rights Agreement will conform as to legal matters to the description thereof in
the Offering Memorandum. 
  
 (j) The authorized
capital stock of the Company conforms as to legal matters to the description thereof contained in the Offering Memorandum. 
  
 (k) Neither the Company nor any of its subsidiaries is in violation of its respective charter or by-laws or in default in the performance
of any obligation, agreement, covenant or condition contained in any indenture, loan agreement, mortgage, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries or their respective property is bound and that is material to the Company and its subsidiaries, taken as a whole, except for such violations or defaults which, singly or in the aggregate, would not have a Material Adverse Effect.

  
 (l) The execution, delivery and performance
of the Operative Documents by the Company, compliance by the Company with all provisions hereof and thereof and the consummation of the transactions contemplated hereby and thereby will not (i) require any consent, approval, authorization or other
order of, or qualification with, any court or governmental body or agency (except such as may be required under the securities or Blue Sky laws of the various states), (ii) conflict with or constitute a breach of any of the terms or provisions of,
or a default under, the charter or by-laws of the Company or any of its subsidiaries or any indenture, loan agreement, mortgage, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the
Company or any of its subsidiaries or their respective property is bound and that is material to the Company and its subsidiaries, taken as a whole, (iii) violate or conflict with any applicable law or any rule, regulation, judgment, order or decree
of any court or any governmental body or agency having jurisdiction over the Company, any of its subsidiaries or their respective property, (iv) result in the imposition or creation of (or the obligation to create or impose) a Lien under, any
agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries or their respective property is bound, or (v) result in the termination, suspension or revocation of any 

  

 10 

 
Material Authorization (as defined below) of the Company or any of its subsidiaries or result in any other impairment of the rights of the holder of any such
Material Authorization, except for such conflicts, breaches, violations, terminations, suspensions, revocations, Liens or defaults which, singly or in the aggregate, would not have a Material Adverse Effect. 
  
 (m) Except as disclosed in the Company’s Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30, 2003, there are no legal or governmental proceedings pending or, to the Company’s knowledge, threatened to which the Company or any of its subsidiaries is or could be (in the case
of threatened proceedings) a party or to which any of their respective property is or could be (in the case of threatened proceeding) subject, except for such proceedings which, if decided adversely to the Company, would not result, singly or in the
aggregate, in a Material Adverse Effect. 
  
 (n)
The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them which is material to the business of the Company and its subsidiaries, in each
case free and clear of all liens, encumbrances and defects except such as are described in the Offering Memorandum or such as do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such
property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do
not interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries, in each case except as described in the Offering Memorandum. 
  
 (o) The Company and its subsidiaries own or possess, or can acquire on reasonable terms, all patents, patent
rights, licenses, inventions, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade names (“Intellectual
Property”) currently employed by them in connection with the business now operated by them, except where the failure to own or possess or otherwise be able to acquire such Intellectual Property would not, singly or in the aggregate,
have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has received any notice of infringement of or conflict with asserted rights of others with respect to any of such Intellectual Property which, singly or in the
aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect. 
  
 (p) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
and in such amounts as are prudent and customary in the businesses in which they are engaged; and neither the Company nor any of its subsidiaries (i) has received notice from any insurer or agent of such insurer that substantial capital improvements
or other material expenditures will have to be made in order to continue such insurance or (ii) has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage from similar insurers at a cost that would not have a Material Adverse Effect. 
  
 (q) Except as disclosed in the Offering Document or the Company’s definitive Proxy Statement filed with the Commission on March 17,
2003 or on Schedule E attached hereto (except that Item 1 to Schedule E shall not be included for purposes of this 

  

 11 

 
representation), no relationship, direct or indirect, exists between or among the Company or any of its subsidiaries on the one hand, and the directors,
officers, stockholders, customers or suppliers of the Company or any of its subsidiaries on the other hand, which would be required by the Act to be described in the Offering Memorandum if the Offering Memorandum were a prospectus included in a
registration statement on Form S-1 file with the Commission. 
  
 (r) The Company and each of its subsidiaries maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s
general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is
permitted only in accordance with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any
differences. Since September 30, 2003, neither the Company nor any of its subsidiaries has made any change in its internal controls that would be reportable in any filing under the Exchange Act pursuant to Item 307 of Regulation S-K. 
  
 (s) All material tax returns required to be filed by the
Company and each of its subsidiaries in any jurisdiction have been filed, other than those filings being contested in good faith, and all material taxes, including withholding taxes, penalties and interest, assessments, fees and other charges due
pursuant to such returns or pursuant to any assessment received by the Company or any of its subsidiaries have been paid, other than those being contested in good faith and for which adequate reserves have been provided. 
  
 (t) Except for Item 6 on Schedule F hereto, neither the
Company nor any of its subsidiaries has violated any foreign, federal, state or local law or regulation relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants
(“Environmental Laws”), any provisions of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), or any provisions of the Foreign Corrupt Practices Act or the rules and regulations
promulgated thereunder, except for such violations which, singly or in the aggregate, would not have a Material Adverse Effect. 
  
 (u) Each of the Company and its subsidiaries has such permits, licenses, consents, exemptions, franchises, authorizations and other
approvals (each, a “Material Authorization”) of, and has made all filings with and notices to, all governmental or regulatory authorities and self-regulatory organizations and all courts and other tribunals, including without
limitation, under any applicable Environmental Laws, as are necessary to own, lease, license and operate its respective properties and to conduct its business, except where the failure to have any such Material Authorization or to make any such
filing or notice would not, singly or in the aggregate, have a Material Adverse Effect. Each such Material Authorization is valid and in full force and effect and each of the Company and its subsidiaries is in compliance with all the terms and
conditions thereof and with the rules and regulations of the authorities and governing bodies having jurisdiction with respect thereto; and no event has occurred (including, without limitation, the receipt of any notice from any authority or
governing body) which allows or, after notice or lapse of time or both, would allow, revocation, suspension or termination of any such Material Authorization or results or, after notice or lapse of time or both, would result in any other impairment
of the rights of the holder of any such Material Authorization held by the Company or 

  

 12 

 
its subsidiaries; and such Material Authorizations held by the Company or its subsidiaries contain no restrictions that are burdensome to the Company or any
of its subsidiaries; except where such failure to be valid and in full force and effect or to be in compliance, the occurrence of any such event or the presence of any such restriction would not, singly or in the aggregate, have a Material Adverse
Effect. 
  
 (v) There are no costs or liabilities
associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any Material Authorization, any related constraints on
operating activities and any potential liabilities to third parties) which would, singly or in the aggregate, have a Material Adverse Effect. 
  
 (w) The accountants, Ernst & Young LLP, that have certified certain of the financial statements and supporting schedules included in
the Offering Document are independent public accountants with respect to the Company, as required by the Act and the Exchange Act. The historical financial statements, together with related schedules and notes, set forth in the Offering Document
comply as to form in all material respects with the requirements applicable to registration statements on Form S-1 under the Act. 
  
 (x) The historical financial statements, together with related schedules and notes forming part of or incorporated by reference into the
Offering Document (and any amendment or supplement thereto), present fairly the consolidated financial position, results of operations and changes in financial position of the Company and its subsidiaries on the basis stated or incorporated by
reference in the Offering Document at the respective dates or for the respective periods to which they apply; such statements and related schedules and notes have been prepared in accordance with generally accepted accounting principles consistently
applied throughout the periods involved, except as disclosed therein; and the other financial and statistical information and data set forth or incorporated by reference in the Offering Document (and any amendment or supplement thereto) are, in all
material respects, accurately presented and prepared on a basis consistent with such financial statements and the books and records of the Company. 
  
 (y) The pro forma financial information included in the Offering Document has been prepared on a basis consistent with the
historical financial statements of the Company and its subsidiaries and give effect to assumptions used in the preparation thereof on a reasonable basis and in good faith and present fairly the historical and proposed transactions contemplated by
the Preliminary Offering Memorandum and the Offering Memorandum. 
  
 (z) The Company is not and, after giving effect to the offering and sale of the Notes and the application of the net proceeds thereof as described in the Offering Memorandum, will not be, an “investment
company,” as such term is defined in the Investment Company Act of 1940, as amended. 
  
 (aa) Except as set forth in the Offering Document or on Schedule G hereto, there are no contracts, agreements or understandings between
the Company and any person granting such person the right to require the Company to file a registration statement under the Act with respect to any securities of the Company or to require the Company to include such securities with the Notes
registered pursuant to any Registration Statement. 
  

 13 

 (bb) Neither the Company nor any of its subsidiaries nor any agent thereof acting on the
behalf of them has taken, and none of them will take, any action that might cause this Agreement or the issuance or sale of the Notes to violate Regulation G (12 C.F.R. Part 207), Regulation T (12 C.F.R. Part 220), Regulation U (12 C.F.R. Part 221)
or Regulation X (12 C.F.R. Part 224) of the Board of Governors of the Federal Reserve System. 
  
 (cc) No “nationally recognized statistical rating organization” as such term is defined for purposes of Rule 436(g)(2) under the
Act (i) has imposed (or has informed the Company that it is considering imposing) any condition (financial or otherwise) on the Company’s retaining any rating assigned to the Company, any securities of the Company or (ii) has indicated to the
Company that it is considering (a) the downgrading, suspension, or withdrawal of, or any review for a possible change that does not indicate the direction of the possible change in, any rating so assigned or (b) any change in the outlook for any
rating of the Company, or any securities of the Company. 
  
 (dd) Since the respective dates as of which information is given in the Offering Memorandum other than as set forth in the Offering Memorandum (exclusive of any amendments or supplements thereto subsequent to the date
of this Agreement), (i) there has not occurred any material adverse change or, to the knowledge of the Company, any development involving a prospective material adverse change in the condition, financial or otherwise, or the earnings, business,
management or operations of the Company and its subsidiaries, taken as a whole, (ii) there has not been any material adverse change or, to the knowledge of the Company, any development involving a prospective material adverse change in the capital
stock or in the long-term debt of the Company or any of its subsidiaries and (iii) neither the Company nor any of its subsidiaries has incurred any material liability or obligation, direct or contingent. 
  
 (ee) Each of the Preliminary Offering Memorandum and the
Offering Memorandum, as of its date, contains all the information specified in, and meeting the requirements of, Rule 144A(d)(4) under the Act. 
  
 (ff) When the Notes are issued and delivered pursuant to this Agreement, the Notes will not be of the same class (within the meaning of
Rule 144A under the Act) as any security of the Company that is listed on a national securities exchange registered under Section 6 of the Exchange Act or that is quoted in a United States automated inter-dealer quotation system. 
  
 (gg) No form of general solicitation or general advertising
(as defined in Regulation D under the Act) was used by the Company, or any of its representatives (other than the Initial Purchasers, as to whom the Company makes no representation) in connection with the offer and sale of the Notes contemplated
hereby, including, but not limited to, articles, notices or other communications published in any newspaper, magazine, or similar medium or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by any
general solicitation or general advertising. No securities of the same class as the Securities have been issued and sold by the Company within the six-month period immediately prior to the date hereof. 
  
 (hh) Prior to the effectiveness of any Registration
Statement, the Indenture is not required to be qualified under the TIA. 
  

 14 

 (ii) No registration under the Act of the Securities is required for the sale of the
Securities to the Initial Purchasers as contemplated hereby or for the Exempt Resales assuming the accuracy of the Initial Purchasers’ representations and warranties and agreements set forth in Section 7 hereof. 
  
 (jj) The Company, together with its subsidiaries Invitrogen
Limited, Molecular Probes, Inc., Invitrogen Finance Corporation, Dexter Holdings and Invitrogen GmbH (the foregoing subsidiaries being collectively referred to as the “Material Subsidiaries”), on a consolidated basis, represent (i)
in excess of 80% of the revenues of the Company and all of its subsidiaries on a consolidated basis (the “Consolidated Revenues”) as set forth on the Company’s Consolidated Statement of Operations for the period ended December
31, 2003 contained in the press release (the “Press Release”) attached as an exhibit to the Current Report on Form 8-K furnished by the Company to the Commission on February 12, 2004, and (ii) in excess of 90% of the total assets of
the Company and its subsidiaries on a consolidated basis (the “Consolidated Assets”) as set forth on the Company’s Consolidated Balance Sheet as of December 31, 2003 contained in the Press Release. 
  
 (kk) Each certificate signed by any officer of the Company
and delivered to the Initial Purchasers or counsel for the Initial Purchasers pursuant to the terms hereof shall be deemed to be a representation and warranty by the Company to the Initial Purchasers as to the matters covered thereby. 
  
 (ll) The Company and each of its officers and directors have
complied in all material respects with (A) the applicable provisions of the Sarbanes-Oxley Act of 2002 and the related rules and regulations promulgated by the Commission under such act or the Exchange Act as are currently in effect except for the
timing requirements for filing reports required to be filed under Section 16(a) of the Exchange Act and (B) the applicable listing and corporate governance rules and regulations of the Nasdaq National Market. The Company (a) has established and
maintains disclosure controls and procedures (as such terms are defined in Rule 13a-14 and 15d-14 under the Exchange Act) and (b) since July 30, 2002, neither the Company nor any of its affiliates has made or modified any loans to any executive
officer or director of the Company. 
  
 The
Company acknowledges that the Initial Purchasers and, for purposes of the opinions to be delivered to the Initial Purchasers pursuant to Section 9 hereof, counsel to the Company and counsel to the Initial Purchasers will rely upon the accuracy and
truth of the foregoing representations and hereby consents to such reliance. 
  
 7. Initial Purchasers’ Representations and Warranties. Each Initial Purchaser, severally and not jointly, represents and warrants to, and agrees with, the Company: 
  
 (a) Such Initial Purchaser is either a QIB or an IAI, in either case, with such knowledge and experience in financial and business matters
as is necessary in order to evaluate the merits and risks of an investment in the Notes. 
  
 (b) Such Initial Purchaser (A) is not acquiring the Securities with a view to any distribution thereof or with any present intention of
offering or selling any of the Securities in a 

  

 15 

 
transaction that would violate the Act or the securities laws of any state of the United States or any other applicable jurisdiction and (B) will be
reoffering and reselling the Securities only to QIBs in reliance on the exemption from the registration requirements of the Act provided by Rule 144A. 
  
 (c) Such Initial Purchaser agrees that no form of general solicitation or general advertising (within the meaning of Regulation D under
the Act) has been or will be used by such Initial Purchaser or any of its representatives in connection with the offer and sale of the Securities pursuant hereto, including, but not limited to, articles, notices or other communications published in
any newspaper, magazine or similar medium or broadcast over television or radio, or any seminar or meeting whose attendees have been invited by any general solicitation or general advertising. 
  
 (d) Such Initial Purchaser agrees that, in connection with
Exempt Resales, such Initial Purchaser will solicit offers to buy the Securities only from, and will offer to sell the Securities only to, Eligible Purchasers. Each Initial Purchaser further agrees that it will offer to sell the Securities only to,
and will solicit offers to buy the Securities only from (A) Eligible Purchasers that such Initial Purchaser reasonably believes are QIBs that agree that (x) the Securities purchased by them may be resold, pledged or otherwise transferred within the
time period referred to under Rule 144(k) (taking into account the provisions of Rule 144(d) under the Act, if applicable) under the Act, as in effect on the date of the transfer of such Securities, only (I) to the Company or any of its
subsidiaries, (II) to a person whom the seller reasonably believes is a QIB purchasing for its own account or for the account of a QIB in a transaction meeting the requirements of Rule 144A under the Act, (III) in an offshore transaction (as defined
in Rule 902 under the Act) meeting the requirements of Rule 904 of the Act, (IV) in a transaction meeting the requirements of Rule 144 under the Act, (V) to an Accredited Institution that, prior to such transfer, furnishes the Trustee a signed
letter containing certain representations and agreements relating to the registration of transfer of such Securities and, if requested by the Company, an opinion of counsel acceptable to the Company that such transfer is in compliance with the Act,
(VI) in accordance with another exemption from the registration requirements of the Act (and based upon an opinion of counsel acceptable to the Company) or (VII) pursuant to an effective registration statement and, in each case, in accordance with
the applicable securities laws of any state of the United States or any other applicable jurisdiction and (y) they will deliver to each person to whom such Securities or an interest therein is transferred a notice substantially to the effect of the
foregoing. 
  
 (e) Such Initial Purchaser agrees
that it will not offer, sell or deliver any of the Securities in any jurisdiction outside the United States except under circumstances that will result in compliance with the applicable laws thereof, and that it will take at its own expense whatever
action is required to permit its purchase and resale of the Securities in such jurisdictions. Such Initial Purchaser understands that no action has been taken to permit a public offering in any jurisdiction outside the United States where action
would be required for such purpose. 
  
 Each
Initial Purchaser acknowledges that the Company, for purposes of the opinions to be delivered to each Initial Purchaser pursuant to Section 9 hereof, counsel to the Company and counsel to the Initial Purchasers will rely upon the accuracy and truth
of the foregoing representations and each Initial Purchaser hereby consents to such reliance. 
  

 16 

 8. Indemnification and Contribution 
  
 (a) The Company agrees to indemnify, defend and hold
harmless each Initial Purchaser, its partners, directors and officers, and any person who controls any Initial Purchaser within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors and assigns of all of the
foregoing persons, from and against any loss, damage, expense, liability or claim (including the reasonable cost of investigation) which, jointly or severally, any such Initial Purchaser or any such person may incur under the Act, the Exchange Act,
the common law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of or is based upon (i) any untrue statement or alleged untrue statement of a material fact contained in the Offering Document or any amendment or
supplement thereto or arises out of or is based upon any omission or alleged omission to state a material fact required to be stated therein or necessary to make the statements made therein not misleading, except insofar as any such loss, damage,
expense, liability or claim arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in and in conformity with information concerning such Initial Purchaser furnished in writing by or on behalf of
such Initial Purchaser through UBS to the Company expressly for use in such Offering Document or arises out of or is based upon any omission or alleged omission to state a material fact in connection with such information required to be stated in
such Offering Document or necessary to make such information not misleading or (ii) any untrue statement or alleged untrue statement made by the Company in Section 6 hereof or the failure by the Company to perform when and as required any agreement
or covenant contained herein. 
  
 If any action,
suit or proceeding (each, a “Proceeding”) is brought against an Initial Purchaser or any such person in respect of which indemnity may be sought against the Company pursuant to the foregoing paragraph, such Initial Purchaser
or such person shall promptly notify the Company in writing of the institution of such Proceeding and the Company shall assume the defense of such Proceeding, including the employment of counsel reasonably satisfactory to such indemnified party and
payment of all fees and expenses; provided, however, that the omission to so notify the Company shall not relieve the Company from any liability which the Company may have to any Initial Purchaser or any such person or otherwise. Such Initial
Purchaser or such person shall have the right to employ its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Initial Purchaser or of such person unless the employment of such counsel
shall have been authorized in writing by the Company in connection with the defense of such Proceeding or the Company shall not have, within a reasonable period of time in light of the circumstances, employed counsel to have charge of the defense of
such Proceeding or such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or them which are different from, additional to or in conflict with those available to the Company (in which case the
Company shall not have the right to direct the defense of such Proceeding on behalf of the indemnified party or parties, but the Company may employ counsel and participate in the defense thereof), in any of which events such reasonable fees and
expenses shall be borne by the Company and paid as incurred (it being understood, however, that the Company shall not be liable for the expenses of more than one separate counsel (in addition to any local counsel) in any one Proceeding or series of
related Proceedings in the same jurisdiction representing the indemnified parties who are parties to such Proceeding). The Company shall not be liable for any settlement of any Proceeding effected without its written consent but if settled with the
written consent of the Company, the Company 

  

 17 

 
agrees to indemnify and hold harmless any Initial Purchaser and any such person from and against any loss or liability by reason of such settlement.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second sentence of this paragraph, then
the indemnifying party agrees that it shall be liable for any settlement of any Proceeding effected without its written consent if (i) such settlement is entered into more than 60 business days after receipt by such indemnifying party of the
afore-said request, (ii) such indemnifying party shall not have fully reimbursed the indemnified party in accordance with such request prior to the date of such settlement and (iii) such indemnified party shall have given the indemnifying party at
least 30 days’ prior notice of its intention to settle. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened Proceeding in respect of which any indemnified
party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter
of such Proceeding and does not include an admission of fault, culpability or a failure to act, by or on behalf of such indemnified party. 
  
 (b) Each Initial Purchaser severally agrees to indemnify, defend and hold harmless the Company, its directors and officers, and any person
who controls the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and the successors and assigns of all of the foregoing persons, from and against any loss, damage, expense, liability or claim (including the
reasonable cost of investigation) which, jointly or severally, the Company or any such person may incur under the Act, the Exchange Act, the common law or otherwise, insofar as such loss, damage, expense, liability or claim arises out of or is based
upon any untrue statement or alleged untrue statement of a material fact contained in and in conformity with information furnished in writing by or on behalf of such Initial Purchaser through UBS to the Company expressly for use in the Offering
Document or any amendment or supplement thereto, or arises out of or is based upon any omission or alleged omission to state a material fact in connection with such information required to be stated in such Offering Document or necessary to make
such information not misleading, it being understood and agreed that the only such information furnished by any Initial Purchaser consists of the following information in the Offering Document furnished on behalf of each Initial Purchaser: under the
caption “Plan of Distribution” paragraphs three, eleven and thirteen; provided, however, that the Initial Purchasers shall not be liable for any losses, claims, damages or liabilities arising out of or based upon the Company’s failure
to perform its obligations under Section 5(a) of this Agreement. 
  
 If any Proceeding is brought against the Company or any such person in respect of which indemnity may be sought against any Initial Purchaser pursuant to the foregoing paragraph, the Company or such person shall
promptly notify such Initial Purchaser in writing of the institution of such Proceeding and such Initial Purchaser shall assume the defense of such Proceeding, including the employment of counsel reasonably satisfactory to such indemnified party and
payment of all fees and expenses; provided, however, that the omission to so notify such Initial Purchaser shall not relieve such Initial Purchaser from any liability which such Initial Purchaser may have to the Company or any such person or
otherwise. The Company or such person shall have the right to employ its own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of the Company or such person unless the employment of such counsel shall have
been authorized in writing by such Initial Purchaser in connection with the 

  

 18 

 
defense of such Proceeding or such Initial Purchaser shall not have, within a reasonable period of time in light of the circumstances, employed counsel to
defend such Proceeding or such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or them which are different from or additional to or in conflict with those available to such Initial Purchaser
(in which case such Initial Purchaser shall not have the right to direct the defense of such Proceeding on behalf of the indemnified party or parties, but such Initial Purchaser may employ counsel and participate in the defense thereof but the fees
and expenses of such counsel shall be at the expense of such Initial Purchaser), in any of which events such fees and expenses shall be borne by such Initial Purchaser and paid as incurred (it being understood, however, that such Initial Purchaser
shall not be liable for the expenses of more than one separate counsel (in addition to any local counsel) in any one Proceeding or series of related Proceedings in the same jurisdiction representing the indemnified parties who are parties to such
Proceeding). No Initial Purchaser shall be liable for any settlement of any such Proceeding effected without the written consent of such Initial Purchaser but if settled with the written consent of such Initial Purchaser, such Initial Purchaser
agrees to indemnify and hold harmless the Company and any such person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second sentence of this paragraph, then the indemnifying party agrees that it shall be liable for any settlement of any Proceeding effected
without its written consent if (i) such settlement is entered into more than 60 business days after receipt by such indemnifying party of the aforesaid request, (ii) such indemnifying party shall not have reimbursed the indemnified party in
accordance with such request prior to the date of such settlement and (iii) such indemnified party shall have given the indemnifying party at least 30 days’ prior notice of its intention to settle. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement of any pending or threatened Proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party,
unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such Proceeding or does not include an admission of fault, culpability or a failure to act, by or on
behalf of such indemnified party. 
  
 (c) If the
indemnification provided for in this Section 8 is unavailable to an indemnified party under subsections (a) and (b) of this Section 8 or insufficient to hold an indemnified party harmless in respect of any losses, damages, expenses, liabilities or
claims referred to therein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, damages, expenses, liabilities or claims (i) in such proportion as is
appropriate to reflect the relative benefits received by the Company on the one hand and the Initial Purchasers on the other hand from the offering of the Notes or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and of the Initial Purchasers on the other in connection with the
statements or omissions which resulted in such losses, damages, expenses, liabilities or claims, as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Initial Purchasers on the
other shall be deemed to be in the same respective proportions as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by the Company and the total underwriting discounts and
commissions received by the Initial Purchasers, bear to 

  

 19 

 
the aggregate public offering price of the Notes. The relative fault of the Company on the one hand and of the Initial Purchasers on the other shall be
determined by reference to, among other things, whether the untrue statement or alleged untrue statement of a material fact or omission or alleged omission relates to information supplied by the Company or by the Initial Purchasers and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, damages, expenses, liabilities and claims referred to
in this subsection shall be deemed to include any legal or other fees or expenses reasonably incurred by such party in connection with investigating, preparing to defend or defending any Proceeding. 
  
 (d) The Company and the Initial Purchasers agree that it
would not be just and equitable if contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in subsection (c) above. Notwithstanding the provisions of this Section 8, no Initial Purchaser shall be required to contribute any amount in excess of the amount by which the total price at which
the Notes underwritten by such Initial Purchaser and distributed to the public were offered to the public exceeds the amount of any damage which such Initial Purchaser has otherwise been required to pay by reason of such untrue statement or alleged
untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Initial Purchasers’ obligations to contribute pursuant to this Section 8 are several in proportion to their respective underwriting commitments and not joint. 
  
 (e) The indemnity and contribution agreements contained in this Section 8 and the covenants, warranties and
representations of the Company contained in this Agreement shall remain in full force and effect regardless of any investigation made by or on behalf of any Initial Purchaser, its partners, directors or officers or any person (including each
partner, officer or director of such person) who controls any Initial Purchaser within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, or by or on behalf of the Company, its directors or officers or any person who controls
the Company within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, and shall survive any termination of this Agreement or the issuance and delivery of the Notes. The Company and each Initial Purchaser agree promptly to notify
each other of the commencement of any Proceeding against it and, in the case of the Company, against any of the Company’s officers or directors in connection with the issuance and sale of the Notes, or in connection with the Offering Document.

  
 9. Conditions of Initial Purchaser’s
Obligations. The several obligations of the Initial Purchasers to purchase the Firm Notes under this Agreement on the Closing Date and the Additional Notes, if any, on any Option Closing Date are subject to the satisfaction of each of the
following conditions. 
  
 (a) All the
representations and warranties of the Company contained in this Agreement shall be true and correct on the Closing Date, or on each Option Closing Date, if any, with the same force and effect as if made on and as of the Closing Date or on each
Option Closing Date, if any. 
  

 20 

 (b) On or after the date hereof, (i) there shall not have occurred any downgrading,
suspension or withdrawal of, nor shall any notice have been given of any potential or intended downgrading, suspension or withdrawal of, or of any review (or of any potential or intended review) for a possible change that does not indicate the
direction of the possible change in, any rating of the Company or any securities of the Company (including, without limitation, the placing of any of the foregoing ratings on credit watch with negative or developing implications or under review with
an uncertain direction) by any “nationally recognized statistical rating organization” as such term is defined for purposes of Rule 436(g)(2) under the Act, (ii) there shall not have occurred any change, nor shall any notice have been
given of any potential or intended change, in the outlook for any rating of the Company or any securities of the Company by any such rating organization and (iii) no such rating organization shall have given notice that it has assigned (or is
considering assigning) a lower rating to the Notes than that on which the Notes were marketed. 
  
 (c) Since the respective dates as of which information is given in the Offering Memorandum other than as set forth in the Offering
Memorandum (exclusive of any amendments or supplements thereto subsequent to the date of this Agreement), (i) there shall not have occurred any change or any development involving a prospective change in the condition, financial or otherwise, or the
earnings, business, management or operations of the Company and its subsidiaries, taken as a whole, (ii) there shall not have been any change or any development involving a prospective change in the capital stock or in the long-term debt of the
Company or any of its subsidiaries and (iii) neither the Company nor any of its subsidiaries shall have incurred any liability or obligation, direct or contingent, the effect of which, in any such case described in clause 9(c)(i), 9(c)(ii) or
9(c)(iii), in UBS’ judgment, is material and adverse and, in UBS’ judgment, makes it impracticable to market the Securities on the terms and in the manner contemplated in the Offering Memorandum. 
  
 (d) You shall have received on the Closing Date a
certificate, dated the Closing Date, and on an Option Closing Date, if any, dated such Option Closing Date, signed by Gregory T. Lucier and C. Eric Winzer, in their capacities as President and Chief Executive Officer, and Chief Financial Officer,
respectively, of the Company, confirming the matters set forth in Sections 6(dd), 9(a) and 9(b) and stating that the Company has complied with all the agreements and satisfied all of the conditions herein contained and required to be complied with
or satisfied on or prior to the Closing Date or Option Closing Date, as the case may be. 
  
 (e) (A) You shall have received on the Closing Date and each Option Closing Date, if any, an opinion (satisfactory to you and counsel for
the Initial Purchasers), dated the Closing Date or such Option Closing Date, as the case may be, of Gray Cary Ware & Freidenrich LLP, counsel for the Company, to the effect that: 
  
 (i)      the Company has been duly incorporated, is validly existing as a
corporation in good standing under the laws of its jurisdiction of incorporation and has the corporate power and authority to carry on its business as described in the Offering Document and to own, lease and operate its properties; 
  
 (ii)     the Notes and the Indenture
have been duly authorized, executed and delivered by the Company; 
  

 21 

 (iii)     the Notes are convertible into shares of Common Stock in
accordance with the terms of the Indenture; the shares of Common Stock initially issuable upon conversion of the Notes have been duly authorized and reserved for issuance upon such conversion and, when issued upon such conversion, will be validly
issued, fully paid and nonassessable, will conform to the description thereof contained in the Offering Memorandum; the Company has filed with the Nasdaq National Market a “Notification Form: Listing of Additional Shares” (the
“Notification”) with respect to the Common Stock initially issuable upon conversion of the Notes; the Company has been advised by the staff of Nasdaq that the Notification was deemed complete and that no additional
information is required by Nasdaq with respect to listing the Common Stock initially issuable upon conversion of the Notes on the Nasdaq National Market and has not received any notification to the contrary from Nasdaq; the Company has the
authorized capital stock as set forth in the Offering Memorandum; and the stockholders of the Company have no pre-emptive or, to the knowledge of such counsel, similar rights with respect to the Notes or the Common Stock issuable upon the conversion
of the Notes; 
  
 (iv)
    this Agreement has been duly authorized, executed and delivered by the Company; 
  
 (v)      The Registration Rights Agreement has been duly authorized, executed and delivered by the Company and is
a valid and binding agreement of the Company enforceable against the Company in accordance with its terms, except as (x) the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally
and (y) rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability; 
  
 (vi)      the statements under the captions “Description of Notes,” “Description of Capital
Stock” and “Certain United States Federal Income Tax Considerations” in the Offering Memorandum, insofar as such statements constitute a summary of the legal matters or documents referred to therein, fairly present in all material
respects such legal matters and documents; 
  
 (vii)    the execution, delivery and performance of this Agreement and the other Operative Documents by the Company, the compliance by the Company with all provisions hereof and thereof and the consummation of the
transactions contemplated hereby and thereby will not: (i) require any consent, approval, Material Authorization or other order of, or qualification with, any court or governmental body or agency (except such as may be required under the securities
or Blue Sky laws of the various states or for filings required by the Registration Rights Agreement), (ii) conflict with or constitute a breach of any of the terms or provisions of, or a default under, the charter or by-laws of the Company or any of
the agreements set forth on Schedule E hereto (the “Material Contracts”), (iii) violate or conflict with any applicable law or any rule or regulation, or, to such counsel’s knowledge, any existing judgment, order or
decree of any court or any governmental body or agency having jurisdiction over the Company or its property, (iv) result in the imposition or creation of (or the obligation to create or impose) a Lien under any of the Material Contracts, or (v) to
such counsel’s knowledge, result in the termination, suspension or revocation of any Material Authorization of the Company; 
  

 22 

 (viii)    except as set forth on Schedule F hereto or in the Offering
Memorandum, such counsel does not know of any legal or governmental proceedings pending to which the Company is a party or to which its property is subject, or threatened with respect to the Company or its property; 
  
 (ix)      the Company is not and,
after giving effect to the offering and sale of the Notes and the application of the net proceeds thereof as described in the Offering Memorandum, will not be, an “investment company” as such term is defined in the Investment Company Act
of 1940, as amended; 
  
 (x)
      except as set forth on Schedule G hereto or in the Offering Memorandum, to such counsel’s knowledge, there are no contracts, agreements or understandings between the Company and any person granting such
person the right to require the Company to file a registration statement under the Act with respect to any securities of the Company or to require the Company to include such securities with the Notes registered pursuant to any Registration
Statement; 
  
 (xi)
     to such counsel’s knowledge, except as set forth on Schedule F hereto or in the Offering Memorandum, the Company has not received any notice of infringement of or conflict with asserted rights of others with
respect to any of the Company’s patent rights, licenses, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks and trade
names which has not been resolved; 
  
 (xii)     the Indenture complies as to form in all material respects with the requirements of the TIA, and the rules and regulations of the Commission applicable to an indenture which is qualified thereunder. It is
not necessary in connection with the offer, sale and delivery of the Notes to the Initial Purchasers in the manner contemplated by this Agreement or in connection with the Exempt Resales to qualify the Indenture under the TIA; and 
  
 (xiii)    no registration under the Act of
the Securities is required for the sale of the Securities to the Initial Purchasers as contemplated by this Agreement or for the Exempt Resales assuming that: (i) each Initial Purchaser is a QIB, (ii) the accuracy of, and compliance with, the
Initial Purchasers’ representations and agreements contained in Section 7 of this Agreement, and (iii) the accuracy of the representations of the Company set forth in Section 6(gg) of this Agreement. 
  
 Such opinion shall also include a statement that such
counsel has no reason to believe that, as of the date of the Offering Memorandum or as of the Closing Date or the Option Closing Date, as the case may be, the Offering Memorandum and all documents incorporated therein by reference, as amended or
supplemented, if applicable (except for the financial statements and other financial data included therein or incorporated therein by reference, as to which such counsel need not express any belief) contains any untrue statement of a material fact
or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 
  

 23 

 The opinion of Gray Cary Ware & Freidenrich LLP described in Section 9(e)(A) above
shall be rendered to you at the request of the Company and shall so state therein. In giving such statement, Gray Cary Ware & Freidenrich LLP may state that their opinion and belief are based upon their participation in the preparation of the
Offering Memorandum and any amendments or supplements thereto and review and discussion of the contents thereof, but are without independent check or verification except as specified. 
  
 (B) You shall have received on the Closing Date and each Option Closing Date, if any, an opinion
(satisfactory to you and counsel for the Initial Purchasers), dated the Closing Date or such Option Closing Date, as the case may be, of John A. Cottingham, General Counsel for the Company, or of foreign counsel to the Company with respect to
certain foreign subsidiaries, to the effect that: 
  
 (i)      each of the Material Subsidiaries has been duly incorporated, is validly existing as a corporation in good standing under the laws of its jurisdiction of incorporation and has the corporate power and
authority to carry on its business as described in the Offering Document and to own, lease and operate its properties. 
  
 (ii)     each of the Company and its Material Subsidiaries is duly qualified and is in good standing as a foreign
corporation authorized to do business in each jurisdiction in which the nature of its business or its ownership or leasing of property requires such qualification, except where the failure to be so qualified would not have a material adverse effect
on the business, prospects, financial condition or results of operations of the Company and its Material Subsidiaries, taken as a whole; 
  
 (iii)    all of the outstanding shares of capital stock of each of the Company’s subsidiaries have been duly
authorized and validly issued and are fully paid and non-assessable and, to such counsel’s knowledge, other than as set forth on Schedule B hereto, are owned of record by the Company, free and clear of any Lien; 
  
 (iv)    to such counsel’s knowledge,
neither the Company nor any of its subsidiaries is in violation of its respective charter or by-laws and neither the Company nor any of its subsidiaries is in default in the performance of any obligation, agreement, covenant or condition contained
in any indenture, loan agreement, mortgage, lease or other agreement or instrument that is material to the Company and its subsidiaries, taken as a whole, to which the Company or any of its subsidiaries is a party or by which the Company or any of
its subsidiaries or their respective property is bound; 
  
 (v)     the execution, delivery and performance of this Agreement and the other Operative Documents by the Company, the compliance by the Company with all provisions hereof and thereof and the
consummation of the transactions contemplated hereby and thereby will not (i) require any consent, approval, Material Authorization or other order of, or qualification with, any court or governmental body or agency (except such as may be required
under the securities or Blue Sky laws of the various states or for filings required by the Registration Rights Agreement), (ii) conflict with or constitute a breach of any of the terms or provisions of, or a default under, the charter or by-laws of
the Company or any of the Company’s subsidiaries or any indenture, loan agreement, 
  

 24 

 
mortgage, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries or their respective property is bound and that is material to the Company and its subsidiaries, taken as a whole, (iii) violate or conflict with any applicable law or any rule or regulation, or, to such counsel’s knowledge, any
existing judgment, order or decree of any court or any governmental body or agency having jurisdiction over the Company, any of the Material Subsidiaries or their respective properties, (iv) result in the imposition or creation of (or the obligation
to create or impose) a Lien under, any agreement or instrument to which the Company or any of the Material Subsidiaries is a party or by which the Company or any of the Material Subsidiaries or their respective property is bound, or (v) to such
counsel’s knowledge, result in the termination, suspension or revocation of any Material Authorization of the Company or any of its subsidiaries; 
  
 (vi)      such counsel does not know of any legal or governmental proceedings pending or threatened to which the
Company or any of its subsidiaries is or could be (with respect to threatened proceedings) a party or to which any of their respective property is or could be (with respect to threatened proceedings) subject, which is likely to result, singly or in
the aggregate, in a material adverse effect on the business, prospects, financial condition or results of operations of the Company and its subsidiaries, taken as a whole; 
  
 (vii)     except as set forth on Schedule G hereto or in the Offering Memorandum, to
such counsel’s knowledge, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Act with respect to any
securities of the Company or to require the Company to include such securities with the Notes registered pursuant to any Registration Statement; and 
  
 (viii)    to such counsel’s knowledge, neither the Company nor any of its subsidiaries has received any notice of
infringement of or conflict with asserted rights of others with respect to any of the Company’s patent rights, licenses, copyrights, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), trademarks, service marks and trade names which has not been resolved and which, singly or in the aggregate, is likely to result in a material adverse effect on the business, prospects, financial condition or
results of operations of the Company and its subsidiaries, taken as a whole. 
  
 Such opinion shall also include a statement that such counsel has no reason to believe that, as of the date of the Offering Memorandum or as of the Closing Date or the Option Closing Date, as the case may be, the
Offering Memorandum and all documents incorporated therein by reference, as amended or supplemented, if applicable (except for the financial statements and other financial data included therein or incorporated therein by reference, as to which such
counsel need not express any belief) contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

  

 25 

 The opinion of John A. Cottingham and of the foreign counsel to the Company described in
Section 9(e)(B) above shall be rendered to you at the request of the Company and shall so state therein. 
  
 (C) You shall have received on the Closing Date and each Option Closing Date, if any, an opinion (satisfactory to you and counsel for the
Initial Purchasers), dated the Closing Date or such Option Closing Date, as the case may be, of Fulbright & Jaworski L.L.P., special New York counsel for the Company, to the effect that: 
  
 (i)    the Notes, when executed and
authenticated in accordance with the provisions of the Indenture and delivered to and paid for by the Initial Purchasers in accordance with the terms of this Agreement, will be entitled to the benefits of the Indenture and will be valid and binding
obligations of the Company, enforceable in accordance with their terms except as (x) the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally and (y) rights of acceleration and
availability of equitable remedies may be limited by equitable principles of general applicability; and 
  
 (ii)   the Indenture is a valid and binding agreement of the Company, enforceable against the Company in accordance with its
terms except as (x) the enforceability thereof may be limited by bankruptcy, insolvency or similar laws affecting creditors’ rights generally and (y) rights of acceleration and the availability of equitable remedies may be limited by equitable
principles of general applicability. 
  
 (f)
    The Initial Purchasers shall have received on the Closing Date and on each Option Closing Date, an opinion, dated the Closing Date, of Latham & Watkins LLP, counsel for the Initial Purchasers, in form and substance
reasonably satisfactory to the Initial Purchasers. 
  
 (g)    The Initial Purchasers shall have received, at the time this Agreement is executed and at the Closing Date and each Option Closing Date, letters dated the date hereof or the Closing Date or an Option Closing Date, as
the case may be, in the form and substance satisfactory to the Initial Purchasers from Ernst & Young LLP, independent public accountants, containing the information and statements of the type ordinarily included in accountants’
“comfort letters” to the Initial Purchasers with respect to the financial statements and certain financial information contained in or incorporated by reference into the Offering Memorandum. 
  
 (h)    The Notes shall have been approved by
the NASD for trading and duly listed in PORTAL. 
  
 (i)     The Initial Purchasers shall have received a counterpart, conformed as executed, of the Indenture which shall have been entered into by the Company and the Trustee. 
  
 (j)     The Company shall have executed
the Registration Rights Agreement and the Initial Purchasers shall have received an original copy thereof, duly executed by the Company. 
  
 (k)    The Company shall not have failed at or prior to the Closing Date or any Option Closing Date, as the case may be, to
perform or comply with any of the agreements herein 

  

 26 

 
contained and required to be performed or complied with by the Company at or prior to the Closing Date or Option Closing Date, as the case may be.

  
 (l) The Initial Purchasers shall have
received on the Closing Date a certificate, dated the Closing Date, and on an Option Closing Date, if any, dated such Option Closing Date, signed by C. Eric Winzer, in his capacity Executive Vice President and Chief Financial Officer of the Company
substantially in the form attached hereto as Exhibit B. 
  
 10. Effectiveness of Agreement and Termination. This Agreement may be terminated at any time on or prior to the Closing Date or an Option Closing Date by the Initial Purchasers by written notice to the Company if any of the
following has occurred: (i) any change, or any development or event involving a prospective change, in the condition (financial or other), business, properties or results of operations of the Company and its subsidiaries taken as one enterprise
which, in the judgment of UBS, is material and adverse and makes it impractical or inadvisable to proceed with completion of the offering or the sale of and payment for the Notes; (ii) any downgrading in the rating of any debt securities of the
Company by any “nationally recognized statistical rating organization” (as defined for purposes of Rule 436(g) under the Act), or any public announcement that any such organization has under surveillance or review its rating of any debt
securities of the Company (other than an announcement with positive implications of a possible upgrading, and no implication of a possible downgrading, of such rating) or any announcement that the Company has been placed on negative outlook; (iii)
any change in U.S. or international financial, political or economic conditions or currency exchange rates or exchange controls as would, in the judgment of UBS, be likely to prejudice materially the success of the proposed issue, sale or
distribution of the Notes, whether in the primary market or in respect of dealings in the secondary market, (iv) any material suspension or material limitation of trading in securities generally on the New York Stock Exchange, or any setting of
minimum prices for trading on such exchange, or any suspension of trading of any securities of the Company on any exchange or in the over-the-counter market; (v) any banking moratorium declared by U.S. Federal or New York authorities; (vi) any major
disruption of settlements of securities or clearance services in the United States or (vii) any attack on, outbreak or escalation of hostilities or act of terrorism involving the United States, any declaration of war by Congress or any other
national or international calamity or emergency if, in the judgment of UBS, the effect of any such attack, outbreak, escalation, act, declaration, calamity or emergency makes it impractical or inadvisable to proceed with completion of the offering
or sale of and payment for the Notes. 
  
 If on the Closing Date
or an Option Closing Date, as the case may be, any one or more of the Initial Purchasers shall fail or refuse to purchase the Notes which it or they have agreed to purchase hereunder on such date and the aggregate principal amount of the Notes which
such defaulting Initial Purchaser or Initial Purchasers, as the case may be, agreed but failed or refused to purchase is not more than one-tenth of the aggregate principal amount of the Notes to be purchased on such date by all Initial Purchasers,
each non-defaulting Initial Purchaser shall be obligated severally, in the proportion which the principal amount of the Notes set forth opposite its name in Schedule A bears to the aggregate principal amount of the Notes which all the non-defaulting
Initial Purchasers, as the case may be, have agreed to purchase, or in such other proportion as you may specify, to purchase the Notes which such defaulting Initial Purchaser or Initial Purchasers, as the case may be, agreed but failed or refused to
purchase on such date; provided that in no event shall the aggregate principal amount of the Notes which any Initial Purchaser has agreed to 

  

 27 

 
purchase pursuant to Section 2 hereof be increased pursuant to this Section 10 by an amount in excess of one-tenth of such principal amount of the Notes
without the written consent of such Initial Purchaser. If on the Closing Date, or an Option Closing Date, as the case may be, any Initial Purchaser or Initial Purchasers shall fail or refuse to purchase the Notes and the aggregate principal amount
of the Notes with respect to which such default occurs is more than one-tenth of the aggregate principal amount of the Notes to be purchased by all Initial Purchasers and arrangements satisfactory to the Initial Purchasers and the Company for
purchase of such the Notes are not made within 48 hours after such default, this Agreement will terminate without liability on the part of any non-defaulting Initial Purchaser and the Company. In any such case which does not result in termination of
this Agreement, either you or the Company shall have the right to postpone the Closing Date, or such Option Closing Date, as the case may be, but in no event for longer than seven days, in order that the required changes, if any, in the Offering
Memorandum or any other documents or arrangements may be effected. Any action taken under this paragraph shall not relieve any defaulting Initial Purchaser from liability in respect of any default of any such Initial Purchaser under this Agreement.

  
 11. Miscellaneous. Notices given pursuant to any
provision of this Agreement shall be addressed as follows: (i) if to the Company to Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California, 92008, attention: Chief Financial Officer and General Counsel, and (ii) if to the Initial
Purchasers, UBS Securities LLC, 299 Park Avenue, New York, New York 10171, Attention: Syndicate Department, or in any case to such other address as the person to be notified may have requested in writing. 
  
 The respective indemnities, contribution agreements, representations,
warranties and other statements of the Company and the Initial Purchasers set forth in or made pursuant to this Agreement shall remain operative and in full force and effect, and will survive delivery of and payment for the Securities regardless of
(i) any investigation, or statement as to the results thereof, made by or on behalf of the Initial Purchasers; the officers or directors of the Initial Purchasers, any person controlling the Initial Purchasers, the Company, the officers or directors
of the Company, or any person controlling the Company, (ii) acceptance of the Securities and payment for them hereunder and (iii) termination of the Agreement. 
  

If for any reason the Notes are not delivered by or on behalf of the Company as provided herein (other than as a result of any termination of this
Agreement pursuant to Section 10), the Company agrees to reimburse the Initial Purchasers for all out-of-pocket expenses (including the fees and disbursements of counsel) incurred by them. Notwithstanding any termination of this Agreement, the
Company shall be liable for all expenses which it has agreed to pay pursuant to Section 5(h) hereof. The Company also agrees to reimburse the Initial Purchasers and its officers, directors and each person, if any, who controls such Initial
Purchasers within the meaning of Section 15 of the Act or Section 20 of the Exchange Act for any and all fees and expenses (including without limitation the reasonable fees and expenses of counsel) incurred by them in connection with enforcing their
rights under this Agreement (including without limitation its rights under Section 8). 
  
 Except as otherwise provided, this Agreement has been and is made solely for the benefit of and shall be binding upon the Company, the Initial Purchasers, the Initial Purchasers’ directors and officers, any
controlling persons referred to herein, the directors of the Company and their 

  

 28 

 
respective successors and assigns, all as and to the extent provided in this Agreement, and no other person shall acquire or have any right under or by
virtue of this Agreement. The term “successors and assigns” shall not include a purchaser of any of the Securities from the Initial Purchasers merely because of such purchase. 
  
 This Agreement shall be governed and construed in accordance with the laws of the State of New York. 
  
 Each of UBS (on behalf of the Initial Purchasers) and the Company (on its
behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) waives all right to trial by jury in any action, proceeding or counterclaim (whether based upon contract, tort or otherwise) in any way arising out
of or relating to this Agreement. 
  
 This Agreement may be signed
in various counterparts which together shall constitute one and the same instrument. 
  

 29 

 Please confirm that the foregoing correctly sets forth the agreement among the Company, and the Initial
Purchasers. 
  

					
	 Very truly yours,

	
	 INVITROGEN CORPORATION

		
	By:	 	 /s/ Gregory T. Lucier

	 	 	

	 	 	 Name:
	 	 Gregory T. Lucier

	 	 	 Title:
	 	 President and Chief Executive Officer

  

					
	 UBS SECURITIES LLC
 BEAR, STEARNS & CO. INC.
 By: UBS SECURITIES LLC

		
	By:	 	/s/ Steven Meehan
	 	 	

	 	 	 Name:
	 	 Steven Meehan

	 	 	 Title:
	 	 Managing Director

  

					
		
	By:	 	/s/ Keith Lockwood
	 	 	

	 	 	 Name:
	 	 Keith Lockwood

	 	 	 Title:
	 	 Associate DirectorMerger Agreement and Plan of Reorganization

 Exhibit 10.1 
  
 MERGER AGREEMENT AND PLAN OF REORGANIZATION 
  
 BY AND AMONG 
  
 PAINCARE HOLDINGS, INC., 
  
 PAINCARE ACQUISITION COMPANY X, INC., 
  
 REW MERGER CORP. 
  
 AND 
  
 ROBERT E. WRIGHT, M.D. 
  
 AND 
  
 KENNETH M. ALO,
M.D. 
  
 EXECUTION DATE: APRIL 29, 2004. 
  

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

	1.	  	DEFINITIONS	  	2
			
	2.	  	TRANSACTION	  	2
				
	 	  	2.1	  	Transaction	  	2
				
	 	  	2.2	  	Effect of the Merger	  	2
				
	 	  	2.3	  	Filing of Certificates of Merger	  	2
				
	 	  	2.4	  	Articles of Incorporation	  	2
				
	 	  	2.5	  	Bylaws	  	3
				
	 	  	2.6	  	Directors and Officers	  	3
				
	 	  	2.7	  	Tax Consequences	  	3
				
	 	  	2.8	  	Additional Actions	  	3
				
	 	  	2.9	  	No Dissenters’ Rights	  	3
				
	 	  	2.10	  	Surrender of Certificates	  	3
					
	 	  	 	  	(a)	 	Company’s Shares	  	3
					
	 	  	 	  	(b)	 	Dividends	  	4
				
	 	  	2.11	  	Medical and Non-Medical Assets	  	4
				
	 	  	2.12	  	Conversion of Shares	  	4
				
	 	  	2.13	  	Shareholder Consent and Release	  	4
				
	 	  	2.14	  	Registration	  	4
				
	 	  	2.15	  	Shareholder’s Obligation to Furnish Information	  	6
				
	 	  	2.16	  	Suspension of Sales Pending Amendment to Prospectus	  	6
				
	 	  	2.17	  	Registration Expenses	  	6
			
	3.	  	TRANSACTION CONSIDERATION	  	7
				
	 	  	3.1	  	Merger Consideration	  	7
				
	 	  	3.2	  	Payment of Closing Consideration	  	7
				
	 	  	3.3	  	Closing Date Adjustments	  	8
					
	 	  	 	  	(a)	 	Transaction Related Adjustment	  	8
					
	 	  	 	  	(b)	 	Financial Statements	  	8
					
	 	  	 	  	(c)	 	Closing Date Balance Sheet	  	8
				
	 	  	3.4	  	Earnout Payment	  	9
					
	 	  	 	  	(a)	 	General	  	9

  

 i 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

					
	 	  	 	  	(b)	 	Security and Pledge Agreements	  	9
					
	 	  	 	  	(c)	 	Installment Payment Discount	  	10
					
	 	  	 	  	(d)	 	Installment Payment Premium	  	10
					
	 	  	 	  	(e)	 	Manner of Payment	  	10
					
	 	  	 	  	(f)	 	Earnout Cap	  	11
					
	 	  	 	  	(g)	 	Definitions for Purposes of Section 3.4	  	11
			
	4.	  	REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDER	  	12
				
	 	  	4.1	  	Organization, Qualification, and Corporate Power	  	12
				
	 	  	4.2	  	Capitalization	  	13
				
	 	  	4.3	  	Authorization	  	13
				
	 	  	4.4	  	Noncontravention	  	13
				
	 	  	4.5	  	Broker’s Fees	  	13
				
	 	  	4.6	  	Title to Assets	  	14
				
	 	  	4.7	  	No Subsidiaries	  	14
				
	 	  	4.8	  	Financial Statements	  	14
				
	 	  	4.9	  	Events Subsequent to Most Recent Year End	  	14
					
	 	  	 	  	(a)	 	Sale or Lease of Assets	  	14
					
	 	  	 	  	(b)	 	Contracts	  	14
					
	 	  	 	  	(c)	 	Change in Contracts	  	15
					
	 	  	 	  	(d)	 	Security Interests	  	15
					
	 	  	 	  	(e)	 	Investments	  	15
					
	 	  	 	  	(f)	 	Debts	  	15
					
	 	  	 	  	(g)	 	Liabilities Unaffected	  	15
					
	 	  	 	  	(h)	 	Claims Unaffected	  	15
					
	 	  	 	  	(i)	 	Articles and Bylaws	  	15
					
	 	  	 	  	(j)	 	Changes in Equity	  	15
					
	 	  	 	  	(k)	 	Distribution	  	15
					
	 	  	 	  	(l)	 	Property Damage	  	15
					
	 	  	 	  	(m)	 	Transactions with Affiliates	  	15
					
	 	  	 	  	(n)	 	Collective Bargaining Agreements	  	15

  

 ii 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

					
	 	  	 	  	(o)	 	Compensation Changes	  	16
					
	 	  	 	  	(p)	 	Employee Benefit Plans	  	16
					
	 	  	 	  	(q)	 	Officers; Directors; Employees	  	16
					
	 	  	 	  	(r)	 	Charitable or Capital Contributions	  	16
					
	 	  	 	  	(s)	 	Ordinary Course of Business	  	16
					
	 	  	 	  	(t)	 	Accounting Practices	  	16
					
	 	  	 	  	(u)	 	Accounts Receivable	  	16
					
	 	  	 	  	(v)	 	In General	  	16
				
	 	  	4.10	  	Undisclosed Liabilities	  	16
				
	 	  	4.11	  	Tax Matters	  	16
					
	 	  	 	  	(a)	 	Tax Returns	  	16
					
	 	  	 	  	(b)	 	Withholding	  	17
					
	 	  	 	  	(c)	 	No Disputes of Claims	  	17
					
	 	  	 	  	(d)	 	No Waivers	  	17
					
	 	  	 	  	(e)	 	No Special Circumstances	  	17
					
	 	  	 	  	(f)	 	Subchapter “S”	  	17
					
	 	  	 	  	(g)	 	Audits of Tax Returns	  	18
					
	 	  	 	  	(h)	 	Period of Assessment	  	18
					
	 	  	 	  	(i)	 	Tax Agreements	  	18
					
	 	  	 	  	(j)	 	Inclusions in Taxable Periods	  	18
					
	 	  	 	  	(k)	 	Consents	  	18
					
	 	  	 	  	(l)	 	Personal Holding Company	  	18
					
	 	  	 	  	(m)	 	Consolidated Tax Returns	  	18
				
	 	  	4.12	  	Real Property	  	18
					
	 	  	 	  	(a)	 	Binding	  	18
					
	 	  	 	  	(b)	 	Continued Validity	  	18
					
	 	  	 	  	(c)	 	No Defaults	  	18
					
	 	  	 	  	(d)	 	Repudiation	  	19
					
	 	  	 	  	(e)	 	No Disputes	  	19
					
	 	  	 	  	(f)	 	Subleases	  	19

  

 iii 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

					
	 	  	 	  	(g)	 	Encumbrances	  	19
					
	 	  	 	  	(h)	 	Approvals	  	19
					
	 	  	 	  	(i)	 	Utilities	  	19
				
	 	  	4.13	  	Intellectual Property	  	19
				
	 	  	4.14	  	Condition of Tangible Assets	  	19
				
	 	  	4.15	  	Contracts	  	19
					
	 	  	 	  	(a)	 	Personal Property Leases	  	19
					
	 	  	 	  	(b)	 	Services	  	20
					
	 	  	 	  	(c)	 	Partnership; Joint Venture	  	20
					
	 	  	 	  	(d)	 	Indebtedness	  	20
					
	 	  	 	  	(e)	 	Confidentiality; Non-Competition	  	20
					
	 	  	 	  	(f)	 	Shareholders’ Agreements	  	20
					
	 	  	 	  	(g)	 	Plans	  	20
					
	 	  	 	  	(h)	 	Employment or Consulting Agreements	  	20
					
	 	  	 	  	(i)	 	Advances; Loans	  	20
					
	 	  	 	  	(j)	 	Adverse Effects	  	20
					
	 	  	 	  	(k)	 	Other Agreements	  	20
				
	 	  	4.16	  	Powers of Attorney	  	21
				
	 	  	4.17	  	Insurance; Malpractice	  	21
				
	 	  	4.18	  	Litigation	  	22
				
	 	  	4.19	  	Health Care Compliance	  	22
				
	 	  	4.20	  	Fraud and Abuse	  	22
				
	 	  	4.21	  	Legal Compliance	  	23
				
	 	  	4.22	  	Rates and Reimbursement Policies	  	23
				
	 	  	4.23	  	Medical Staff	  	23
				
	 	  	4.24	  	Employees	  	24
				
	 	  	4.25	  	Employee Benefits	  	24
					
	 	  	 	  	(a)	 	Plans	  	24
					
	 	  	 	  	(b)	 	Compliance	  	24
					
	 	  	 	  	(c)	 	Reports and Descriptions	  	24

  

 iv 

 TABLE OF CONTENTS 
  

												
	 	  	 	  	 	 	 	 	 	 	  	Page

					
	 	  	 	  	(d)	 	 	Contributions	  	24
					
	 	  	 	  	(e)	 	 	Qualified Plan	  	24
					
	 	  	 	  	(f)	 	 	Market Value	  	24
					
	 	  	 	  	(g)	 	 	Copies	  	25
					
	 	  	 	  	(h)	 	 	Maintenance of Plans	  	25
						
	 	  	 	  	 	 	 	(i)	 	 Reportable Events
	  	25
						
	 	  	 	  	 	 	 	(ii)	 	 Prohibited Transactions
	  	25
				
	 	  	4.26	  	Physicians and Other Providers	  	25
					
	 	  	 	  	(a)	 	 	Licenses	  	25
					
	 	  	 	  	(b)	 	 	Controlled Substances	  	25
					
	 	  	 	  	(c)	 	 	Actions	  	25
						
	 	  	 	  	 	 	 	(i)	 	 Malpractice Actions
	  	25
						
	 	  	 	  	 	 	 	(ii)	 	 Disciplinary Proceedings
	  	25
						
	 	  	 	  	 	 	 	(iii)	 	 Criminal Proceedings
	  	26
						
	 	  	 	  	 	 	 	(iv)	 	 Investigation
	  	26
						
	 	  	 	  	 	 	 	(v)	 	 Mental Illnesses
	  	26
						
	 	  	 	  	 	 	 	(vi)	 	 Substance Abuse
	  	26
						
	 	  	 	  	 	 	 	(vii)	 	 Professional Ethics
	  	26
						
	 	  	 	  	 	 	 	(viii)	 	 Application for Licensure
	  	26
				
	 	  	4.27	  	Guaranties	  	26
				
	 	  	4.28	  	Environment, Health, and Safety	  	26
					
	 	  	 	  	(a	)	 	Compliance	  	26
					
	 	  	 	  	(b	)	 	Permits and Licenses	  	26
					
	 	  	 	  	(c	)	 	Notices	  	26
					
	 	  	 	  	(d	)	 	Hazardous Substances	  	27
				
	 	  	4.29	  	Certain Business Relationships with the Company and its Affiliates	  	27
				
	 	  	4.30	  	Third-party Payors	  	27
				
	 	  	4.31	  	Bank Accounts	  	27
				
	 	  	4.32	  	Tax Status	  	27
				
	 	  	4.33	  	Binding Obligation	  	28

  

 v 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

				
	 	  	4.34	  	No Corporate Practice or Fee Splitting	  	28
				
	 	  	4.35	  	Intentionally Omitted	  	28
				
	 	  	4.36	  	Securities Representation	  	28
					
	 	  	 	  	(a)	 	No Registration of PainCare Shares; Investment Intent	  	28
					
	 	  	 	  	(b)	 	Resale Restrictions	  	28
					
	 	  	 	  	(c)	 	Ability to Bear Economic Risk	  	28
					
	 	  	 	  	(d)	 	Accredited Investor	  	29
					
	 	  	 	  	(e)	 	No Registration	  	29
				
	 	  	4.37	  	HIPAA	  	29
				
	 	  	4.38	  	Improper and Other Payments	  	29
				
	 	  	4.39	  	Accounts Receivable	  	29
				
	 	  	4.40	  	Medical Waste	  	29
				
	 	  	4.41	  	No Untrue or Inaccurate Representation or Warranty	  	30
			
	5.	  	REPRESENTATIONS AND WARRANTIES OF THE ACQUIRING COMPANIES	  	30
				
	 	  	5.1	  	Organization of PainCare and Subsidiary	  	30
				
	 	  	5.2	  	Authorization of Transaction	  	30
				
	 	  	5.3	  	No Conflict or Violation	  	30
				
	 	  	5.4	  	Consents and Approvals	  	31
				
	 	  	5.5	  	Disclosure Documents	  	31
				
	 	  	5.6	  	Capitalization	  	31
				
	 	  	5.7	  	Litigation	  	31
				
	 	  	5.8	  	No Undisclosed Liabilities	  	32
				
	 	  	5.9	  	No Brokers	  	32
				
	 	  	5.10	  	Material Misstatements or Omissions	  	32
			
	6.	  	CLOSING; TERMINATION	  	32
			
	7.	  	CLOSING DELIVERIES	  	32
				
	 	  	7.1	  	Deliveries of the Company and the Shareholder	  	32
					
	 	  	 	  	(a)	 	Consents and Approvals	  	32
					
	 	  	 	  	(b)	 	Termination of Agreements	  	33

  

 vi 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

					
	 	  	 	  	(c)	 	Company Stock	  	33
					
	 	  	 	  	(d)	 	Corporate Authorization	  	33
					
	 	  	 	  	(e)	 	Secretary’s Certificate	  	33
					
	 	  	 	  	(h)	 	Other documents	  	33
				
	 	  	7.2	  	Deliveries of PainCare	  	33
					
	 	  	 	  	(a)	 	Transaction Consideration	  	33
					
	 	  	 	  	(b)	 	Resolutions	  	33
					
	 	  	 	  	(c)	 	Other Documents	  	33
			
	8.	  	CONDITIONS TO THE OBLIGATIONS OF THE PARTIES	  	34
				
	 	  	8.1	  	Conditions for the Benefit of PainCare and the Subsidiary	  	34
				
	 	  	8.2	  	Conditions for the Benefit of the Shareholder	  	34
			
	9.	  	COVENANTS	  	34
				
	 	  	9.1	  	Operations Pending Closing	  	34
				
	 	  	9.2	  	Deliveries Pending Closings	  	34
				
	 	  	9.3	  	Distribution of Sub-Chapter S Income by the Company	  	34
				
	 	  	9.4	  	Post-Closing General Covenants	  	34
				
	 	  	9.5	  	Tax Returns	  	35
				
	 	  	9.6	  	Transitions	  	35
				
	 	  	9.7	  	Litigation Support	  	35
				
	 	  	9.8	  	Consents	  	35
				
	 	  	9.9	  	Operational Covenants	  	36
				
	 	  	9.10	  	Capital Adjustments	  	36
			
	10.	  	SURVIVAL AND INDEMNIFICATION	  	37
				
	 	  	10.1	  	Survival of Representations and Warranties	  	37
				
	 	  	10.2	  	Indemnification Provisions for the Benefit of PainCare and Subsidiary	  	37
				
	 	  	10.3	  	Indemnification Provisions for the Benefit of the Shareholder	  	38
				
	 	  	10.4	  	Matters Involving Third Parties	  	38
					
	 	  	 	  	(a)	 	Notification	  	38
					
	 	  	 	  	(b)	 	Defense by Indemnifying Party	  	38
					
	 	  	 	  	(c)	 	Satisfactory Defense	  	38

  

 vii 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	 	 	  	 	  	Page

					
	 	  	 	  	(d)	 	Conditions	  	39
				
	 	  	10.5	  	Right to Set-Off	  	39
				
	 	  	10.6	  	Materiality	  	39
				
	 	  	10.7	  	Limitation	  	40
			
	11.	  	RESTRICTIVE COVENANTS; CONFIDENTIALITY	  	40
				
	 	  	11.1	  	Restrictive Covenants	  	40
					
	 	  	 	  	(a)	 	Restricted Period	  	40
					
	 	  	 	  	(b)	 	Consideration	  	40
					
	 	  	 	  	(c)	 	Third-Party Beneficiaries	  	41
				
	 	  	11.2	  	Defenses	  	41
				
	 	  	11.3	  	No Running of Covenant During Breach	  	41
				
	 	  	11.4	  	Blue Pencil Doctrine	  	41
				
	 	  	11.5	  	Confidentiality, Press Releases, and Public Announcements	  	41
				
	 	  	11.6	  	Conduct of Business	  	42
				
	 	  	11.7	  	No Third-Party Beneficiaries	  	44
			
	12.	  	MISCELLANEOUS	  	44
				
	 	  	12.1	  	Entire Agreement	  	44
				
	 	  	12.2	  	Succession and Assignment	  	44
				
	 	  	12.3	  	Counterparts	  	44
				
	 	  	12.4	  	Headings	  	44
				
	 	  	12.5	  	Notices	  	44
				
	 	  	12.6	  	Governing Law; Jurisdiction; Attorney’s Fees	  	45
				
	 	  	12.7	  	Amendments and Waivers	  	46
				
	 	  	12.8	  	Severability	  	46
				
	 	  	12.9	  	Expenses	  	46
				
	 	  	12.10	  	Further Assurances	  	46
				
	 	  	12.11	  	Construction	  	46
				
	 	  	12.12	  	Survival	  	46
				
	 	  	12.13	  	Incorporation of Exhibits and Schedules	  	47
				
	 	  	12.14	  	Submission to Jurisdiction	  	47

  

 viii 

 TABLE OF CONTENTS 
  

											
	 	  	 	  	 	  	 	  	 	  	Page

			
	13.	  	RESCISSION	  	47
				
	 	  	13.1	  	The Rescission	  	47
				
	 	  	13.2	  	Return to Status Quo	  	48
				
	 	  	13.3	  	Additional Covenants	  	48

  

 ix 

 MERGER AGREEMENT AND PLAN OF REORGANIZATION 
  
 THIS MERGER AGREEMENT AND PLAN OF REORGANIZATION (the
“Agreement”) is made and entered into effective the 29th day of April, 2004 (the “Execution
Date”) by and among PAINCARE HOLDINGS, INC., a Florida corporation (“PainCare”), PAINCARE ACQUISITION COMPANY X, INC., a Florida corporation (“Subsidiary”), in which PainCare and the Subsidiary are sometimes
referred to herein as the “Acquiring Companies”, and REW MERGER CORP., a Colorado corporation formerly known as Denver Pain Management, P.C. (the “Company”), and ROBERT E WRIGHT, M.D., an individual
(“Dr. Wright”), and KENNETH M. ALO, M.D., an individual (“Dr. Alo”) . 
  
 RECITALS 
  
 A. The Company owns all the non-medical assets used in the operation of DENVER PAIN MANAGEMENT, P.C., (the “PC”) which operates a medical practice (hereinafter sometimes called the
“Business”) at 7447 E. Berry Avenue, Ste. 150, Greenwood Village, Colorado 80111 (hereinafter sometimes called the “Center”) and Dr. Wright and Dr. Alo are licensed medical providers in the State of Colorado and own all of the
issued and outstanding shares of stock in the Company (the “Company Shares”) and the PC (the “PC Shares”); 
  
 B. PainCare is in the business of acquiring the non-medical assets of medical practices and entering into management services agreements with
practices entities associated with the acquired practice; 
  
 C. PainCare desires to enter into this Agreement in order for the Subsidiary, which is a wholly-owned subsidiary of PainCare, to acquire the assets of the Company; 
  
 D. Immediately prior to closing, Dr. Wright will (i) sell sixty-seven percent (67%) of his company shares to the
Wright Nongrantor Trust (U/D/T 2004), an Irrevocable Nongrantor Trust (the “Dr. Wright Trust”), and (ii) assign his remaining company shares to “R. E. Wright FLP,” a Nevada Limited Partnership (the “Dr. Wright
Partnership”). 
  
 E. Immediately prior to the Closing, Dr.
Alo will (i) sell sixty-seven percent (67%) of his Company Shares to the “Alo Nongrantor Trust,” an Irrevocable Non-Grantor Trust (the “Dr. Alo Trust”), and (ii) assign his remaining Company Shares to Delta KMA Two, FLP, a Nevada
limited partnership (the “Dr. Alo Partnership”). 
  
 F.
Hereinafter Dr. Wright, the Dr. Wright Trust, the Dr. Wright Partnership, Dr. Alo, the Dr. Alo Trust and the Dr. Alo Partnership will collectively sometimes be referred to herein as the “Shareholder” and sometimes Dr. Wright, the Dr.
Wright Trust, the Dr. Wright Partnership, Dr. Alo, the Dr. Alo Trust, the Dr. Alo Partnership, and the Company will collectively sometimes be referred to herein as the “Shareholder” or sometimes the “Sellers.” PainCare, the
Subsidiary, and the Sellers are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
  

 1 

 G. In connection with this acquisition, PainCare desires to have Subsidiary enter into a
management services agreement with the PC, in which the management services agreement is the significant inducement for the Subsidiary to acquire the assets of the Company; 
  
 H. All of the Parties hereto desire to enter into this Agreement to effectuate the Merger, as hereinafter defined, of
the Company with and into Subsidiary pursuant to the terms and conditions of this Agreement; and 
  
 I. It is the intention of the Parties for the Merger contemplated herein to qualify as a tax-free reorganization pursuant to Sections 368(a)(1)(A)
and 368(a)(2)(D) of the Code. 
  
 NOW, THEREFORE, in
consideration of the premises and the actual promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the receipt and adequacy of which are hereby conclusively acknowledged, the Parties,
intending to become legally bound, hereby agree as follows: 
  
 TERMS AND CONDITIONS 
  
 1. DEFINITIONS. All
capitalized words that are not capitalized for purposes of grammar and which are not defined in the text of this Agreement are defined terms with their definitions set forth on Exhibit 1. 
  
 2. TRANSACTION. 
  
 2.1 Transaction. Upon the terms and subject to the conditions hereof and in accordance with the provisions of the Colorado Corporation Code
(the “Colorado Act”) and the Florida Business Corporation Act (the “Florida Act”), the Company shall be merged with and into Subsidiary (the “Merger”) and the separate existence of the Company shall thereupon cease, and
Subsidiary, as the surviving corporation (the “Surviving Corporation”), shall continue to exist under and be governed by the Florida Act (the “Transaction”). 
  
 2.2 Effect of the Merger. At and after the Statutory Merger Time, as defined in Section 2.3 below, the effect
of the Merger shall, in all legal respects, be as provided in the Colorado Act and the Florida Act. From and after the Statutory Merger Time, the Surviving Corporation shall continue to be a Florida corporation. 
  
 2.3 Filing of Certificates of Merger. The Merger shall be
legally effected by the filing at the time of the Closing or as soon as practicable thereafter, of the Articles of Merger (the “Articles of Merger”), substantially in the form of Exhibit 2.3 attached hereto, with the Secretary of the State
of Florida and the Secretary of the State of Colorado in accordance with the provisions of the Florida Act and the Colorado Act, respectively (hereinafter the “Statutory Merger Time”). The Parties shall take any and all other lawful
actions and do any and all other lawful things necessary to cause the Merger to become effective. 
  
 2.4 Articles of Incorporation. As of the Statutory Merger Time, the articles of incorporation of Subsidiary, as in effect immediately prior
to the Statutory Merger Time, shall be 

  

 2 

 
the articles of incorporation of the Surviving Corporation until thereafter amended in accordance with applicable law. 
  
 2.5 Bylaws. As of the Statutory Merger Time, the bylaws of
Subsidiary, as in effect immediately prior to the Statutory Merger Time, shall be the bylaws of the Surviving Corporation until thereafter amended in accordance with its terms and applicable law. 
  
 2.6 Directors and Officers. As of the Statutory Merger Time,
the directors and officers of Subsidiary immediately prior to the Statutory Merger Time shall be the directors and officers of the Surviving Corporation. Each director and officer of the Surviving Corporation shall hold office in accordance with the
articles of incorporation and bylaws of the Surviving Corporation. The Company shall cause to be delivered to Subsidiary the written resignation of all of the directors and officers of the Company, which resignations shall be unconditional and
effective as of the Closing Date (as defined in Section 6 below). 
  
 2.7 Tax Consequences. It is intended by the Parties hereto that the Merger shall constitute a tax-free reorganization within the meaning of Sections 368(a)(1)(A) and 368(a)(2)(D) of the Code. 
  
 2.8 Additional Actions. If, at any time after the Closing, the
Surviving Corporation shall consider or be advised that any further acts are necessary or desirable: (a) to vest, perfect or confirm, of record or otherwise, in the Surviving Corporation, title to and possession of any property or right of the
Company acquired or to be acquired by reason of, or as a result of, the Merger; or (b) otherwise to carry out the purposes of this Agreement, then the Shareholder shall be deemed to have granted to the Surviving Corporation an irrevocable power of
attorney to execute and deliver all such deeds, assignments and assurances in law and to do all other acts necessary or proper to vest, perfect or confirm title to and possession of such property or rights in the Surviving Corporation and otherwise
to carry out the purposes of this Agreement; and the officers and directors of the Surviving Corporation are fully authorized in the name of the Shareholder and the Company to take any and all such actions. 
  
 2.9 No Dissenters’ Rights. As a result of the unanimous
approval of the transactions contemplated herein by the Shareholder; neither the Shareholder, nor any other party, is entitled to dissenters’ rights under the laws of the State of Colorado or the State of Florida. 
  
 2.10 Surrender of Certificates. 
  
 (a) Company’s Shares. At the Closing (or,
the Extended Time, as the case may be), the Shareholder shall be required to surrender to Subsidiary the original stock certificates evidencing two hundred (200) shares of stock issued and outstanding, which immediately prior to the Closing Date
represented all of the Company Shares (the “Certificate”) (together with all stock powers duly endorsed to Subsidiary). Until so surrendered, each Certificate which immediately prior to the Closing Date represented the Company Shares
(other than Company Shares held in the Company treasury) shall upon and after the Closing Date (or, the Extended Time, as the case may be) by virtue of the Merger be deemed for all purposes to represent and evidence only the right to receive the
Merger Consideration, as hereinafter defined, as provided in this Agreement. As of the Closing Date, the stock transfer books of the Company shall be closed and no transfer of the Company Shares shall be made at any time thereafter. 
  

 3 

 (b) Dividends. No dividends or other distributions declared or made with
respect to the PainCare Shares with a record date after the Closing will be paid to the holder of any unsurrendered Certificate with respect to the PainCare Shares represented thereby until the holder of record of such Certificate shall surrender
such Certificate. Subject to applicable law, following surrender of any such Certificate, there shall be paid to the record holder of the Certificate representing whole PainCare Shares issued in exchange therefor, without interest, at the time of
such surrender, the amount of dividends or other distributions with a record date after the Closing payable with respect to such whole PainCare Shares. 
  
 2.11 Medical and Non-Medical Assets. Those assets of the Company which require a medical license to own or utilize, such as medical records
and any pharmaceutical supplies set forth in Section 2.11(a) of the Disclosure Schedule (the “Medical Assets”), shall not become the possession of Subsidiary pursuant to the Merger. The PC shall own all of the Medical Assets, as of the
Statutory Merger Time. Those assets of the Company which do not require a medical license to own or utilize, such cash, fixed assets, accounts receivable, etc. set forth in Section 2.11(b) of the Disclosure Schedule (the “Non-Medical
Assets”) which comprise all of the Non-Medical Assets of its predecessor company, Denver Pain Management, P.C., shall become the property and possession of Subsidiary pursuant to the Merger. 
  
 2.12 Conversion of Shares. Each share of capital stock of
Subsidiary issued and outstanding immediately prior to the Closing shall continue to represent one (1) validly issued, fully paid and non-assessable share of capital stock of the Surviving Corporation after the Merger. By virtue of the Merger and
without any action on the part of the Shareholder the Company Shares shall be converted into the Merger Consideration. The PainCare Shares to be received by the Shareholder as part of the Merger Consideration shall be subject to restrictions of the
sale, transfer or distribution thereof as set forth in Section 4.36. 
  
 2.13 Shareholder Consent and Release. The Shareholder hereby consents to the Transaction and approves the execution and delivery of this Agreement and the transactions contemplated hereby. Effective on the Closing Date, the
Shareholder hereby releases the Company from any and all claims he may, could or will have, whether arising before or after the Closing Date, against the Company as a result of the Shareholder having served as a stockholder, director, officer,
employee, agent, or in any other capacity of the Company; provided, however, such release shall not operate to release the Company (or the Surviving Corporation as successor to the Company) from (i) Shareholder’s rights (whether arising
under the Company’s By-Laws or by statute) to indemnification, or (ii) the obligation to make the distributions of pre-Closing Date income as permitted under this Agreement, or (iii) claims, if any, arising from Shareholder serving as a
guarantor or joint-obligor with respect to those certain obligations of the Company as identified in Section 2.13 of the Disclosure Schedule. 
  
 2.14 Registration. 
  
 (a) PainCare hereby represents to the Shareholder that it is obligated pursuant to those certain Registration Rights Agreements (the
“Registration Rights Agreements”) dated December February 27, 2004, and March 22, 3004 among PainCare and Laurus Master Fund, Ltd., to file a Form S-3 Registration Statement (the “Registration Statement”) with the SEC no later
than April 30, 2004. PainCare hereby agrees that it will include in the Registration Statement for purposes of registration in accordance with the provisions contained in the 

  

 4 

 
Registration Rights Agreement and the Registration Statement all of the PainCare Shares that will or may be issued to the Shareholder as part of the Closing
Consideration and the Intended Installment Payments (hereinafter the “Registrable Shares”). If, for whatever reason, such Registration Statement does not become effective with the SEC or if PainCare is required by the SEC to remove the
Registrable Shares from the Registration Statement then, in such event, the following provisions dealing with registration rights shall apply. 
  
 (b) Subject to Section 2.14(a) above, if within the three (3) year period commencing on the Execution Date PainCare proposes for any
reason to register the PainCare Shares under the Securities Act other than a registration in connection with an exchange offer (Form S-4) or filed in connection with an employee stock option or other benefit plan (Form S-8, or any substitute form
that may be adopted by the Commission), PainCare shall promptly give written notice to the Shareholder of its intention to so register the PainCare Shares and, upon written request by the Shareholder, given within twenty (20) days after delivery of
any such notice by PainCare, to include in such registration PainCare Shares held by the Shareholder (which request shall specify the number of PainCare Shares proposed to be included in such registration), PainCare shall attempt to cause all such
PainCare Shares to be included in such registration on the same terms and conditions as the securities otherwise being included in such registration; provided however, that if the managing underwriters advise PainCare that the inclusion of the
PainCare Shares proposed to be included in such registration would interfere with the successful marketing (including pricing) of the PainCare Shares proposed to be registered by PainCare, then if such registration is in part an underwritten primary
or secondary registration on behalf of PainCare, PainCare shall include in such registration the PainCare Shares requested to be included in such registration, pro rata from among the holders of any and all PainCare shares to be
registered pursuant to such registration according to the number of shares proposed by each holder to be included. In the event PainCare determines not to pursue, or to withdraw, a registration as to which it has given notice pursuant to this
section, the Shareholder shall have no further rights hereunder with respect to such proposed registration. Notwithstanding any other provision of this Section to the contrary, PainCare shall not be required to include any of the PainCare Shares in
a registration statement relating to an underwritten offering of PainCare’s securities unless the Shareholder accepts the terms of the underwriting as agreed upon between PainCare and the underwriters selected by it, including, without
limitation, any Underwriter’s Cutback and/or Lockup, and the Shareholder agrees to promptly execute and/or deliver such documents in connection with such registration as PainCare or the managing underwriter may reasonably request. 

 
 (c) The Shareholder may exercise his rights under Section
2.14(b) above on an unlimited number of occasions. PainCare shall pay all Registration Expenses (as defined below) of any registration effected under this Section, except that in the event of withdrawal by the Shareholder, the Shareholder shall pay
(or reimburse PainCare for) the amount of registration, filing or listing fees relating to his PainCare Shares included in the registration and shall pay the fees of PainCare’s counsel associated with such withdrawal, unless such withdrawal is
due to the Shareholder obtaining material adverse information that was not known by him at the time he requested inclusion of his PainCare Shares in the registration. 
  
 (d) The Shareholder may not participate in any registration under this Section which is underwritten unless
he agrees to sell such PainCare Shares on the basis provided in any underwriting agreement (with terms not inconsistent herewith and customary in underwriting 

  

 5 

 
agreements for secondary distributions) approved by PainCare, provided that the Shareholder shall not be required to make any representations or warranties
to PainCare or the underwriters (other than representations and warranties regarding such Shareholder and such Shareholder’s intended method of distribution). 
  
 2.15 Shareholder’s Obligation to Furnish Information. PainCare may require Shareholder to furnish
PainCare such information regarding the distribution of such securities as PainCare may from time to time reasonably request. If the failure by the Shareholder to furnish such information as expeditiously as possible would prevent (i) the
registration statement relating to such registration from being declared effective by the Securities Exchange Commission, or (ii) members of the National Association of Securities Dealers, Inc. from participating in the distribution of the PainCare
Shares proposed to be registered, PainCare may exclude the Shareholder’s PainCare Shares from such registration. 
  
 2.16 Suspension of Sales Pending Amendment to Prospectus. 
  
 (a) The Shareholder agrees that, upon receipt of any notice from PainCare of the happening of any event of
that requires PainCare not to proceed with the registration, or if PainCare has decided not to proceed with the registration for any reason, the Shareholder shall forego the disposition of any PainCare Shares covered by the registration statement or
prospectus until he is advised in writing by PainCare that the use of the applicable prospectus may be resumed and, if so directed by PainCare, the Shareholder shall deliver to PainCare (at PainCare’s expense, except as hereinafter provided)
all copies, other than permanent file copies, then in Shareholder’s possession of any prospectus covering such PainCare Shares. 
  
 (b) The Shareholder agrees that he shall, as expeditiously as possible, notify PainCare at any time when a prospectus relating to a
registration statement covering such Shareholder’s PainCare Shares is required to be delivered under the Securities Act, of the happening of any event which requires changes to be made in the registration statement or any related prospectus so
that such registration statement or prospectus shall not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading as a result of any
information provided by the Shareholder for inclusion in such prospectus included in such registration statement and, at the request of PainCare, as expeditiously as possible prepare and furnish to it such information as may be necessary so that,
after incorporation into a supplement or amendment of such prospectus as thereafter delivered to the purchasers of such PainCare Shares, the information provided by such Shareholder shall not include an untrue statement of a material fact or a
misstatement of a material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances under which they are made, not misleading and, in such event the expenses of delivery to PainCare of copies
of any prospectus in the Shareholder’s possession shall be at the expense of the Shareholder. 
  
 2.17 Registration Expenses. 
  
 (a) All expenses incident to PainCare’s performance of or compliance with its obligations under this Section 2, including without
limitation all (i) registration and filing fees, (ii) fees and expenses of compliance with securities laws, (iii) printing expenses, (iv) messenger and delivery expenses, (v) internal expenses, (vi) reasonable fees and disbursements of its 

  

 6 

 
counsel and its independent certified public accountants (including “comfort” letters), (vii) securities act liability insurance, (viii) reasonable
fees and expenses of any special experts retained by PainCare in connection with the registration hereunder, and (ix) reasonable fees and expenses of other persons retained by PainCare (all such expenses being referred to herein as
“Registration Expenses”) shall be borne by PainCare. 
  
 (b) Notwithstanding the foregoing, the following costs and expenses shall be excluded from the term “Registration Expenses”: (i) all underwriting discounts and commissions, (ii) all applicable transfer
taxes, (iii) the fees and disbursements of any counsel retained by the Shareholder, and (iv) except as provided in Section 2.17(a), all other costs, fees, and expenses incurred by the Shareholder in connection with the exercise of his registration
rights hereunder. 
  
 3. TRANSACTION CONSIDERATION. 
  
 3.1 Merger Consideration. The aggregate merger consideration
(the “Merger Consideration”) shall consist of (i) the Closing Consideration (the “Closing Consideration”) as hereafter defined, and (ii) the Earnout Payment as determined under Section 3.4 below. Subject to the provisions set
forth in Section 3.2 below, adjustment as provided in Section 3.3 below and subject to the rights of PainCare as set forth in Section 13 below, PainCare shall deliver the Closing Consideration to the Shareholder (in the amounts and denominations
indicated in Section 3.2 below) at the times indicated below subject to the satisfaction of the Closing Conditions. Such Closing Consideration shall equal Three Million Seven Hundred Fifty Thousand and 00/100 Dollars ($3,750,000), which shall be
comprised of: (i) One Million Eight Hundred Seventy Five Thousand and 00/100 Dollars ($1,875,000) (the “Closing Cash”), plus (ii) Six Hundred Sixty Seven Thousand Two Hundred Sixty (667,260) PainCare Shares, valued at Two Dollars and
81/100 Cents ($2.81) per share and having an aggregate value of One Million Eight Hundred Seventy Five Thousand and 00/100 Dollars ($1,875,000)(the “Closing PainCare Shares”). 
  
 3.2 Payment of Closing Consideration. 
  
 The Closing Consideration shall be payable as follows: 
  
 (a) Subject to adjustment as provided in Section 3.3 below and subject to the rights of PainCare as set
forth in Section 13 below, PainCare shall deliver the Closing Cash to the Shareholder on or before December 15, 2004; and 
  
 (b) Subject to adjustment as provided in Section 3.3 below and subject to the rights of PainCare as set forth in Section 13 below,
PainCare shall deliver the Closing PainCare Shares to Arthur Graves, Esq., counsel for the Shareholder (“Mr. Graves”), in the denominations indicated in Disclosure Schedule 3.2(c). The certificates evidencing the Closing PainCare Shares
shall bear the following legend: 
  
 “The sale, transfer,
hypothecation, negotiation, pledge, assignment, encumbrance or other disposition of this share certificate and the shareholdings represented hereby are subject to all of the terms, conditions and provisions of Section 13 of that certain Merger
Agreement dated as of 

  

 7 

 
April 29, 2004, by and among PainCare Holdings, Inc. and certain of its shareholders.” 
  
 Mr. Graves shall hold the Closing PainCare Shares, in trust, for the benefit of PainCare and the Shareholder until December 15, 2004 subject
to the rights of adjustment as provided in Section 3.3 below and subject to the rights of PainCare as set forth in Section 13 below. 
  
 3.3 Closing Date Adjustments. The Closing Consideration shall be subject to adjustment as follows: 
  
 (a) Transaction Related Adjustments. The
Closing Cash shall be reduced by the amount of any cash payments made by the Company or the Acquiring Companies with respect to any expenses paid on behalf of the Shareholder or the Company except as otherwise specifically allowed pursuant to this
Agreement. 
  
 (b) Financial
Statements. The Company has prepared financial statements consisting of (i) a balance sheet and statement of operations in accordance with the cash method of accounting as of and for the year ended December 31, 2003 (the “Annual
Financial Statements”); and (ii) a balance sheet and statement of operations as of and for the quarters ended March 31, 2003 and 2004; (the “Interim Financial Statements”) all of which are included in Section 3.3(b) of the Disclosure
Schedule. The Annual Financial Statements and Interim Financial Statements have been prepared in accordance with the cash method of accounting. The Annual Financial Statements and the Interim Financial Statements (collectively, the “Financial
Statements”) present fairly the financial condition of the Company as of such dates and the results of the operations of the Company for such periods, are correct and complete, and are consistent with the books and records of the Company (which
books and records are correct and complete). 
  
 (c) Closing Date Balance Sheet. Within forty-five (45) days after the Closing Date, PainCare or its Affiliate will prepare and deliver to Drs. Wright and Alo a balance sheet of the Company as of the close of business on the
Closing Date prepared in accordance with GAAP (the “Closing Date Balance Sheet”). Within ten (10) business days after PainCare’s delivery of the Closing Date Balance Sheet to Drs. Wright and Alo, Drs. Wright and Alo shall, in a
written notice to PainCare, either accept or describe in reasonable detail any proposed adjustments to the Closing Date Balance Sheet and the reasons therefore, and shall include pertinent calculations. If Drs. Wright and Alo fail to deliver notice
of acceptance or objection to the Closing Date Balance Sheet within such ten (10) business day period, the Shareholder shall be deemed to have accepted the Closing Date Balance Sheet. Except in the case of a dispute with respect to the Closing Date
Balance Sheet, within ten (10) business days after delivery of the Closing Date Balance Sheet (the “Adjustment Payment Date”), the Shareholder shall pay the Other Net Equity Adjustment (as defined below) to PainCare. In the event that
PainCare and Drs. Wright and Alo are not able to agree on the Closing Date Balance Sheet within thirty (30) days from and after the receipt by PainCare of any objections raised by Drs. Wright and Alo, then either Party shall each have the right to
require that such disputed determinations be submitted to an independent certified public accountant or accounting firm that PainCare shall select, for computation or verification in accordance with the provisions of this Agreement, and the Net
Equity Adjustment shall be paid by the Shareholder to PainCare within ten (10) business days after receipt of the accountant’s computation or verification. The foregoing provisions for 

  

 8 

 
certified public accounting firm review shall be final and binding upon the Parties and there shall be no right of appeal from such decision. Such accounting
firm’s fees and expenses for such disputed determination shall be borne by the Party whose determination has been modified by such accounting firm’s report or by all Parties in proportion to the relative amount each Party’s
determination has been modified. Any payments due under this Section 3.3 shall bear interest at eight percent (8%) per annum from the Adjustment Payment Date. 
  

If the final Closing Date Balance Sheet reflects Cash of the Company that is less than One Hundred Thousand and 00/100 Dollars
($100,000) (the “Required Cash”), or Net Shareholder’s Equity (as defined below) of the Company that is less than Two Hundred Fifty Thousand and 00/100 Dollars ($250,000)(“Agreed Net Equity”), then the Closing Cash shall be
reduced and PainCare may keep dollar for dollar (the “Net Equity Adjustment”) by (i) an Amount equal to the Required Cash less Cash reflected on the Closing Date Balance Sheet, and (ii) the difference between (x) the Agreed Net Equity; and
(y) the Net Shareholder’s Equity set forth in the Closing Date Balance Sheet. “Net Shareholder’s Equity” shall mean the book value of the Company’s tangible Non-Medical Assets plus its accounts receivable (less the Required
Cash) net of all liabilities of the Company. 
  
 3.4 Earnout
Payment. 
  
 (a) General.
Subject to the condition that the Surviving Corporation achieves Formula Period Profits (as defined in Subsection (f) below) of at least One Million Five Hundred Thousand and 00/100 Dollars ($1,500,000) (the “Earnings Threshold”) in each
of the three (3) successive twelve (12) month calendar periods beginning on the first of the first month immediately following the Closing Date unless the Closing occurs on the first day of a month in which case the first 12 month period shall begin
on the Closing Date, (each such twelve (12) month calendar period shall be referred to herein as a “Formula Period”), then PainCare shall pay to the Shareholder a total amount of additional consideration of Three Million Seven Hundred
Fifty Thousand and 00/100 Dollars ($3,750,000) for the Formula Periods, payable in three equal annual installments of One Million Two Hundred Fifty Thousand and 00/100 Dollars ($1,250,000) (the “Intended Installment Payment”) in the form
of consideration and subject to adjustment as provided in Section 3.4(d) below. The Shareholder hereby acknowledges and agrees that the Intended Installment Payments to be made by PainCare, if earned, are expressly subordinate to the rights and
obligations to the Laurus Master Fund, Ltd. (‘Laurus”) as provided in those certain Securities Purchase Agreements, Security Agreements and Pledge Agreements between PainCare and Laurus dated February 27, 2004, and March 22, 2004. Payment
of the Intended Installment Payment is secured by a pledge of Subsidiary’s stock pursuant to a Stock Pledge Agreement (the “PainCare Stock Pledge Agreement”). 
  
 (b) Security and Pledge Agreements. It is hereby acknowledged by the parties that the
Surviving Corporation will likely only achieve the subject Earnings Threshold by virtue of the accrual and payment of that certain Management Fee as defined in that certain Management Services Agreement by and between the PC and the Surviving
Corporation of even date herewith. In order to insure that that such Management Fee is paid as required by the PC, Dr Wright has agreed that certain personal assets will be pledged to secure such payment. To that end, the Surviving Corporation will
enter into with Dr Wright a security and pledge agreement in the form attached hereto as Exhibit 3.4(b) (hereinafter, the “Wright Pledge Agreement”). 
  

 9 

 (c) Installment Payment Discount. Notwithstanding Section 3.4(a) or (b)
above, if the Surviving Corporation fails to achieve the Earnings Threshold in a Formula Period, the amount of the Intended Installment Payment for such Formula Period shall be recalculated to equal the product of the Intended Installment Payment,
multiplied by the Installment Payment Discount (as defined below) (the “Adjusted Installment Payment”). The “Adjusted Installment Payment” shall equal (i) the Formula Period Profits (as defined in Subsection (f) below) for such
Formula Period divided by the Earnings Threshold; multiplied by: (ii) ninety percent (90%) if the Formula Period Profits are $1,200,000 or more but less than the Earnings Threshold; or (iii) seventy-five percent (75%) if the Formula Period Profits
are $900,000 or more but less than $1,200,000; (iv) sixty percent (60%) if the Formula Period Profits are $500,000 or more but less than $900,000, or (v) no Installment Payment if the Formula Period Profits are less than $500,000. 
  
 (d) Installment Payment Premium.
Notwithstanding Section 3.4(b), if (i) the Shareholder receives the Adjusted Installment Payment from PainCare in a Formula Period rather than the Intended Installment Payment as a result of the Formula Period Profits equaling less than the
Earnings Threshold for such Formula Period, and (ii) the Subsidiary’s Formula Period Profits exceed the Earnings Threshold in the Formula Period immediately subsequent to the Formula Period for which the Installment Payment Discount
corresponded, then PainCare shall pay to the Shareholder the Installment Payment Premium (as defined below). The “Installment Payment Premium” shall equal the product of (A) the Formula Period Profits for the Formula Period in which the
Installment Payment Premium is calculated less the Earnings Threshold, multiplied by (B) Seventy-five percent (75%). The Installment Payment Premium shall be paid to the Shareholder in the same percentages, form and time as the Installment Payments
(as defined in Subsection (d) below) are due for the Formula Period for which the Installment Payment Premium is calculated. 
  
 (e) Manner of Payment. Within sixty (60) days after the end of each Formula Period, PainCare or its Affiliate shall prepare
and deliver to Drs. Wright and Alo a financial statement presenting the Formula Period Profits for the Surviving Corporation for the applicable Formula Period (the “Formula Period Profits Statement”). Ten (10) business days after delivery
of the Formula Period Profits Statement, Drs. Wright and Alo shall in a written notice to PainCare either accept or describe in reasonable detail any proposed adjustments to the Formula Period Profits Statement and the reasons therefore, and shall
include pertinent calculations. If Drs. Wright and Alo fails to deliver notice of acceptance or objection to the Formula Period Profits Statement within such ten (10) business day period, the Shareholder shall be deemed to have accepted the Formula
Period Profits Statement. If Drs. Wright and Alo accepts or fails to object to the Formula Period Profits Statement within the ten (10) business day period set forth above, then within ninety (90) days after the end of the Formula Period, PainCare
shall pay to the Shareholder the Intended Installment Payment or the Adjusted Installment Payment (each an “Installment Payment”, and collectively, the “Installment Payments”) along with any Installment Payment Premium owed in
accordance with Subsection (c) above as follows: (i) fifty percent (50%) of the Installment Payment shall be made in cash via wiretransfer to a bank accounts designated by the Shareholder at least ten (10) business days prior to the end of the
Formula Period; and (ii) fifty percent (50%) of the Installment Payment shall be made in PainCare Shares priced at Fair Market Value (as defined below) per one share of PainCare common stock for all Formula Periods. In the event PainCare and Drs.
Wright and Alo 

  

 10 

 
are not able to agree on the Formula Period Profits Statement within thirty (30) days from and after the receipt by PainCare of any objections raised by Drs.
Wright and Alo, PainCare and Drs. Wright and Alo shall each have the right to require that such disputed determinations be submitted to an independent certified public accountant or accounting firm that PainCare shall select, for computation or
verification in accordance with the provisions of this Agreement, and the Installment Payment shall be paid by PainCare to the Shareholder within fifteen (15) days after receipt of the accountant’s computation or verification. The foregoing
provisions for certified public accounting firm review shall be final and binding upon the Parties and there shall be no right of appeal from such decision. All Installment Payments earned will be paid equally to each Shareholder. 
  
 (f) Earnout Cap. Notwithstanding anything to
the contrary in this Section 3, in no event whatsoever shall the aggregate amount of the Installment Payments paid to the Shareholder from PainCare in cash, in PainCare Shares or any other form of consideration exceed Three Million Seven Hundred
Fifty Thousand and 00/100 Dollars ($3,750,000). 
  
 (g) Definitions for Purposes of Section 3. For purposes of Section 3 of this Agreement: 
  
 (i) “Fair Market Value” shall mean the value of the PainCare Shares determined as follows: 
  
 (1) if the principal market for the PainCare Shares is a
national securities exchange, then the “Fair Market Value” of the PainCare Shares shall equal the thirty (30) day trailing average of the closing ask prices of the PainCare Shares as reported by such exchange or on a composite tape
reflecting transactions on such exchange; or 
  
 (2) if the principal market for the PainCare Shares is not a national securities exchange, but the price of the PainCare Shares is quoted on the National Association of Securities Dealers Automated Quotation System (“NASDAQ”)
Stock Market, and (A) actual closing price information is available with respect to the PainCare Shares, then the “Fair Market Value of the PainCare Shares shall equal the thirty (30) day trailing average of the closing ask prices of such stock
on the NASDAQ Stock Market; or (B) actual closing price information is not available with respect to the PainCare Shares, then the “Fair Market Value” of the PainCare Shares shall equal the thirty (30) day trailing average of the
bid prices per share of such stock on the NASDAQ Stock Market; or 
  
 (3) if the principal market for the PainCare Shares is neither a national securities exchange and such stock is not quoted on NASDAQ, then the “Fair Market Value” of the PainCare Shares shall equal the
thirty (30) day trailing average of the closing ask prices of the PainCare Shares as reported by the OTC Bulletin Board Service or by National Quotation Bureau, Incorporated, or a comparable service selected by PainCare; or 
  
 (4) if subsections (f)(i)(1)-(3) above are inapplicable or
if no trades have been made or no quotes are available for such day with respect to the PainCare Shares, then the “Fair Market Value” of the PainCare Shares shall be determined by an independent third party appraiser selected by PainCare.
Within ten (10) days after the effective date of the appraiser’s appointment, the appraiser shall deliver an appraisal of the Fair Market 

  

 11 

 
Value of the PainCare Shares, which shall be binding and conclusive on the Parties. The cost of any appraisal hereunder shall be shared equally by the
Parties, and each Party shall be responsible and financially liable for its or his own attorneys’ fees; and 
  
 (5) with the understanding that notwithstanding the Fair Market Value ascribed to the PainCare Shares pursuant to subsections 3.4(f)(1),
(2), (3) or (4) above in no event shall the Fair Market Value of the PainCare Shares ever be less than Two and 50/00 Dollars ($2.50) per share. 
  
 (ii) “Formula Period Profits” shall mean the Surviving Corporation’s earnings before deductions for interest, taxes,
depreciation and amortization (“EBITDA”) as calculated utilizing GAAP by PainCare’s independent certified public accountants for the applicable Formula Period where possible, and as calculated by PainCare for quarterly and less than
quarterly data for such Formula Period. Notwithstanding the foregoing, the calculation of the Formula Period Profits shall not include any costs or expenses related to: (i) the corporate overhead of PainCare or other administrative or similar
charges that PainCare might impose upon the Subsidiary, except those charges for services provided directly to and for the benefit of the Subsidiary; (ii) any non-recurring charges, losses, profits, gains, or non-cash adjustments not related to the
ongoing operations of the Subsidiary’s business, including but not limited to discontinued operations, extraordinary items, acquisition costs and goodwill charges incurred in connection with the transactions contemplated hereby (excluding the
write-off of any goodwill with respect to the Surviving Corporation in accordance with FASA 142), or unusual or infrequent items as such terms are defined pursuant to generally accepted accounting principles, (iii) any charge related to grants or
exercises of options pursuant to the Independent Contractor Agreement. 
  
 4.
REPRESENTATIONS AND WARRANTIES OF THE SHAREHOLDER. The Shareholder represents and warrants to the Acquiring Companies that the statements contained in this Section 4 are correct and complete as of the date of this Agreement, except as
set forth in the disclosure schedule accompanying this Agreement or any other separate writing referencing this Agreement from the Shareholder or its legal counsel which specifically references the applicable section and describes the excepted item
in sufficient detail (hereinafter, collectively and individually the “Disclosure Schedule”). The Disclosure Schedule will be arranged in paragraphs corresponding to the numbered paragraphs contained in this Section 4 to the Agreement.

  
 4.1 Organization, Qualification, and Corporate
Power. The Company is a corporation duly organized, validly existing, and in good standing under the laws of the State of Colorado. The Company has full power and authority and all licenses, permits and authorizations necessary to carry on
the businesses in which it is currently engaged and to own and use the properties owned and used by it. Section 4.1 of the Disclosure Schedule lists all of the officers and members of the Board of Directors of the Company, as of the date immediately
preceding the Closing Date. The Company has made available to the Acquiring Companies correct and complete copies of the minute book, articles of incorporation and bylaws of the Company, as amended to date. Copies of the minute book (containing the
records of meetings of the stockholders, the board of directors and any committees of the board of directors), the stock certificate books and stock record books of the Company are correct and complete in all material respects and will have been
delivered to PainCare prior to or at the Statutory Merger Time. The 

  

 12 

 
Company is not in default under or in violation of any provision of its articles of incorporation or bylaws. 
  
 4.2 Capitalization. The entire authorized capital stock of the
Company consists of Fifty Thousand (50,000) shares of common stock (the “Shares”), of which two hundred (200) Shares are issued and outstanding. All of the issued and outstanding Company Shares have been duly authorized, are validly
issued, fully paid, and nonassessable and are held of record by the Shareholder. The Shareholder has good title to the Company Shares free and clear of any and all liens, claims, security interests or other encumbrances of any Person. There are no
outstanding or authorized options, warrants, purchase rights, subscription rights, redemption rights, conversion rights, exchange rights, or other contracts or commitments that could require the Company to issue, sell, or otherwise cause to become
outstanding any of its capital stock. There are no outstanding or authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to the Company. There are no stockholders’ agreements, voting trusts, proxies,
or other agreements or understandings with respect to the voting of the capital stock of the Company. 
  
 4.3 Authorization. The Company has full power and authority (including full corporate power and authority) and Drs. Wright and Alo on behalf
of each Shareholder has all necessary authority to execute, bind each Shareholder and deliver this Agreement and to perform its obligations hereunder. The execution, delivery and performance of this Agreement by the Company has been duly authorized
and approved by its board of directors and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement and the transactions contemplated hereby. The Company has given the Shareholder any and all notice
required to be given to the Shareholder under applicable law. This Agreement constitutes the valid and legally binding obligation of the Company and the Shareholder, enforceable in accordance with its terms and conditions. 
  
 4.4 Noncontravention. Except as set forth in Section 4.4 of the
Disclosure Schedule, neither the execution and the delivery of this Agreement by the Company or the Shareholder, nor the consummation of the transactions contemplated hereby will: (a) violate any constitution, statute, regulation, rule, injunction,
judgment, order, decree, ruling, or other restriction of any government, governmental agency or any other third party whatsoever, or court to which the Company or the Shareholder are subject, or any provision of the articles of incorporation or
bylaws of the Company; or (b) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice under any agreement,
contract, lease, license, instrument or other arrangement to which the Company or the Shareholder are a party or by which either the Company or the Shareholder is bound or to which any of the Company’s assets are subject (or result in the
imposition of any Security Interest upon any of its assets). Except as set forth in Section 4.4 of the Disclosure Schedule, the Shareholder and the Company need not give any notice to, make any filing with, or obtain any authorization, consent, or
approval of any government or governmental agency or any other third party whatsoever in order for the Parties to consummate the transactions contemplated by this Agreement. 
  
 4.5 Broker’s Fees. Except as disclosed in Section 4.5 of the Disclosure Schedule, the Shareholder has not
entered into any broker or finder’s agreement for which he, the Company or 

  

 13 

 
PainCare is required to pay any Liability or obligation to pay any fees, expenses, or commissions to any consultant, broker, finder, or agent. 
  
 4.6 Title to Assets. Section 4.6 of the Disclosure Schedule
contains a complete, true and correct list of all of the assets of the Company. Except as to assets disposed of in the ordinary course of business subsequent to the date hereof and as otherwise contemplated by this Agreement, the Company has good
and marketable title to, or a valid leasehold interest in, the properties and assets used by it, located on its premises, or shown on the Closing Date Balance Sheet or acquired after the date thereof, free and clear of all Security Interests. Except
for the Medical Assets which are owned by PC, the assets set forth in Section 4.6, in conjunction with any assets which the Company leases, constitute all of the assets used by the Company in connection with its business as presently conducted and
all assets necessary or appropriate for the continued operation of the Company’s business. 
  
 4.7 No Subsidiaries. The Company has no Subsidiaries and does not control, directly or indirectly, or have any direct or indirect equity
participation in any corporation, partnership, limited liability company, trust or other business association. 
  
 4.8 Financial Statements. Attached as Section 3.3(b) of the Disclosure Schedule are copies of the Financial Statements. Except as provided
in the Interim Financial Statements, or as fully disclosed in Section 4.8 of the Disclosure Schedule, the Company does not have any Liabilities or obligations (whether accrued, absolute, contingent, whether due or to become due or otherwise i.e.,
accounts payable, accrued expenses) which might be or become a charge against the Company since the date of the Interim Financial Statements. The Shareholder acknowledges and agrees that PainCare and Subsidiary have relied upon the representations
of Drs. Wright and Alo that the income of the PC and the Surviving Corporation will substantially increase over the next several years in order to justify the payment of the Transaction Consideration. Drs. Wright and Alo agree to use their best
efforts to maintain and grow such revenue streams for the benefit of the PC, PainCare and the Subsidiary and will take no action or omit to take any action that may otherwise have a material adverse effect on such revenues or otherwise cause such
revenue streams to be diverted to any other entity or individual including the Shareholder. 
  
 4.9 Events Subsequent to Most Recent Year End. Except as disclosed in Section 4.9 of the Disclosure Schedules, since December 31, 2003 (the “Most Recent Year End”), there has not been any
material adverse change in the business, financial condition, operations, results of operations, or future prospects of the PC or the Company. Without limiting the generality of the foregoing, since the Most Recent Year End: 
  
 (a) Sale or Lease of Assets. Neither the PC or
the Company has sold, leased, transferred, or assigned any of its assets, tangible or intangible, other than for fair market value in the ordinary course of its business; 
  
 (b) Contracts. Neither the PC or the Company has entered into any agreement, contract, lease,
or license (or series of related agreements, contracts, leases, and licenses) outside the ordinary course of business; 
  

 14 

 (c) Change in Contracts. No third party (or PC or Company) has accelerated,
terminated, modified, or canceled any agreement, contract, lease, or license (or series of related agreements, contracts, leases, and licenses) to which the Company or PC is a party or by which it is bound and neither the Shareholder, the Company
nor PC has any intent to do any of the foregoing or has received a verbal or written indication of any third party’s intent to do any of the foregoing; 
  
 (d) Security Interests. Neither the PC or the Company has had imposed any Security Interest upon any of its assets, tangible
or intangible; 
  
 (e) Investments.
Neither the PC or the Company has made any capital investment in, any loan to, or any acquisition of the securities or assets of, any other Person (or series of related capital investments, loans, and acquisitions); 
  
 (f) Debts. Neither the PC or the Company has
issued any note, bond, or other debt security or created, incurred, assumed, or guaranteed any indebtedness for borrowed money or capitalized lease obligation; 
  

(g) Liabilities Unaffected. Neither the PC or the Company has delayed or postponed the payment of accounts payable and
other Liabilities or accelerated the collection of accounts, notes or other receivables; 
  
 (h) Claims Unaffected. Neither the PC or the Company has canceled, compromised, waived, or released any right or claim (or
series of related rights and claims) outside the ordinary course of its business; 
  
 (i) Articles and Bylaws. There has been no change made or authorized in the articles of incorporation or bylaws of PC or the
Company; 
  
 (j) Changes in Equity.
Neither the PC or the Company has issued, sold, or otherwise disposed of any of its capital stock, or granted any options, warrants, or other rights to purchase or obtain (including upon conversion, exchange, or exercise) any of its capital stock;

  
 (k) Distribution. Except for
distributions of subchapter S income as permitted by Section 9.3 below, neither the Company or PC has declared, set aside, or paid any dividend or made any distribution with respect to its capital stock (whether in cash or in kind) or redeemed,
purchased, or otherwise acquired any of its capital stock; 
  
 (l) Property Damage. Neither the PC or the Company has experienced any damage, destruction, or loss (whether or not covered by insurance) to its property or assets; 
  
 (m) Transactions with Affiliates. Neither the
PC or the Company has made any loan to, or entered into any other transaction with, any of its directors, officers and employees; 
  
 (n) Collective Bargaining Agreements. Neither the PC or the Company has entered into any collective bargaining agreement,
written or oral, or modified the terms of any existing such contract or agreement; 
  

 15 

 (o) Compensation Changes. Neither the PC or the Company has granted any
increase in the base compensation of any of its directors, officers, and employees; 
  
 (p) Employee Benefit Plans. Neither the PC or the Company has adopted, amended, modified, or terminated any bonus,
profit-sharing, incentive, severance, or other plan, contract, or commitment for the benefit of any of its directors, officers, and employees (or taken any such action with respect to any other Employee Benefit Plan); 
  
 (q) Officers; Directors; Employees. Neither
the PC or the Company has made any change in the employment terms for any of its directors, officers and employees, other than to terminate such agreements as required herein; 
  
 (r) Charitable or Capital Contributions. Neither the PC or the Company has made or pledged to
make any charitable or other capital contribution; 
  
 (s) Ordinary Course of Business. There has not been any other occurrence, event, incident, action, failure to act, or transaction outside the ordinary course of business involving PC or the Company; 
  
 (t) Accounting Practices. There has not been
any change in any method of accounting or accounting principle, estimate or practice of PC or the Company; 
  
 (u) Accounts Receivable. Neither the PC or the Company has accelerated the collection of any Accounts Receivable or any
other amounts owed to it; and 
  
 (v) In
General. Neither the Company, PC nor the Shareholder has committed to do any of the foregoing. 
  
 4.10 Undisclosed Liabilities. Neither the Company or the PC has any Liability and there is no basis for any present or future action, suit,
proceeding, hearing, investigation, complaint, claim, or demand against it giving rise to any Liability, except for: (a) Liabilities disclosed in the Disclosures Schedule; (b) contractual obligations incurred in the ordinary course of business; and
(d) Liabilities which have arisen after the Interim Balance Sheet in the ordinary course of business (none of which results from, arises out of, relates to, is in the nature of, or was caused by any breach of contract, breach of warranty, tort,
infringement, or violation of law). As of the Closing, other than the current trade accounts payable, leasehold obligations and accrued payroll and benefit obligations, neither the Company or the PC shall not have any unpaid liabilities, other than
those listed in the Section 4.10 Disclosure Schedule, including, but not limited to, any bank debt, capital leases or any general or professional liability claims, or be obliged in any other way to provide funds in respect of, or to guarantee or
assume, any debt, obligation or dividend of any person, except endorsements in the ordinary course of business in connection with the deposit, in banks or other financial institutions, of items for collection. 
  
 4.11 Tax Matters. 
  
 (a) Tax Returns. Except as set forth in
Disclosure Schedule 4.11, the Company has filed all Tax Returns it was required to file. All such Tax Returns were correct and complete in all respects and were filed on a timely basis. All Taxes owed by the Company 

  

 16 

 
(whether or not shown on any Tax Return) have been paid. The Company currently is not the beneficiary of any extension of time within which to file any Tax
Return. No claim is currently pending by an authority in a jurisdiction where the Company is or may be subject to taxation by that jurisdiction. There are no Security Interests on any of the assets of the Company or the PC that arose in connection
with any failure (or alleged failure) to pay any Tax. 
  
 (b) Withholding. The Company has withheld, and remitted when due, all Taxes required to have been withheld or paid in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or
other third party. 
  
 (c) No Disputes of
Claims. No Shareholder or director or officer (or employee responsible for Tax matters) of the Company or the PC expects any authority to assess any additional Taxes for any period for which Tax Returns have been filed. There is no dispute
or claim concerning any Tax Liability of the Company or the PC either: (a) claimed or raised by any authority in writing; or (b) as to which any Shareholder, directors and officers (and employees responsible for Tax matters) of the Company or the PC
has Knowledge based upon personal contact with any agent of such authority. Section 4.11 of the Disclosure Schedule lists all federal, state, local, and foreign income Tax Returns filed with respect to the Company for taxable periods ended on or
after December 31, 2003, indicates those Tax Returns that have been audited, and indicates those Tax Returns that currently are the subject of audit. The Shareholder has made available to PainCare correct and complete copies of all federal income
Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by any of the Company and its Affiliates since December 31, 2003. 
  
 (d) No Waivers. The Company has not waived any statute of limitations in respect of Taxes or
agreed to any extension of time with respect to a Tax assessment or deficiency. 
  
 (e) No Special Circumstances. The Company has not made any payments, is not obligated to make any payments, nor is a party
to any agreement that under certain circumstances could obligate it to make any payments that will not be deductible under Code Section 280G. PC has not been a United States real property holding corporation within the meaning of Code Section
897(c)(2) during the applicable period specified in Code Section 897(c)(1)(A)(ii). PC has disclosed on its federal income Tax Returns all positions taken therein that could give rise to a substantial understatement of federal income Tax within the
meaning of Code Section 6662. 
  
 (f)
Subchapter “S”. The Company has elected, by the unanimous consent of its shareholders and in compliance with all applicable legal requirements, to be taxed under Subchapter “S” of the Code and corresponding
provisions under any applicable state and local laws, and such elections are currently in full force and effect for the Company. No action has been taken by the Company or the Shareholder that may result in the revocation of any such elections. The
Company has no “Subchapter C earnings and profits,” as defined in Code Section 1362(d). The Company has no “net unrealized built-in gain,” as such term is defined in Code Sections 1374(d)(1) and 1374(d)(8). The Company has no
Liability, absolute or contingent, for the payment of any income Taxes under the Code or under Subchapter “S” of the Code. 
  

 17 

 (g) Audits of Tax Returns. No Tax Return of the Company is currently under
audit or examination by any taxing authority, and neither the Shareholder nor the Company has received a written notice stating the intention of any taxing authority to conduct such an audit or examination. Each deficiency resulting from any audit
or examination relating to Taxes by any taxing authority has been paid, except for deficiencies being contested in good faith. The revenue agents’ reports related to any prior audits and examinations are attached as part of Section 4.11 of the
Disclosure Schedule. 
  
 (h) Period of
Assessment. There is no agreement or other document extending, or having the effect of extending, the period of assessment or collection of any Taxes. 
  

(i) Tax Agreements. The Company is not a party to or bound by any tax sharing agreement, tax indemnity obligation or
similar agreement with respect to Taxes, including any advance pricing agreement, closing agreement or other agreement relating to Taxes with any taxing authority. 
  
 (j) Intentionally Omitted. 
  
 (k) Consents. The Company has not filed a consent pursuant to or agreed to the application of
Code Section 341(f). 
  
 (l) Personal
Holding Company. The Company has not, during the five (5) year period ending on the Closing Date, been a personal holding company within the meaning of Code Section 541. 
  
 (m) Consolidated Tax Returns. The Company has never filed or been included in any combined or
consolidated Tax Return with any other person or been a member of an Affiliated Group filing a consolidated federal income Tax Return. 
  
 4.12 Real Property. The Company does not own any real property. Section 4.12 of the Disclosure Schedule lists and describes briefly all real
property leased or subleased by PC. The Shareholder has made available to PainCare and Subsidiary correct and complete copies of the leases and subleases listed in Section 4.12 of the Disclosure Schedule (as amended to date). With respect to each
lease and sublease listed in Section 4.12 of the Disclosure Schedule: 
  
 (a) Binding. The lease or sublease is legal, valid, binding, enforceable, and in full force and effect; 
  
 (b) Continued Validity. The lease or sublease will continue to be legal, valid, binding, enforceable, and in full force and
effect on identical terms following the consummation of the transactions contemplated hereby; 
  
 (c) No Defaults. The Company is not in breach or default under the lease or sublease and no third party is in breach or
default under the lease or sublease, and no event has occurred which, with notice or lapse of time, would constitute a breach or default or permit termination, modification or acceleration thereunder; 
  

 18 

 (d) Repudiation. Neither the Company nor any other party to the lease has
repudiated any provision of the lease or sublease; 
  
 (e) No Disputes. There are no disputes, oral agreements, or forbearance programs in effect as to the lease or sublease; 
  
 (f) Subleases. With respect to each sublease, the representations and warranties set forth in subsections 4.12(a) through
4.12(e) above are to Shareholder’s Knowledge true and correct with respect to the underlying lease; 
  
 (g) Encumbrances. None of the Company or its Affiliates has assigned, transferred, conveyed, mortgaged, deeded in trust, or
encumbered any interest in the leasehold or subleasehold; 
  
 (h) Approvals. All facilities leased or subleased thereunder have received all approvals of governmental authorities (including licenses and permits) required in connection with the operation thereof and
have been operated and maintained in accordance with applicable laws, rules, and regulations; and 
  
 (i) Utilities. All facilities leased or subleased thereunder are supplied with utilities and other services reasonably
necessary for the operation of said facilities. 
  
 4.13
Intellectual Property. The Company and the PC own or has the right to use pursuant to a valid license, sublicense, agreement, or permission all Intellectual Property necessary or desirable for the operation of the businesses of the
Company and the PC as presently conducted and as presently proposed to be conducted. No claim or demand of any Person has been made, nor is there any proceeding that is pending, or to the Shareholder’s Knowledge, threatened, which challenges
the rights of the Company or the PC with respect to any Intellectual Property or asserts that the Company or the PC is infringing or otherwise in conflict with or is required to pay any royalty or license fee with respect to any Intellectual
Property. 
  
 4.14 Condition of Tangible Assets.
Each tangible asset of the Company and the PC are free from defects (patent and latent), has been maintained in accordance with normal industry practice, is in good operating condition and repair (subject to normal wear and tear), and is suitable,
designed and intended for the purposes for which it presently is used by Drs. Wright and Alo, the PC and the Company and is not outdated in comparison with the assets used for similar purposes by similar businesses. 
  
 4.15 Contracts. Section 4.15 of the Disclosure Schedule lists
the following contracts and other agreements, written or oral, to which the Company and the PC was a party immediately preceding the Closing: 
  
 (a) Personal Property Leases. Any agreement (or group of related agreements) for the lease of personal property to or from
any Person providing for lease payments; 
  

 19 

 (b) Services. Any agreement (or group of related agreements) for the
furnishing or receipt of services, the performance of which will extend over a period of more than one (1) year; 
  
 (c) Partnership; Joint Venture. Any agreement constituting a partnership or joint venture; 
  
 (d) Indebtedness. Any agreement (or group of
related agreements) under which it has created, incurred, assumed, or guaranteed any indebtedness for borrowed money, or any capitalized lease obligation; 
  
 (e) Confidentiality; Non-Competition. Any agreement concerning confidentiality or non-competition; 
  
 (f) Shareholders’ Agreements. Any
agreement by and between the Shareholder and any Affiliate of the Company; 
  
 (g) Plans. Any profit sharing, stock option, stock purchase, stock appreciation, deferred compensation, severance, or other plan or arrangement for the benefit of its current or former directors,
officers, and employees; 
  
 (h) Employment
or Consulting Agreements. Any agreement for the employment of any individual on a full-time or part-time or the engagement of any individual as a consultant or independent contractor, or otherwise compensating an individual for services
rendered or to be rendered to the Company; 
  
 (i) Advances; Loans. Any agreement under which the Company has advanced or loaned any amount to any of its directors, officers and employees outside the ordinary course of business; 
  
 (j) Adverse Effects. Any agreement under which
the consequences of a default or termination could have a material adverse effect on the business, financial condition, operations, results of operations or future prospects of the Company; and 
  
 (k) Other Agreements. Any other agreement (or
group of related agreements) the performance or rendering of which involves consideration in excess of Five Thousand and No/100 Dollars ($5,000.00). 
  
 The Shareholder has made available to PainCare and Subsidiary a correct and complete copy of each written agreement listed in Section 4.15 of the
Disclosure Schedule (as amended to date) and a written summary setting forth the terms and conditions of each oral agreement referred to in Section 4.15 of the Disclosure Schedule. With respect to each such agreement: (i) the agreement is
legal, valid, binding, enforceable, and in full force and effect; (ii) there shall be no breach or other violation resulting from the consummation of the transactions contemplated hereby; (iii) the Company is not in default or breach and no other
party is in breach or default, and no event has occurred which with notice or lapse of time would constitute a breach or default, or permit termination, modification, or acceleration, under the agreement; and (iv) neither the Company nor any other
party has repudiated any provision of the agreement. None of the 

  

 20 

 
agreements listed in Section 4.15 of the Disclosure Schedule requires the consent or approval of any Person, or any compensation or payment to be made
to any such Person by reason of the transactions contemplated by this Agreement, or the merger of the Company with and into another Person. 
  
 4.16 Powers of Attorney. Except as set forth in Section 4.16 of the Disclosure Schedule, there are no outstanding powers of attorney
executed on behalf of the Company or the PC. 
  
 4.17
Insurance; Malpractice. Section 4.17 of the Disclosure Schedule contains a list and brief description of all policies or binders of fire, liability, product liability, workers compensation, health and other forms of insurance policies
or binders currently in force insuring against risks to which the Company and PC has been a party, a named insured or otherwise the beneficiary of coverage at any time during the five (5) years immediately preceding the Closing Date. Section 4.17 of
the Disclosure Schedule contains a description of all current malpractice liability insurance policies of Drs. Wright and Alo, the Company, PC and PC’s professional employees and all predecessor policies in effect. Except as set forth on
Section 4.17 of the Disclosure Schedule: (a) neither the Company, PC, or its professional employees, nor Drs. Wright and Alo has, during the five (5) years immediately preceding the Closing Date, filed a written application for any insurance
coverage relating to PC’s business or property which has been denied by an insurance agency or carrier; and (b) the Company, PC, PC’s professional employees and Drs. Wright and Alo has been continuously insured for professional malpractice
claims during the same period. Section 4.17 of the Disclosure Schedule also sets forth a list of all claims for any insured loss in excess of Five Thousand and 00/100 Dollars ($5,000) per occurrence filed by the Company, PC, PC’s professional
employees or Drs. Wright and Alo during the five (5) years immediately preceding the Closing Date, including workers compensation, general liability, environmental liability and professional malpractice liability claims. With respect to each
insurance policy listed in Section 4.17 of the Disclosure Schedule: (i) the policy is legal, valid, binding, enforceable, and in full force and effect; (ii) the policy will continue to be legal, valid, binding, enforceable, and in full force and
effect on identical terms following the consummation of the transactions contemplated hereby; (iii) neither the Company, PC, Drs. Wright or Alo, other health care professionals nor any other party to the policy is in breach or default (including
with respect to the payment of premiums or the giving of notices), and no event has occurred which, with notice or the lapse of time, would constitute such a breach or default, or permit termination, modification, or acceleration, under the policy;
(iv) neither the Company, PC, or Drs. Wright or Alo have repudiated any provision thereof and no other party to the policy has repudiated any provision thereof; (v) there is no claim pending under any of such policies as to which coverage has been
questioned, denied or disputed by the underwriter(s) of such policies or any notice that a defense will be afforded with reservation of rights; (vi) neither the Company, PC, or Drs. Wright or Alo have not received: (A) any notice that any issuer of
any such policy has filed for protection under applicable bankruptcy laws or is otherwise in the process of liquidating or has been liquidated; or (B) any other indication that such policies are no longer in full force and effect or that the issuer
of any such policy is no longer willing or able to perform its obligations thereunder; and (vii) neither Drs. Wright or Alo nor PC or the Company has received any written notice from or on behalf of any insurance carrier issuing such policies, that
there will hereafter be a cancellation, or an increase in a deductible or non-renewal of existing policies. The Company and PC have been covered during the past five (5) years by 

  

 21 

 
insurance in scope and amount customary and reasonable for the business in which it has engaged during the aforementioned period. 
  
 4.18 Litigation. Except as noted in Section 4.18 of the
Disclosure Schedule, there is no litigation, arbitration, governmental claim, investigation or proceeding, pending or, to Shareholder’s Knowledge, threatened, against the Company, PC, or Drs. Wright or Alo at law or in equity, before any court,
arbitration tribunal or governmental agency. Each of the Sellers has no knowledge of any facts on which claims may hereafter be made against the Company or PC that will have a Material Adverse Effect on the Company or the PC. All medical malpractice
claims, general liability incidents and incident reports relating to the Business have been submitted to the Company’s or PC’s insurer. All claims made or, to Shareholder’s Knowledge, threatened against the Company or PC or Drs.
Wright or Alo in excess of the deductible are covered under Dr. Wright’s, Dr. Alo’s or PC’s or the Company’s current insurance policies. Section 4.18 of the Disclosure Schedule provides a complete list of all general liability
incidents, incident reports and malpractice claims relating to the Business or the Center that have for the five (5) year period prior to the date hereof. 
  
 4.19 Health Care Compliance. PC is (and the Company was) participating or otherwise authorized to receive reimbursement from Medicare and
Medicaid and is a party to other third-party payor agreements set forth in Section 4.19 of the Disclosure Schedule. All necessary certifications and contracts required for participation in such programs are in full force and effect and have not been
amended or otherwise modified, rescinded, revoked or assigned, and no condition exists or event has occurred which in itself or with the giving of notice or the lapse of time or both would result in the suspension, revocation, impairment, forfeiture
or non-renewal of any such third-party payor program. The Company and PC is in compliance in all material respects with the requirements of all such third-party payors applicable thereto. None of the Company, PC, its physician employees, the
Shareholder, or immediate family members of the Shareholder or other physician employees, have any financial relationship (whether investment interest, compensation interest, or otherwise) with any entity to which any of the foregoing refer
patients, except for such financial relationships that qualify for exceptions to state and federal laws restricting physician referrals to entities in which they have a financial interest. 
  
 4.20 Fraud and Abuse. The Company, PC, Drs. Wright and Alo, and
all persons and entities providing professional services for PC have not engaged in any activities which are prohibited under 42 U.S.C. § 1320a-7b, or the regulations promulgated thereunder pursuant to such statutes, or related state or local
statutes or regulations, or which are prohibited by rules of professional conduct, including the following: (a) knowingly and willfully making or causing to be made a false statement or representation of a material fact in any application for any
benefit or payment; (b) knowingly and willfully making or causing to be made any false statement or representation of a material fact for use in determining rights to any benefit or payment; (c) failing to disclose Knowledge by a claimant of the
occurrence of any event affecting the initial or continued right to any benefit or payment on its own behalf or on behalf of another, with intent to fraudulently secure such benefit or payment; and (d) knowingly and willfully soliciting or receiving
any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind or offering to pay or receive such remuneration: (A) in return for referring an individual to a person for the furnishing or
arranging for the furnishing of any item or service for which payment may be made in whole or in part by Medicare or Medicaid; or (B) in return for purchasing, leasing, or ordering or arranging for or recommending 

  

 22 

 
purchasing, leasing, or ordering any good, facility, service or item for which payment may be made in whole or in part by Medicare or Medicaid. PC has at all
times complied with the requirements of Colorado Statutes which prohibit physicians who have an ownership, investment or beneficial interest in certain health care facilities from referring patients to such facilities for the provisions of
designated and other health services, and has at all times complied with the Colorado Statutes. Furthermore, the Company and PC has filed all reports required to be filed by the State of Colorado and federal law regarding compensation arrangements
and financial relationships between a physician and an entity to which the physician refers patients. 
  
 4.21 Legal Compliance. The Company, PC and its predecessors and Affiliates have complied with all applicable Laws (including rules,
regulations, codes, injunctions, judgments, orders, decrees, and rulings of federal, state, local, and foreign governments (and all agencies thereof)), and no action, suit, proceeding, hearing, complaint, claim, demand, notice or investigation has
been filed or commenced, or to the Knowledge of the Shareholder, the Company and PC, threatened against the Company or PC alleging any failure so to comply. PC and all physicians and other health care professionals engaged or employed by PC (or
associated with PC as a result of being engaged or employed by the Company or PC) have all permits and licenses required by applicable Law, have made all required regulatory filings and are not in violation of any such permit or license. The Company
and PC are lawfully operated in accordance with the requirements of all applicable Laws and have in full force and effect all authorizations and permits necessary to operate a medical practice saving those owned by the PC. There are no outstanding
notices of deficiencies relating to the Company or PC issued by any governmental authority or third-party payor requiring conformity or compliance with any applicable law or condition for participation with such governmental authority or third-party
condition for participation with such governmental authority or third-party payor. Neither the Company or PC have not received notice and PC and Shareholder has no knowledge or reason to believe that, such necessary authorizations may be revoked or
not renewed in the ordinary course of business. 
  
 4.22
Rates and Reimbursement Policies. The jurisdiction in which PC is located does not currently impose any restrictions or limitations on rates which may be charged to private pay patients receiving services provided by PC except for
restrictions promulgated by Colorado law and regulation on charging of excessive fees and limitations on charges for and profits from the sale of medications, goods and devices and free samples. Neither the Company nor PC has any rate appeal
currently pending before any governmental authority or any administrator of any third-party payor program. PC and the Shareholder have no Knowledge of any applicable Law, which affects rates or reimbursement procedures which has been enacted,
promulgated or issued within the eighteen (18) months preceding the date of this Agreement or any such legal requirement proposed or currently pending in the State of Colorado which could have a Material Adverse Effect on the Company, PC, their
business or operations, or may result in the imposition of additional Medicaid, Medicare, charity, free care, welfare, or other discounted or government assisted patients at PC or require PC to obtain any necessary authorization which PC does not
currently possess. Neither PC nor the Shareholder have Knowledge of any impending proposed reduction in reimbursement from third party or other payors nor Knowledge of any threatened termination of payor contracts. 
  
 4.23 Medical Staff. Except as set forth on Section 4.23 of the
Disclosure Schedule, the Shareholder has no Knowledge of a physician who is providing services on behalf of the PC 

  

 23 

 
who plans, or has threatened to terminate his or her employment or other relationship with the Company. None of the physicians providing services on behalf
of the PC (or formerly for the Company) currently have plans to retire from the practice of medicine in the next three (3) years. 
  
 4.24 Employees. Except as set forth on Section 4.24 of the Disclosure Schedule: (a) there is no unfair labor practice charge or complaint
pending or threatened relating to the business of the Company or PC; and (b) payment in full to all of the employees of the Company and PC of all wages, salaries, commissions, bonuses, benefits, and other compensation lawfully due and owing to such
employees or otherwise arising under any policy, practice, agreement, plan, program, statute, or other law as of the Closing Date has been made. 
  
 4.25 Employee Benefits. 
  
 (a) Plans. Section 4.25 of the Disclosure Schedule lists each Employee Benefit or health and welfare plan that PC or the
Company maintains or to which the Company or PC contributes. 
  
 (b) Compliance. Each such Employee Benefit Plan (and each related trust, insurance contract, or fund) complies in form and in operation in all material respects with its terms and with the applicable
requirements of ERISA, the Code and other applicable laws. 
  
 (c) Reports and Descriptions. All required reports and descriptions (including Form 5500 Annual Reports, Summary Annual Reports, PBGC-1’s, and Summary Plan Descriptions) have been filed or
distributed appropriately with respect to each such Employee Benefit Plan. The requirements of Part 6 of Subtitle B of Title I of ERISA and of Code Section 4980B have been met with respect to each such Employee Benefit Plan which is an Employee
Welfare Benefit Plan. 
  
 (d)
Contributions. All contributions (including all employer contributions and employee salary reduction contributions) which are due have been paid to each such Employee Benefit Plan which is an Employee Pension Benefit Plan and all
contributions for any pay period ending on or before the Closing Date which are not yet due have been paid to each such Employee Pension Benefit Plan or accrued in accordance with the past custom and practice of the Company and PC. All premiums or
other payments due for all periods ending on or before the Closing Date have been paid with respect to each such Employee Benefit Plan which is an Employee Welfare Benefit Plan. 
  
 (e) Qualified Plan. Each such Employee Benefit Plan which is an Employee Pension Benefit Plan
and is intended to meet the requirements of a “qualified plan” under Code Section 401(a) meets such requirements and has received, within the last two (2) years, a favorable determination letter from the IRS. 
  
 (f) Market Value. The market value of assets
under each such Employee Benefit Plan which is an Employee Pension Benefit Plan (other than any Multiemployer Plan) equals or exceeds the present value of all vested and nonvested Liabilities thereunder determined in accordance with PBGC methods,
factors, and assumptions applicable to an Employee Pension Benefit Plan terminating on the date for determination. 
  

 24 

 (g) Copies. The Shareholder has delivered to PainCare and Subsidiary
correct and complete copies of the plan documents and summary plan descriptions, the most recent determination letter received from the IRS, the most recent Form 5500 Annual Report, and all related trust agreements, insurance contracts, and other
funding agreements which implement each such Employee Benefit Plan. 
  
 (h) Maintenance of Plans. With respect to each Employee Benefit Plan that PC maintains, ever has maintained, or to which it contributes, ever has contributed, or ever has been required to contribute:

  
 (i) Reportable Events. No such
Employee Benefit Plan which is an Employee Pension Benefit Plan has been completely or partially terminated or been the subject of a Reportable Event as to which notices would be required to be filed with the PBGC. No proceeding by the PBGC to
terminate any such Employee Pension Benefit Plan has been instituted or threatened; and 
  
 (ii) Prohibited Transactions. There have been no Prohibited Transactions with respect to any such Employee Benefit Plan. No
Fiduciary has any Liability for breach of fiduciary duty or any other failure to act or comply in connection with the administration or investment of the assets of any such Employee Benefit Plan. No action, suit, proceeding, hearing, or
investigation with respect to the administration or the investment of the assets of any such Employee Benefit Plan (other than any Multiemployer Plan), other than routine claims for benefits, is pending or threatened. The Shareholder, the Company
and PC have no Knowledge of any basis for any such action, suit, proceeding, hearing, or investigation. 
  
 4.26 Physicians and Other Providers. During the five (5) years preceding the Closing Date, each physician, and other health care provider
who is or was employed by, or who renders or has rendered services on behalf of, the PC or the Company: 
  
 (a) Licenses. Has been duly licensed and registered, and in good standing by the State of Colorado to engage in the practice
of medicine, and said license and registration have not been suspended, revoked or restricted in any manner; 
  
 (b) Controlled Substances. Has current controlled substances registrations issued by the State of Colorado and the U.S. Drug
Enforcement Administration, which registrations have not been surrendered, suspended, revoked or restricted in any manner; 
  
 (c) Actions. Except as set forth on Section 4.26 of the Disclosure Schedule, has not been a party or subject to: 

 
 (i) Malpractice Actions. Any malpractice
suit, claim (whether or not filed in court), settlement, settlement allocation, judgment, verdict or decree; 
  
 (ii) Disciplinary Proceedings. Any disciplinary, peer review or professional review investigation, proceeding or action
instituted by any licensure board, hospital, medical school, physical therapy school, health care facility or entity, professional society or association, third party payor, peer review or professional review committee or body, or governmental
agency; 
  

 25 

 (iii) Criminal Proceedings. Any criminal complaint, indictment or criminal
proceedings; 
  
 (iv)
Investigation. Any investigation or proceedings, whether administrative, civil or criminal, relating to an allegation of filing false health care claims, violating anti-kickback or fee-splitting laws, or engaging in other billing
improprieties; 
  
 (v) Mental
Illnesses. Any organic or mental illness or condition that impairs or may impair such physician’s ability to practice; 
  
 (vi) Substance Abuse. Any dependency on, habitual use or episodic abuse of alcohol or controlled substances, or any
participation in any alcohol or controlled substance detoxification, treatment, recovery, rehabilitation, counseling, screening or monitoring program; 
  
 (vii) Professional Ethics. Any allegation, or any investigation or proceeding based on any allegation of violating
professional ethics or standards, or engaging in illegal, immoral or other misconduct (of any nature or degree), relating to his or her practice; or 
  
 (viii) Application for Licensure. Any denial or withdrawal of an application in any state for licensure as a physician or
physical therapist, for medical staff privileges at any hospital or other health care entity, for board certification or recertification, for participation in any third party payment program, for state or federal controlled substances registration,
or for malpractice insurance. 
  
 4.27 Guaranties.
Saving the guaranties listed in Section 4.27 of the Disclosure Schedule, the Company nor PC is not a guarantor or otherwise liable for any Liability or obligation (including indebtedness) of any other Person. 
  
 4.28 Environment, Health, and Safety. 
  
 (a) Compliance. Each of the Company, PC and
its predecessors and Affiliates has complied and is in material compliance with all Environmental, Health, and Safety Requirements. 
  
 (b) Permits and Licenses. Without limiting the generality of the foregoing, each of the Company, PC and its Affiliates has
obtained and complied in all material respects with, and is in compliance in all material respects with, all permits, licenses and other authorizations that are required pursuant to Environmental, Health, and Safety Requirements for the occupation
of its facilities and the operation of its business; a list of all such permits, licenses and other authorizations is set forth on Section 4.28 of the Disclosure Schedule. 
  
 (c) Notices. None of the Company, PC nor its predecessors or Affiliates has received any
written or oral notice, report or other information regarding any actual or alleged violation of Environmental, Health, and Safety Requirements, or any Liabilities or potential Liabilities (whether accrued, absolute, contingent, unliquidated or
otherwise), including any investigatory, remedial or corrective obligations, relating to any of them or its facilities arising under Environmental, Health, and Safety Requirements. 
  

 26 

 (d) Hazardous Substances. None of the Company, PC or its predecessors or
Affiliates has treated, stored, disposed of, arranged for or permitted the disposal of, transported, handled, or released any substance, including without limitation any hazardous substance, or owned or operated any property or facility (and no such
property or facility is contaminated by any such substance) in a manner that has given or would give rise to liabilities, including any Liability for response costs, corrective action costs, personal injury, property damage, natural resources
damages or attorney fees, pursuant to the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended, the Solid Waste Disposal Act, as amended or any other Environmental, Health, and Safety Requirements. 
  
 (e) Neither the Company nor PC has not received any
communication (written or oral), whether from a governmental authority, citizens’ group, employee or otherwise, that alleges that the Business or PC is not in full compliance with Environmental Laws, or that PC is otherwise subject to liability
under Environmental Laws, and to the Shareholder’s Knowledge, there are no circumstances that may prevent or interfere with such full compliance in the future. There is no Environmental Claim (as defined below) pending or, to the
Shareholder’s Knowledge, threatened against the Company, PC, the Business or the Center. 
  
 (f) The Shareholder has no Knowledge of any actions, activities, circumstances, conditions, events or incidents, including, but not
limited to, the release, emission, discharge, presence or disposal of any Hazardous Substances that could form the basis of any Environmental Claim against the Company, PC, the Business or the Center, or Sellers in connection with the Business or
the Center. 
  
 4.29 Certain Business Relationships with PC
and its Affiliates. Except as contemplated hereby with respect to the Company and the PC, neither the Shareholder nor any of his Affiliates have been involved in any business arrangement or relationship with PC and its Affiliates within the
past twelve (12) months, and none of the Shareholder and his Affiliates owns any asset, tangible or intangible, which is material to the business of any of the Company, PC and its Affiliates. 
  
 4.30 Third-party Payors. Section 4.30 of the Disclosure
Schedule sets forth an accurate, correct and complete list of PC’s third-party payors. Neither the Company, PC nor the Shareholder has received any notice nor has any Knowledge that any third-party payor intends to terminate or materially
reduce its business with, or reimbursement to, the Company or PC. Neither the Shareholder, the Company or PC has any reason to believe that any third-party payor will cease to do business with the Company and PC after, or as a result of, the
consummation of any transactions contemplated hereby. Neither the Shareholder, the Company nor PC knows of any fact, condition or event which would adversely affect its relationship with any third-party payor. 
  
 4.31 Bank Accounts. Section 4.31 of the Disclosure Schedule
sets forth all of the bank and security accounts and all safe deposit boxes maintained by the Company and the PC and all lines of credit owned or used by the Company or the PC, and the names of all persons with authority to withdraw funds from, or
execute drafts or checks on, each such account. 
  
 4.32 Tax
Status. The Shareholder is not a “nonresident alien individual” or “foreign corporation” for purposes of Code Section 897(a)(1). 
  

 27 

 4.33 Binding Obligation. This Agreement constitutes the valid and legally binding
obligation of the Shareholder, enforceable in accordance with its terms and conditions. 
  
 4.34 No Corporate Practice or Fee Splitting. The Shareholder does not have any Knowledge that the actions, transactions or relationships arising from, and contemplated by, the Transaction violate any
law, rule or regulation relating to the corporate practice of medicine or fee splitting. The Shareholder accordingly agrees that he will not and will not cause any other Party, in an attempt to void or nullify this Agreement or any document related
to the Transaction or any relationship involving PainCare or Subsidiary to sue, claim, aver, allege or assert that any such document or any such relationship violates any law, rule or regulation relating to the corporate practice of medicine or fee
splitting. 
  
 4.35 Intentions. Drs. Wright and Alo
intend to continue managing the business operations of the PC on an as needed basis for the next three (3) years and does not know of any fact or condition that adversely affects, or in the future may adversely effect, his ability or intention to
manage the business of the PC on an as needed basis for the next three (3) years. 
  
 4.36 Securities Representation. 
  
 (a) No Registration of PainCare Shares; Investment Intent. The Shareholder acknowledges that the PainCare Shares to be delivered pursuant to this Agreement have not been and will not be registered under
the Securities Act and may not be resold without compliance with the Securities Act. The PainCare Shares to be acquired by the Shareholder pursuant to this Agreement are being acquired solely for his own account, for investment purposes only and
with no present intention of distributing, selling or otherwise disposing of them in connection with a distribution other than in compliance with the Securities Act. 
  
 (b) Resale Restrictions. The Shareholder covenants, warrants and represents that none of the
PainCare Shares issued to Shareholder will be offered, sold, assigned, pledged, hypothecated, transferred or otherwise disposed of except after full compliance with all of the applicable provisions of the Securities Act and the rules of regulations
of the Commission and applicable state securities laws, and this Agreement. 
  
 (c) Ability to Bear Economic Risk. The Shareholder covenants, warrants and represents that he is able to bear the economic risk of an investment in PainCare Shares acquired pursuant to this Agreement and
can afford to sustain a total loss of such investment and has such Knowledge and experience in financial and business matters that he is capable of evaluating the merits and risks of the proposed investment and therefore has the capacity to protect
his own interests in connection with the acquisition of the PainCare Shares. The Shareholder, and the Shareholder’s purchaser representative, if any, have received copies of PainCare’s most recent 10-KSB, 10-QSB and 8-K filings and have
had an adequate opportunity to ask questions and receive answers from the officers of PainCare concerning any and all matters relating to the background and experience of the officers and directors of PainCare, the plans for the operations of the
business of PainCare, and any plans for additional acquisitions and the like. The Shareholder, and the Shareholder’s purchaser representative, if any, have asked any and all questions in the nature described in the preceding sentence and all
questions have been answered to such individual’s satisfaction. 
  

 28 

 (d) Accredited Investor. Each Shareholder covenants, represents and
warrants that he is an: (a) individual with a net worth (either individually or jointly with his respective spouse) in excess of One Million and No/100 Dollars ($1,000,000.00); or (b) individual who had an income in excess of Two Hundred Thousand
and No/100 Dollars ($200,000.00) in each of 2002 and 2003, or had a joint income with his spouse in excess of Three Hundred Thousand and No/100 Dollars ($300,000.00) in each of 2002 and 2003, and has a reasonable expectation of reaching the same
income level in 2004. 
  
 (e) No
Registration. The Shareholder understands, agrees and acknowledges that the PainCare Shares have not been registered under the Colorado Securities Act or the Securities Act in reliance upon exemption provisions contained therein which
PainCare believes are available. 
  
 4.37 HIPAA.
Schedule 4.37 lists and describes all plans and other efforts of Drs. Wright and Alo with respect to the practice locations to comply with the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), including the final
regulations promulgated thereunder, whether such plans and efforts have been put in place or are in process. Schedule 4.37 includes but is not limited in any manner whatsoever to any privacy compliance plan of Sellers in place or in development, and
any plans, analyses or budgets relating to information systems including but not limited to necessary purchases, upgrades or modifications to effect HIPAA compliance. 
  
 4.38 Improper and Other Payments. (a) Neither the Company, PC, any director, officer, employee thereof, nor
any agent or representative of the Company, PC nor any person acting on behalf of any of them, has made, paid or received any unlawful bribes, kickbacks or other similar payments to or from any person or authority, (b) no contributions have been
made, directly or indirectly, by the Company or PC to a domestic or foreign political party or candidate; and (c) the internal accounting controls of the Company and PC are believed by the Shareholder to be adequate to detect any of the foregoing
under current circumstances. 
  
 4.39 Accounts
Receivable. Schedule 4.39 sets forth a list, accurate, correct and complete in all respects, of all outstanding accounts and notes receivable of the Company and the PC as of the last day of the month immediately preceding the Closing Date.
All outstanding accounts and notes receivable reflected on Schedule 4.39 are due and valid claims against account debtors for services rendered in accordance with the usual business practices and historical collection experience of the Company and
to the best of Shareholder’s knowledge are subject to no counterclaims, and have been outstanding for the periods indicated in the aging analysis at Schedule 4.39. The Shareholder know of no reason why such accounts receivable would not be
collectible by the Company according to approximately the same ratios as accounts receivable have been historically collectible by the Company. All outstanding accounts and notes receivable included on Schedule 4.39 arose in the ordinary course of
business. The Company has not incurred any liabilities to customers for discounts, returns, promotional allowances or otherwise, except as provided in the Financial Statements 
  
 4.40 Medical Waste. With respect to the generation, transportation, treatment, storage, and disposal, or other
handling of Medical Waste, the Company and PC, with respect to the business, has complied with all Medical Waste Laws (as hereinafter defined). 
  

 29 

 “Medical Waste” includes, but is not limited to, (a) pathological waste, (b)
blood, (c) sharps, (d) wastes from surgery or autopsy, (e) dialysis waste, including contaminated disposable equipment and supplies, (f) cultures and stocks of infectious agents and associated biological agents, (g) contaminated animals, (h)
isolation wastes, (i) contaminated equipment, (j) laboratory waste, and (k) various other biological waste and discarded materials contaminated with or exposed to blood, excretion, or secretions from human beings or animals. “Medical
Waste” also includes any substance, pollutant, material, or contaminant listed or regulated under the Medical Waste Tracking Act of 1988, 42 U.S.C. §§6992, et seq. (“MWTA”). 
  
 “Medical Waste Law” means the following, including
regulations promulgated and orders issued thereunder, all as may be amended from time to time: the MWTA; the U.S. Public Vessel Medical Waste Anti-Dumping Act of 1988, 33 USCA §§2501 et seq.; the Marine Protection, Research, and
Sanctuaries Act of 1972, 33 USCA §§1401 et seq.; the Occupational Safety and Health Act, 29 USCA §§651 et seq.; the United States Department of Health and Human Services, National Institute for Occupational Self-Safety and Health
Infectious Waste Disposal Guidelines, Publication No. 88-119; and any other federal, state, regional, county, municipal, or other local laws, regulations, and ordinances insofar as they purport to regulate Medical Waste, or impose requirements
relating to Medical Waste. 
  
 4.41 No Untrue or Inaccurate
Representation or Warranty. No representation or warranty by Sellers contains or will contain any untrue statement of fact, or omits or will omit to state a fact necessary to make the statements and information contained in this Section 4
not misleading. 
  
 5. REPRESENTATIONS AND WARRANTIES OF THE ACQUIRING
COMPANIES. The Acquiring Companies represent and warrant to the Shareholder that the statements contained in this Section 5 are correct and complete as of the Closing Date. 
  
 5.1 Organization of PainCare and Subsidiary. PainCare is a corporation duly organized, validly existing, and
in good standing under the laws of the State of Florida. Subsidiary is a corporation duly organized, validly existing and in good standing under the laws of the State of Florida. 
  
 5.2 Authorization of Transaction. PainCare and Subsidiary have full power and authority (including full
corporate power and authority) to execute and deliver this Agreement and to perform its obligations hereunder. This Agreement constitutes the valid and legally binding obligation of PainCare, enforceable in accordance with its terms and conditions.
The execution and delivery of this Agreement has been approved and authorized by the Board of Directors of PainCare. 
  
 5.3 No Conflict or Violation. Neither the execution and delivery of this Agreement nor the consummation of the transactions
contemplated hereby will result in (a) a violation of or a conflict with any provision of the Certificate or Articles of Incorporation or bylaws of the PainCare or Subsidiary, (b) a breach of, or a default under, any term or provision of any
contract, agreement, indebtedness, lease, commitment, license, franchise, permit, authorization or concession to which the PainCare or Subsidiary is a party, which breach or default could reasonably be expected to have a Company material adverse
effect on the business or financial condition of the PainCare or Subsidiary or its ability to consummate the transactions 

  

 30 

 
contemplated hereby or (c) a violation by the PainCare or Subsidiary of any statute, rule, regulation, ordinance, code, order, judgment, writ, injunction,
decree or award, which violation could reasonably be expected to have a material adverse effect on the business or financial condition of the PainCare or Subsidiary, or their ability to consummate the transactions contemplated hereby. 
  
 5.4 Consents and Approvals. Except as set forth on Disclosure
Schedule 5.4, no notice to, declaration, filing or registration with, or authorization, consent or approval of, or permit from, any domestic or foreign governmental or regulatory body or authority, or any other person or entity, is required to be
made or obtained by the PainCare or Subsidiary in connection with the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby. 
  
 5.5 Disclosure Documents. PainCare has delivered or Stockholder has had the opportunity to obtain and review
PainCare’s Form 10-KSB for the year ending December 31, 2003, Form S-3/A filed with the SEC on March 4, 2004, Form 14A (Definitive Proxy) filed with the SEC on February 17, 2004 and current Forms 8-K (the “PainCare Disclosure
Documents”). The PainCare Disclosure Documents are true and correct in all material respects and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in
light of the circumstances under which such statements were made, not misleading. To the knowledge of PainCare nothing has occurred after the date of the documents contained in the Disclosure Documents that would individually or in the aggregate
have a material adverse effect on PainCare. 
  
 5.6
Capitalization. The authorized capital stock of PainCare consists of 75,000,000 shares of Common Stock, $.0001 par value per share, which as of April 1, 2004, approximately 28,000,000 shares are issued and outstanding, 10,000,000
shares of “blank check” preferred none of which have been issued or are outstanding. All of the PainCare Shares are, and all shares of PainCare Shares to be issued pursuant to this Agreement will be, validly issued, fully paid and
non-assessable. Disclosure Schedule 5.6(a) hereto sets forth a listing of all options, warrants and outstanding PainCare securities which are convertible (with or without the payment of consideration) into shares of the Common Stock of PainCare,
including all contingently issuable shares of such Common Stock issuable pursuant to agreements outstanding as of April 1, 2004. Disclosure Schedule 5.6(b) also sets forth the terms of any financing proposed to be raised by PainCare in connection
with the transactions contemplated by this Agreement. 
  
 5.7
Litigation. Except as set forth in Disclosure Schedule 5.7, there is no charge, complaint, action, order, writ, injunction, judgment or decree outstanding or claim, suit, litigation, proceeding, labor dispute, arbitrable action or
investigation (collectively, “Actions”) pending or, to the knowledge of the PainCare, threatened against, relating to or affecting (i) the PainCare or its assets or the operation of the business of the PainCare as currently operated and as
proposed to be operated, (ii) any Employee Plan of PainCare or any trust or other funding instrument, fiduciary or administrator thereof or (iii) the transactions contemplated by this Agreement, before or by any federal, state, municipal or other
governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, any of which is reasonably expected to result in a loss not covered by insurance in excess of $100,000 or reasonably expected to have a material
adverse effect on PainCare. To the knowledge of the PainCare, the PainCare is not in default with respect to any judgment, order, writ, injunction or decree of any court or governmental agency, and there are no unsatisfied judgments against the

  

 31 

 
PainCare or the business of the PainCare. Except as set forth in Disclosure Schedule 5.7, each Action pending or, to the knowledge of the PainCare,
threatened (whether or not disclosed in Disclosure Schedule 5.7), is covered by insurance of reputable and solvent insurance companies. 
  
 5.8 No Undisclosed Liabilities. Except as set forth in Disclosure Schedule 5.8, to the knowledge of PainCare, PainCare has no liabilities or
obligations (absolute, accrued, contingent or otherwise) except (i) liabilities that are reflected and reserved against on PainCare’s audited balance sheet dated December 31, 2003 (the “PainCare Balance Sheet Date”) that have not been
paid or discharged since the date thereof and (ii) liabilities incurred by PainCare since the PainCare Balance Sheet Date in the ordinary course of business consistent with past practice (none of which relates to any breach of contract, breach of
warranty, tort, infringement or violation of law or arose out of any complaint, action, suit or proceeding except those which individually or in the aggregate could not have a material adverse effect on PainCare). 
  
 5.9 No Brokers. There is no obligation on the part of PainCare
to pay any finder’s fee, brokerage commission or similar payment in connection with the transactions contemplated hereby. 
  
 5.10 Material Misstatements Or Omissions. To the knowledge of PainCare, no representations or warranties by PainCare in this Agreement, nor
any document, exhibit, statement, certificate or schedule furnished or to be furnished to the Shareholder pursuant hereto, or in connection with the transactions contemplated hereby, contains or will contain any untrue statement of a material fact,
or omits or will omit to state any material fact necessary to make the statements or facts contained therein not misleading. 
  
 6. CLOSING; TERMINATION. The closing of the Transaction (the “Closing”) shall be effective between the Parties as of 12:00 p.m. Eastern Daylight
Time on April 29, 2004 (the “Closing Date”). However, in the event that the Parties have not satisfied all of the conditions necessary to Close by the Closing Date including, without limitation, the completion, review and approval of all
the disclosure schedules (hereinafter the “Closing Conditions”) then, in such event, either Party may extend the time period for satisfying such Closing Conditions until 4:00 p.m. Pacific Time, May 15, 2004 (hereinafter the “Extended
Time”) with the understanding and agreement that if the Closing Conditions are completed to the mutual satisfaction of the parties by the Extended Time that this Transaction shall be effective as of the Closing Date. In the event that the
Closing Conditions have not been completed to the mutual satisfaction of the parties by the Extended Time, this Agreement may be terminated by either Party unless the Parties through their respective legal counsel otherwise agree in writing to an
additional extension of time not to exceed ten (10) consecutive days beginning on the day immediately following the Extended Time for satisfying such Closing Conditions. 
  
 7. CLOSING DELIVERIES. 
  
 7.1 Deliveries of the Company and the Shareholder. At or prior to the Closing Date or the Extended Time, as the case may be, the Company and
the Shareholder shall deliver to the Acquiring Companies the following: 
  
 (a) Consents and Approvals. Copies of all authorizations, consents, and approvals of governments, governmental agencies and third parties referred to in Section 4.4(a) of the Disclosure Schedule;

  

 32 

 (b) Termination of Agreements. Copies of documents effectuating the
termination of any and all written employment and independent contractor agreements, compensation agreements, buy-sell agreements, factoring agreements, and other similar agreements entered into by the Company and which are in effect immediately
preceding the Closing, which terminations shall each include a complete release of the Company from all known or unknown obligations or liabilities; 
  
 (c) Company Stock. The Certificates and stock powers, duly endorsed, transferring the Company Stock to Subsidiary and the
officer and director resignations required in Section 4.6; 
  
 (d) Corporate Authorization. A certified copy of resolution(s) of the Shareholder and board of directors of the Company and PC which authorizes the Transaction in accordance with: (a) applicable law; (b)
the Company’s and PC’s articles of incorporation and bylaws; and (c) all other requirements for proper corporate authorization; 
  
 (e) Secretary’s Certificate. A certificate of the secretary of the Company certifying that the minute books, articles
of incorporation and bylaws of the Company, attached as exhibits to such certificate, are true, correct, and complete; and 
  
 (f) Other documents. Such other instruments or documents as may be necessary or appropriate to carry out the Transactions
including without limitation fully executed Employment Agreements for Dr. Wright and Dr. Alo, a fully executed Management Services Agreement, a fully executed Wright Pledge Agreement, fully executed Articles of Merger, a termination, if necessary,
of that certain accounts receivable purchase and lien agreement by and between the Company and Injury Finance, LLC, and evidence as required by PainCare of the satisfaction or removal of all debts, claims or encumbrances of the Company, the PC and
their assets and than the Permitted Indebtedness described in Section 7.1(f) of the Disclosure Schedules. 
  
 7.2 Deliveries of PainCare. At or prior to the Closing Date or the Extended Time, as the case may be, PainCare shall deliver to the
Shareholder the following: 
  
 (a)
Transaction Consideration. The Transaction Consideration; 
  
 (b) Resolutions. A certified copy of the resolution of the board of directors of PainCare, and the sole shareholder and members of the board of directors of Subsidiary, authorizing the Transaction; and

  
 (c) Other documents. Such other
instruments or documents as may be necessary or appropriate to carry out the Transactions, including (i) a mutually agreeable and executed employment agreements for Dr. Wright and Dr. Alo, (ii) the PainCare Stock Pledge Agreement, (iii) a fully
executed Management Services Agreement, and (iv) fully executed Articles of Merger. 
  

 33 

 8. CONDITIONS TO THE OBLIGATIONS OF THE PARTIES. The obligations of the Parties to Close are subject to the
satisfaction of the following respective conditions by the Extended Time unless waived by the Party for whose benefit the condition applies. 
  
 8.1 Conditions for the Benefit of PainCare and the Subsidiary. (a) The representations and warranties of the Shareholder, PC and the Company
in this Agreement and all information contained in any exhibit, certificate, schedule or attachment hereto or in any writing delivered by, or on behalf of the Shareholder, PC or the Company shall be true and correct when made and shall be true and
correct in all material respects on the Closing Date (and the Extended Time) as though then made, except as expressly provided for herein, and (b) the Shareholder, PC and the Company shall have performed and complied with all agreements, covenants
and conditions and shall have made all deliveries required by this Agreement to be performed, delivered and complied with by them prior to the Extended Time. 
  
 8.2 Conditions for the Benefit of the Shareholder. (a) The representations and warranties of PainCare in this Agreement and all information
contained in any exhibit, certificate, schedule or attachment hereto or in any writing delivered by, or on behalf of PainCare or the Subsidiary shall be true and correct when made and shall be true and correct in all material respects on the Closing
Date (and the Extended Time) as though then made, except as expressly provided for herein, and (b) the Shareholder, PC and the Company shall have performed and complied with all agreements, covenants and conditions and shall have made all deliveries
required by this Agreement to be performed, delivered and complied with by them prior to the Extended Time. 
  

	9.	COVENANTS. The Parties covenant and agree as follows: 

  
 9.1 Operations. As of the Statutory Merger Time, the PC and the Subsidiary will execute and deliver to each other the Management Services
Agreement and Drs. Wright and Alo and the PC will execute and deliver the Employment Agreement. Drs. Wright and Alo shall be designated by the Subsidiary as the Medical Group Administrator under the Management Services Agreement. 
  
 9.2 Deliveries. PainCare will promptly deliver and make
available to Shareholder copies of any filings made by it under the Securities Act or the Securities Exchange Act, including the exhibits thereto and any correspondence with the Securities Exchange Commission or its staff. 
  
 9.3 Distributions of Sub-Chapter S Income by the Company. Not
later than the Statutory Merger Time, one hundred percent (100%) of the taxable income (as determined by using the cash method of accounting) of the Company and the PC allocated to Shareholder prior to the Closing Date shall have been distributed to
the Shareholder subject to the requirement that Shareholder shall insure that as of the Closing Date that the Company will have a minimum cash balance of One Hundred Thousand Dollars ($100,000). The Shareholder shall not be entitled to any
additional distributions or payments with respect to taxable income of the Company (i) for the period ending after the Closing Date, other than as specifically set forth in this Agreement. 
  
 9.4 Post-Closing General Covenant. In the event that at any
time after the Closing any further action is necessary to carry out the purposes of this Agreement, each of the 

  

 34 

 
Parties will take such further action (including the execution and delivery of such further instruments and documents) as any other Party may reasonably
request, all at the sole cost and expense of the requesting Party; provided, however, that the costs and expenses associated with the taking of any action necessary to execute or deliver to PainCare any stock powers and such other instruments of
transfer as may be necessary to transfer ownership of the Company’s Shares by the Shareholder shall be borne by the Shareholder. 
  
 9.5 Tax Returns. Drs. Wright and Alo shall be responsible for preparing and filing all income or franchise Tax Returns of the Company
relating to periods of time prior to the Closing Date. PainCare and the Subsidiary will provide to Drs. Wright and Alo access to all books and records of the Company necessary to the preparation of such Tax Returns and the Subsidiary, as the
successor to the Company will execute such Tax Returns. The Shareholder will take no positions on the Tax Returns of the Company that relate to the tax period prior to the Closing Date that could adversely affect the Company or PainCare after the
Closing. The Shareholder will provide PainCare with an opportunity to review and comment on such Tax Returns (including any amended returns). PainCare will be responsible for preparing and filing all income and franchise Tax Returns of the Company
relating to periods after the Closing. The income of the Company will be apportioned to the period up to the Closing Date and the period from and after the Closing Date in accordance with the provisions of Code Section 1362(e)(6)(D) by closing the
books of the Company as of the close of business on the last calendar day immediately preceding the Closing Date, with recognition that the Company files on that basis of a cash rather than accrual method. The Acquiring Companies shall be solely
responsible for any taxes due arising from conversion to the accrual method. 
  
 9.6 Transition. Neither the Shareholder nor the Company nor the PC will take any action that is designed, intended or likely to have the effect of discouraging any lessor, licensor, customer, supplier or
other business associate of the Company or the PC from maintaining the same business relationships with the Company and the PC after the Closing as he, she or it maintained with the Company and the PC prior to the Closing. 
  
 9.7 Litigation Support. In the event and for so long as any
Party actively is contesting or defending against any action, suit, proceeding, hearing, investigation, charge, complaint, claim or demand in connection with: (a) any transaction contemplated under this Agreement; or (b) any fact, situation,
circumstances, status, condition, activity, practice, occurrence, event, incident, action, failure to act, or transaction on or prior to the Closing Date involving the Company, each of the Parties will cooperate with the contesting or defending
Party and its or his counsel in the contest or defense, at the sole cost and expense of the contesting or defending Party except to the extent that the contesting or defending party is entitled to indemnification therefor under this Agreement.

  
 9.8 Consents. The Shareholder hereby covenants
and agrees that he will use his best efforts to obtain all authorizations, consents, and approvals set forth in Section 4.4(b) of the Disclosure Schedule. If such consent, approval or agreement is not obtained, or if an attempted assignment thereof
would affect the rights of the parties thereunder so that such parties would not in fact receive all such rights, the Parties will cooperate in any arrangement designed to provide for the Parties to receive the benefits under any such contract,
including enforcement for the benefit of PainCare and Subsidiary of any and all rights of the Shareholder against a third party thereto arising out of the breach or cancellation by such third party or otherwise. 
  

 35 

 9.9 Operational Covenants. Without the prior written consent of Shareholder, which shall
not be unreasonably withheld, PainCare shall not, prior to the conclusion of the third Formula Period except in the case of a rescission of this Agreement as provided in Section 11 below: 
  
 (a) reorganize the Surviving Corporation, whether by
integrating or consolidating the business of the Surviving Corporation with other operating units of PainCare or its subsidiaries or affiliates, except in the case that at the time of such integration or consolidation such transaction could not
reasonably be expected to have a material adverse effect on the Formula Period Profits; 
  
 (b) effect any reassignment, reprioritization, reallocation, restructuring, or reduction of the Surviving Corporation’s human or
other resources, their research and development initiatives, or their marketing programs, except in a manner that at the time of such event could not reasonably be expected to have a material adverse effect on the Formula Period Profits or that are
reasonably necessary in light of the Surviving Corporation’s results of operation; 
  
 (c) amend the articles of incorporation or bylaws of the Surviving Corporation in any manner that at the time of such amendment could
reasonably be expected to have a material adverse effect on the Formula Period Profits; 
  
 (d) cause the Surviving Corporation to become a party to or terminate any agreement which at the time such agreement is entered into or
terminated could reasonably be expected to have a material adverse effect on the Formula Period Profits or that is reasonably necessary in light of the Surviving Corporation’s results of operation; 
  
 (e) cause the Surviving Corporation to undertake actions
outside the ordinary course of its business which at the time of such undertaking could reasonably be expected to have a material adverse effect on the Formula Period Profits; 
  
 (f) sell a material portion of the Surviving Corporation or its assets, merge the Surviving Corporation with
any other entity, sell a controlling interest in the Surviving Corporation, or make any fundamental change in the business of the Surviving Corporation unless such action(s) at the time of such undertaking could not reasonably be expected to have a
material adverse effect on the Formula Period Profits or that is reasonably necessary in light of the Surviving Corporation’s results of operation; 
  
 The parties hereby acknowledge and agree that the foregoing covenants in this Section 9.9 shall become null and void and of no further
force or effect if the Formula Period Profits of the Surviving Corporation beginning December 1, 2004 in each of any two (2) consecutive Formula Period calendar quarters are less than $600,000, or if the Formula Period Profits of the Surviving
Corporation in one (1) Formula Period calendar quarter is less than $100,000. 
  
 9.10 Capital Adjustments. In the event of a stock dividend, recapitalization, or merger in which PainCare is the surviving corporation, split-up, combination or exchange of 

  

 36 

 
shares or the like which results in a change in the number or kind of shares of common stock which is outstanding immediately prior to such event, the rights
of the Shareholder to receive PainCare Shares in respect of this Agreement and the price thereof, shall be appropriately adjusted in the same manner as the number and kind of shares a shareholder of PainCare who owned the same number and kind of
shares immediately prior to such event. Such adjustments shall be made in good faith by the Board of Directors of PainCare, whose determination shall be conclusive and binding on all parties, subject to manifest error. 
  
 In case of any consolidation or merger of PainCare with or
into another party or parties or the conveyance of all or substantially all of the assets of PainCare to another party or parties or a share exchange transaction involving more than 50% of the issued and outstanding common stock of PainCare, the
PainCare Shares and right to receive PainCare Shares shall thereafter be convertible into the number of shares of stock, options or other securities or property to which a shareholder of the PainCare who owned the same number and kind of shares
prior to such event would have been entitled upon such consolidation, merger, conveyance, conversion or exchange; and, in any such case, appropriate adjustment shall be made in the application of the provisions herein set forth with respect to the
rights and interest thereafter of the Shareholder’s right to receive PainCare Shares, to the end that the provisions set forth herein shall thereafter be applicable, as nearly as reasonably possible, in relation to any shares of stock or other
property thereafter deliverable upon the Shareholder’s entitlement to same. 
  

	10.	SURVIVAL AND INDEMNIFICATION. 

  
 10.1 Survival of Representations and Warranties. All of the representations, warranties, covenants, and agreements including but not limited
to the restrictive covenants and the indemnification provisions contained in this Agreement are material and have been relied upon by the Parties hereto and shall survive the Closing for their applicable statute of limitations. The representations
and warranties contained herein shall not be affected by any investigation, verification or examination by any Party or by anyone on behalf of such Party. 
  
 10.2 Indemnification Provisions for the Benefit of PainCare and Subsidiary. In the event of: (a) a misrepresentation (or in the event any
third party alleges facts that, if true, would mean a misrepresentation) of any of the Shareholder’s or the Company’s representations and/or warranties contained in this Agreement; (b) a breach (or in the event any third party alleges
facts that, if true, would mean a breach) of any of the Shareholder’s or the Company’s covenants contained in this Agreement, or; (c) any Liability of the Shareholder, the Company or the PC of any nature whatsoever accrued or existing as
of the Closing Date or related to actions or inactions of the Shareholder, the Company or the PC which occurred prior to the Closing Date, unless such Liability is reflected on the Financial Statements, the Closing Date Balance Sheet, or Section
10.2 of the Disclosure Schedule and the Subsidiary explicitly agrees as documented in Section 10.2 of the Disclosure Schedule to assume or take the assets of the Company subject to, as the case may be, then the Shareholder agrees to indemnify
PainCare and Subsidiary from and against any Adverse Consequences PainCare and/or the Subsidiary may incur or suffer through and after the date of the claim for indemnification resulting from, arising out of, relating to, in the nature of, or caused
by the misrepresentation or breach (or alleged breach) or non-disclosed Liability which is not explicitly assumed or the assets taken subject to. No provision of this Agreement, including but not in any way limited to, any “Knowledge”

  

 37 

 
qualifiers or materiality standards in the representations and warranties of the Shareholder, shall have any effect on the Shareholder’s obligation to
provide indemnity of any Liability arising prior to the Closing Date which was required but omitted from the Disclosure Schedule unless such Liability was incurred on behalf of the Company by Subsidiary under the Management Agreement. 
  
 10.3 Indemnification Provisions for the Benefit of the
Shareholder. In the event of a misrepresentation or breach (or in the event any third party alleges facts that, if true, would mean a misrepresentation or breach) of any of PainCare’s or Subsidiary’s representations, warranties,
and covenants contained in this Agreement, then PainCare and Subsidiary agree to indemnify the Shareholder from and against any Adverse Consequences the Shareholder may suffer through and after the date of the claim for indemnification resulting
from, arising out of, relating to, in the nature of, or caused by the breach (or the alleged breach). 
  
 10.4 Matters Involving Third Parties. 
  
 (a) Notification. If any third party shall notify any Party (the “Indemnified Party”) with respect to any matter
(a “Third Party Claim”) which may give rise to a claim for indemnification against the other Party (the “Indemnifying Party”) pursuant to this Section 10, then the Indemnified Party shall promptly notify the Indemnifying Party
thereof in writing; provided, however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless the Indemnifying Party thereby is prejudiced and
then only to the extent that the Indemnifying Party is actually prejudiced. 
  
 (b) Defense by Indemnifying Party. The Indemnifying Party shall have the right to defend the Indemnified Party against the Third Party Claim with counsel of its choice satisfactory to the Indemnified
Party so long as: (i) the Indemnifying Party notifies the Indemnified Party in writing within ten (10) business days after the Indemnified Party has given notice of the Third Party Claim that the Indemnifying Party will indemnify the Indemnified
Party from and against any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the Third Party Claim; (ii) the Indemnifying Party provides the Indemnified Party with
evidence reasonably acceptable to the Indemnified Party that the Indemnifying Party will have the financial resources to defend against the Third Party Claim and fulfill the Indemnifying Party’s indemnification obligations hereunder; (iii) the
Third Party Claim involves only money damages and does not seek an injunction or other equitable relief; (iv) settlement of, or an adverse judgment with respect to, the Third Party Claim is not, in the good faith judgment of the Indemnified Party,
likely to establish a precedential custom or practice adverse to the continuing business interests of the Indemnified Party; and (e) the Indemnifying Party conducts the defense of the Third Party Claim actively and diligently. 
  
 (c) Satisfactory Defense. So long as the
Indemnifying Party is conducting the defense of the Third Party Claim in accordance with Section 10.4(b) above: (i) the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of the Third Party
Claim; (ii) the Indemnified Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the prior written consent of the Indemnifying Party (not to be withheld or delayed
unreasonably); and (iii) 

  

 38 

 
the Indemnifying Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the prior
written consent of the Indemnified Party (not to be withheld or delayed unreasonably) and any such settlement must include a complete release of the Indemnified Party. 
  
 (d) Conditions. In the event any of the conditions in Section 10.4(b) above is or becomes
unsatisfied, however: (i) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, the Third Party Claim in any manner it reasonably may deem appropriate (and the Indemnified
Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith); (ii) the Indemnifying Party will reimburse the Indemnified Party promptly and periodically for the costs of defending against the Third Party
Claim (including reasonable attorneys’ fees and expenses); and (iii) the Indemnifying Party will remain responsible for any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or
caused by the Third Party Claim to the fullest extent provided in this Section 10. 
  
 10.5 Right to Set-Off. If any such cost, loss, damage, expense, liability, claim, or obligation occurs or is incurred by PainCare or Subsidiary, PainCare or Subsidiary shall have the right, after written
notice to the Shareholder, at PainCare’s or Subsidiary’s option and in addition to any other actions permitted by law, to offset the amount of any such cost, loss, damage, expense, liability, obligation or claim against amounts due from
PainCare or Subsidiary to the Shareholder, including the right to offset any post-closing payment due from PainCare or Subsidiary to the Shareholder under this Agreement or any other agreement. 
  
 10.6 Materiality. Notwithstanding any provision in this
Agreement to the contrary, the indemnifying Party’s obligation to indemnify the Indemnified Party in connection with a breach of any representation, warranty, covenant or other agreement included in this Agreement, and the amount of damages to
be indemnified, shall be determined without regard to any “material”, “materiality” (or correlative meanings”) or “Material Adverse Effect” qualifications, provisions or exceptions set forth in such representation,
warranty, covenant or other agreement, each of which shall be deemed to be given for the purposes of this Section 10 as though there were no such qualifications, provisions or exceptions. 
  
 10.7 Limitation. The indemnification provisions set forth in this Section 10 shall be limited to all claims in
excess of Twenty Five Thousand and 00/100 Dollars ($25,000) (the “Threshold”). Once a claim exceeds the Threshold, if a Party is entitled to indemnification under this Section 10, such party shall recover all appropriate funds from the
first dollar of damages. Further, the indemnitors shall not be liable for any liabilities resulting from claims that are covered by any insurance policy or other indemnity or contribution agreement unless, and only to the extent that, the full limit
of such insurance policy, indemnity or contribution agreement has been exceeded. The Party entitled to indemnification shall have a duty to mitigate its damages. Notwithstanding the foregoing, a Party’s obligation to indemnify under this
Article 10 shall be limited to an amount equal to $3,750,000 plus the amount of any Earnout Installment Payments paid or due pursuant to Section 3.4 of this Agreement prior to any reduction of such Installment Payments permitted under Section
3.4(g); provided however that such cap shall not be applicable to Sections 4.1, 4.2, 4.3, 4.8, 4.10, 4.11, 4.17, 4.18, 4.19, 4.20, 4.22, 4.25, 4.27, 4.36, 4.37 and 4.38. 
  

 39 

	11.	RESTRICTIVE COVENANTS; CONFIDENTIALITY. 

  
 11.1 Restrictive Covenants. 
  
 (a) Restricted Period. Drs. Wright and Alo hereby agree that during the time period commencing as of the Closing Date and
continuing for a period of four (4) years thereafter (the “Restricted Period”), neither Drs. Wright and Alo nor any of their Affiliates, shall, other than on behalf of the PC, PainCare or Subsidiary, directly or indirectly, for himself, or
on behalf of any other corporation, person, firm, partnership, association, or any other entity whatsoever (whether as an individual, agent, servant, employee, employer, officer, director, shareholder, investor, principal, consultant or in any other
capacity whatsoever) take any action or undertake any matter set forth in 11.1(a)(i)-(ii) below; provided, however, that the Restricted Period shall terminate upon the earlier to occur of (i) any bankruptcy, liquidation or assignment for the benefit
of creditors applicable to either PainCare or Subsidiary, or (ii) upon a default by PainCare or Subsidiary in any material covenant or term of this Agreement to be performed after the Closing or any material covenant or term of the Management
Services Agreement if Drs. Wright and Alo shall have given written notice of such default to PainCare and such default shall not have been cured within 30 business days after the giving of such notice. 
  
 (i) Establish, operate or provide physician services at any
medical office, hospital, clinic or out-patient and/or ambulatory treatment or diagnostic facility or become employed by, or serve as a health care consultant or medical director to any health care provider providing services similar to those
provided by PainCare or Subsidiary, or engage or participate in or finance any business which engages in direct competition with the business being conducted by PainCare or the Surviving Corporation at such time, anywhere within a one hundred (100)
mile radius of the Company or the PC; 
  
 (ii)
Solicit or engage in the solicitation of, or serve or accept any business from patients, insurance companies, managed care plans, employers or other customers of the business conducted by the PC or the Surviving Corporation for services competitive
with those of the PC or the Subsidiary, and their successors and assigns; 
  
 (iii) Request, induce or advise any patients, insurance companies, managed care plans, suppliers, vendors, employers or other customers of the business conducted by the PC or the Subsidiary to withdraw, curtail or
cancel their business or other relationships with the PC or the Subsidiary, or assist, induce, help or join any other person or entity in doing any of the above activities; or 
  
 (iv) Induce or attempt to influence any employee of the PC, PainCare, and/or its subsidiaries including the
Subsidiary Company, to terminate his or her employment with the PC, PainCare, and/or its subsidiaries including the Subsidiary, or to hire, recruit or solicit any such employee, whether or not so induced or influenced. 
  
 (b) Consideration. PainCare, Subsidiary and
Drs. Wright and Alo have carefully considered the nature and extent of the restrictions imposed by this Section 11.1 and the rights and remedies conferred upon PainCare and Subsidiary hereunder and hereby expressly acknowledge and agree that: (i)
the restricted territory, period, and activities are reasonable and are necessary and fully required to protect the legitimate business interests of PainCare and 

  

 40 

 
Subsidiary; (ii) any violation of the terms of these restrictive covenants would have a substantial detrimental effect on PainCare’s and
Subsidiary’s businesses; (iii) the restrictive covenants do not stifle Drs. Wright and Alo’s inherent skill and experience; and (iv) would not operate as a bar to any of Drs. Wright and Alo’s means of support. Because of the
difficulty of measuring economic losses to PainCare and the Surviving Corporation as a result of the breach of the foregoing covenants, and because of the immediate and irreparable damage that would be caused to PainCare and the Surviving
Corporation for which it would have no other adequate remedy, Drs. Wright and Alo agrees that, in the event of a breach by him of the foregoing covenants, the covenants set forth in this Section 11.1 may be enforced by PainCare and the Surviving
Corporation by injunctions and restraining orders, in addition to all other available legal remedies. 
  
 (c) Third-Party Beneficiaries. All successors and assigns of PainCare, Subsidiary, all Affiliates of PainCare and
Subsidiary, and all successors and assigns of such Affiliates are third-party beneficiaries of the restrictive covenants contained in this Section 11.1 and the provisions of this Section 11.1 are intended for the benefit of, and may be enforced by,
PainCare’s and Subsidiary’s successors and assigns and PainCare’s and Subsidiary’s Affiliates and such Affiliates’ successors and assigns. 
  
 11.2 Intentionally Omitted. 
  
 11.3 No Running of Covenant During Breach. The covenants set forth in this Section 11 shall apply for the
applicable periods as set forth above. If Drs. Wright and Alo violates such covenants, and PainCare, the Surviving Corporation or any of their successors and assigns or Affiliates bring a legal action for injunctive or other relief, such party
bringing the action shall not, as a result of the time involved in obtaining the relief, be deprived of the benefit of the full period of the covenant period, unless a court of competent jurisdiction holds that the covenant is not enforceable in
whole or in part. Accordingly, for any time period that Drs. Wright and Alo is in violation of the covenant, such time period shall not be included in calculating the applicable time period of the covenant. 
  
 11.4 Blue Pencil Doctrine. The covenants set forth in this
Section 11 are severable and separate, and the unenforceability of any specific covenant shall not affect the provisions of any other covenant. Moreover, in the event any court of competent jurisdiction shall determine that the scope, time or
territorial restrictions set forth are unreasonable, then it is the intention of the parties that such restrictions be enforced to the fullest extent which the court deems reasonable, and the Agreement shall thereby be reformed. 
  
 11.5 Confidentiality, Press Releases, and Public Announcements.

  
 (a) No Party shall issue any press release or
make any public announcement relating to the subject matter of this Agreement without the prior written approval of the other Parties. 
  
 (b) The Parties covenant and agree that from and after the Execution Date, neither of the Parties nor their Affiliates (to the extent any
such Affiliate has received Confidential Information as defined below or Trade Secrets, as defined below) shall disclose, divulge, furnish or make accessible to anyone any Confidential Information or Trade Secrets, or 

  

 41 

 
in any way use any Confidential Information or Trade Secrets in the conduct of any business; provided, however, that nothing in this Section 11.5 will
prohibit the disclosure of any Confidential Information or Trade Secrets which is required to be disclosed by a Party or any of its or his Affiliates in connection with any court action or any proceeding before any authority. Notwithstanding the
foregoing, in the case of a disclosure contemplated by this Section 11.5, no disclosure shall be made until the disclosing Party shall give notice to the non-disclosing Party of the intention to disclose such Confidential Information or Trade
Secrets so that the non-disclosing Party may contest the need for disclosure, and the disclosing Party will cooperate (and will cause its or his Affiliates and their respective representatives to cooperate) with the non-disclosing in connection with
any such proceeding. Notwithstanding any provision of this Agreement which may be to the contrary, the foregoing provisions restricting the use of Confidential Information and Trade Secrets shall survive the Closing for the time period equal to five
(5) years from the Execution Date. For the purpose of this Agreement, the term “Confidential Information” shall mean all records, files, reports, protocols, policies, manuals, databases, processes, procedures, computer systems, materials
and other documents pertaining to the operations of a Party and the term “Trade Secrets” shall mean information, including a formula, pattern, compilation, program, device, method, technique, or process that: (i) derives independent
economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use; and (ii) is the subject of efforts that are
reasonable under the circumstances to maintain its secrecy. 
  
 11.6 Conduct of Business. From the date hereof through the Closing, the Shareholder shall, except as contemplated by this Agreement, or as consented to by PainCare in writing, cause the Company and the PC to be operated in the
ordinary course and in accordance with past practice and will not take any action inconsistent with this Agreement or with the consummation of the Closing. Without limiting the generality of the foregoing, the Company and the PC shall not, and, with
respect to the Company and the PC, the Shareholder shall not, except as specifically contemplated by this Agreement, as set forth in Section 11.6 of the Disclosure Schedule, or as consented to by PainCare in writing: 
  
 (a) change or amend the organizational documents of the
Company or the PC; 
  
 (b) enter into, extend,
materially modify, terminate or renew any lease or any contract, except modifications, extensions or renewals of contracts in the ordinary course of business or as contemplated by this Agreement; 
  
 (c) sell, assign, transfer, convey, lease, mortgage, pledge
or otherwise dispose of or encumber any of the assets or any interests therein of the Company or the PC except in the ordinary course of business and, without limiting the generality of the foregoing, the Company and the PC will maintain, dispose
of, and sell inventory consistent with past practices; 
  
 (d) incur any liability for indebtedness for borrowed money, guarantee the obligations of others, indemnify or agree to indemnify others or, except in the ordinary course of business, incur any other liability; 
  
 (e) take any action with respect to the grant of any bonus,
severance or termination pay (otherwise than pursuant to policies or agreements of the Company or the PC in 

  

 42 

 
effect on the date hereof that are described in the Disclosure Schedule) or with respect to any increase of benefits payable under its severance or
termination pay policies or agreements in effect on the date hereof or increase in any manner the compensation or fringe benefits of any employee of the Company or the PC or pay, any benefit not required by any existing Employee Plan or policy;

  
 (f) make any change in the key management
structure of the Company or the PC, including, without limitation, the hiring of additional officers or the termination of existing officers; 
  
 (g) adopt, enter into or amend any Employee Plan, agreement (including, without limitation, any collective bargaining or employment
agreement), trust, fund or other arrangement for the benefit or welfare of any employee, except for any such amendment as may be required to comply with applicable regulations; 
  
 (h) fail to maintain all Employee Plans in accordance with applicable Regulations; 
  
 (i) acquire by merger or consolidation with, or merge or
consolidate with, or purchase substantially all of the assets of, or otherwise acquire any material assets or business of, any corporation, partnership, association or other business organization or division thereof or acquire any subsidiary;

  
 (j) willingly allow or permit to be done any
act by which any of the insurance policies of the Company, PC or Drs. Wright and Alo may be suspended, impaired or canceled; 
  
 (k) enter into, renew, modify or revise any agreement or transaction relating to the Company or the PC with any of their Affiliates except
as contemplated by this Agreement; 
  
 (l) fail
to maintain the assets of the Company or the PC in substantially their current state of repair, excepting normal wear and tear, or fail to replace (consistent with the Company’s past practice) inoperable, worn-out or obsolete or destroyed
assets; 
  
 (m) make any loans or advances
relating to the Company or the PC to any partnership, firm, individual, or corporation, except for expenses incurred in the ordinary course of business consistent with past practice; 
  
 (n) fail to comply in all material respects with all laws and regulations applicable to the Company and the
PC; 
  
 (o) intentionally do any other act which
would cause any representation or warranty of the Company, PC or the Shareholder in this Agreement to be or become untrue, or any covenant in this Agreement to be breached, in any material respect; 
  
 (p) fail to use reasonable efforts consistent with past
business practice to (i) maintain the Company and the PC so that the services of its officers, employees, consultants and agents will remain available to it on and after the Closing Date, (ii) maintain existing relationships with suppliers,
patients, customers and others having business dealings with the 

  

 43 

 
Company and PC and (iii) otherwise preserve the goodwill of the business of the Company and PC so that such relationships and goodwill will be preserved on
and after the Closing Date; 
  
 (q) enter into
any agreement, or otherwise become obligated, to do any action prohibited hereunder; 
  
 (r) except as provided herein, declare, set aside for payment, or pay any dividend or distribution in respect of any capital stock of the
Company or PC, redeem, purchase or otherwise acquire any of the Company’s PC’s equity securities; or otherwise transfer any of the assets of the Company or PC to or on behalf of any Shareholder of the Company or PC or any Affiliate of the
Company or PC, including, without limitation, any payment of principal of or interest on any debt owed to any of the foregoing or any payment of a bonus, fee or other payment to any of the foregoing as an employee of the Company or PC; or

  
 (t) fail to comply with all applicable
filing, payment, withholding, collection and record retention obligations under all applicable federal, state, local or foreign Tax laws. 
  
 11.7 No Third-Party Beneficiaries. Other than with respect to the restrictive covenants set forth in Section 11, this Agreement shall not
confer any rights or remedies upon any Person other than the Parties and their respective successors and permitted assigns. 
  
 12. MISCELLANEOUS. 
  
 12.1 Entire Agreement. This Agreement (including the documents referred to herein) constitutes the entire agreement between the Parties and
supersedes any prior understandings, agreements, or representations by or between the Parties, written or oral, to the extent they related in any way to the subject matter hereof. 
  
 12.2 Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties
named herein and their respective successors, assigns, distributees, heirs, and grantors of any revocable trusts of a Party hereto. No Party may assign either this Agreement or any of its or his rights, interests, or obligations hereunder without
the prior written approval of the other Parties; provided, however, PainCare and Subsidiary, may, without the prior consent of the other Party, assign this Agreement to their Affiliates. 
  
 12.3 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed
an original but all of which together will constitute one and the same instrument. 
  
 12.4 Headings. The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 
  
 12.5 Notices. All notices, requests, demands, claims, and other
communications hereunder will be in writing. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly given: (a) upon receipt if it is sent by facsimile, (b) the next business day if sent by reputable overnight
courier, or (c) five (5) days after mailing if by 

  

 44 

 
certified mail return receipt requested, postage prepaid, and addressed or otherwise sent to the intended recipient as set forth below: 
  

			
	If to PainCare or Subsidiary:	  	PainCare Holdings, Inc.
	 	  	37 North Orange Avenue
	 	  	Suite 500
	 	  	Orlando, Florida 32801
	 	  	Attention: CEO
		
	If to the Shareholder:	  	Kenneth M. Alo, M.D.
	 	  	5899 S. Colorado Blvd.
	 	  	Greenwood Village, CO 80121
	 	  	Facsimile: (303) 689-8730
	 	  	Robert E. Wright, M.D.
	 	  	7447 E. Berry Avenue, Ste. 150
	 	  	Greenwood Village, Colorado 80111
		
	If to the Company:	  	REW Merger Corporation
	 	  	7447 E. Berry Avenue, Ste. 150
	 	  	Greenwood Village, Colorado 80111
		
	With a copy in each case to:	  	Arthur A. Graves, III, Esq.
	 	  	The Oxford Law Firm
	 	  	P.O. Box 8708 – Dept. #621
	 	  	Newport Beach, CA 92660

  
 Any Party may send any notice,
request, demand, claim, or other communication hereunder to the intended recipient at the address or facsimile number set forth above using any other means (including personal delivery, messenger service, ordinary mail, or electronic mail), but no
such notice, request, demand, claim, or other communication shall be deemed to have been duly given unless and until it actually is received by the intended recipient. Any party may change the address or facsimile number to which notices, requests,
demands, claims, and other communications hereunder are to be delivered by giving the other Party notice in the manner herein set forth. 
  
 12.6 Governing Law; Jurisdiction; Attorney’s Fees. This Agreement, and all proceedings hereunder, shall be governed by and construed in
accordance with the domestic laws of the State of Florida without giving effect to any choice or conflict of law provision or rule (either of the State of Colorado or any other jurisdiction) that would cause the application of the laws of any
jurisdiction other than the State of Florida. In the event of any suit under this Agreement or otherwise between the parties hereto, the prevailing Party shall be entitled to all reasonable attorney’s fees and costs to be included in any
judgment recovered. In addition, the prevailing Party shall be entitled to recover reasonable attorney’s fees and costs incurred in enforcing any judgment arising from a suit under this Agreement. This post-judgment attorney’s 

  

 45 

 
fees and costs provision shall be severable from the other provisions of this Agreement and shall survive any judgment on such suit and is not to be deemed
merged into the judgment. 
  
 12.7 Amendments and
Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by the Parties. No waiver by any Party of any default, misrepresentation, or breach of warranty or covenant hereunder,
whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence and
all waivers must be in writing, signed by the waiving Party, to be effective. 
  
 12.8 Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and
provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction. 
  
 12.9 Expenses. Except as set forth herein, Shareholder shall bear and be responsible and shall pay for all costs and expenses (including,
but not limited to, legal and accounting fees and expenses) incurred by Shareholder, the Company and the PC in connection with this Agreement and the transactions contemplated hereby. 
  
 12.10 Further Assurances. Each Party shall, at the reasonable request of any other Party hereto, execute and
deliver to such other Party all such further instruments, assignments, assurances and other documents, and take such actions as such other Party may reasonably request in connection with the carrying out the terms and provisions of this Agreement.

  
 12.11 Construction. Any reference to any
federal, state, local, or foreign statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. Nothing in the Disclosure Schedule shall be deemed adequate to disclose an
exception to a representation or warranty made herein, unless the Disclosure Schedule identifies the exception with reasonable particularity. The Parties intend that each representation, warranty, and covenant contained herein shall have independent
significance. If any Party has breached any representation, warranty, or covenant contained herein in any respect, the fact that there exists another representation, warranty, or covenant relating to the same subject matter (regardless of the
relative levels of specificity) which the Party has not breached shall not detract from nor mitigate the fact that the Party is in breach of the first representation, warranty, or covenant. 
  
 12.12 Survival. All of the representations, warranties,
covenants and agreements including but not limited to Sections 4, 6, 7, 9, 10, 11, 12 and 13 made by the Parties in this Agreement or pursuant hereto in any certificate, instrument or document shall survive the consummation of the transactions
described herein shall survive for all applicable statute of limitations, and may be fully and completely relied upon by Sellers and the Acquiring Companies, as the case may be, notwithstanding any investigation heretofore or hereafter made by any
of them or on behalf of any of them, and shall not be deemed merged into any instruments or agreements delivered at Closing or thereafter. 
  

 46 

 12.13 Incorporation of Exhibits and Schedules. The following are incorporated herein by
reference and made a part hereof: (i) all exhibits and schedules (including the Disclosure Schedules) identified in this Agreement; (ii) the recitals first set forth above; and (iii) any other document, memorandum and/or letter signed by the Parties
or their legal counsel with instructions to incorporate such document, memorandum and/or letter into to this Section. 
  
 12.14 Submission to Jurisdiction. With respect to any legal proceeding brought by PainCare which arises out of or relates to this Agreement
or the transactions contemplated hereby, exclusive jurisdiction and venue with respect to such matter shall lie in any state or federal court within Denver County, CO. With respect to any legal proceeding brought by the Shareholder or the Company
which arises out of or relates to this Agreement or the transactions contemplated hereby, exclusive jurisdiction and venue with respect to such matter shall lie in any state or federal court within Orange County, FL. Each party to this Agreement
hereby irrevocably waives, to the fullest extent permitted by law, any objections which it may now or hereafter have to the laying of the venue of any such proceeding brought in such a court and any claim that any such proceeding brought in such a
court has been brought in an inconvenient forum. 
  
 13. RESCISSION

  
 13.1 The Rescission. If at any time subsequent
to the Closing and up to and until December 1, 2004, PainCare determines that (i) there has been “Inadequate Financial Performance” (as defined below) by the PC, or (ii) the PC, the Company, the Subsidiary and/or any Shareholder has
breached any material representation, warranty and/or covenant of this Agreement or any other agreement executed in connection herewith then, in such event, PainCare shall have the right by providing written notice to the Shareholder and Mr. Graves
to rescind this Merger transaction and all related transactions and related agreements with respect thereto (the “Rescission”). 
  
 For purposes of this Agreement the term “Inadequate Financial Performance” shall mean any one or more of the following:

  
 (a) The failure of the PC to pay its bills
and obligations including, without limitation, the Management Fee as they become due and owing; or 
  
 (b) The failure of the PC to realize as calculated by PainCare’s accountants utilizing GAAP the following minimum amounts of net
operating income (excluding the Operations Fee and the Base Management Fee as set forth in the Management Agreement): 
  

	 	(i)	for the calendar month of May 2004, $25,000; 

  

	 	(ii)	for the calendar month of June 2004, $50,000; 

  

	 	(iii)	for the calendar month of July 2004, $75,000; 

  

	 	(iv)	for the calendar month of August 2004, $100,000; 

  

	 	(v)	for the calendar month of September 2004, $125,000; 

  

	 	(vi)	for the calendar month of October 2004, $150,000; or 

  

	 	(vii)	for the calendar month of November 2004, $175,000; 

  

 47 

 or, 
  
 (c). The failure of the PC to collect at least 40% of its gross billings for each of the foregoing described
periods within at least 90 days of the date of such billing. 
  
 13.2 Return to Status Quo. In the event of a Rescission of this transaction by PainCare the parties shall immediately undertake the following: 
  
 (a) The Shareholder, the PC, and Mr. Graves, as Trustee of the Closing PainCare Shares, shall return to
PainCare all Merger Consideration paid or delivered by PainCare to same and PainCare shall keep the Closing Cash and all other the Merger Consideration. Such Merger Consideration shall be delivered to PainCare free of any and all Security Interests.

  
 (b) The Shareholder will immediately
reimburse PainCare for all out of pocket costs, expenses, compensation and or debts or claims incurred or paid by PainCare or its Affiliates in connection with this transaction, this Agreement and any other agreement or undertaking in connection
herewith. 
  
 (c) The Shareholder and the PC will
execute any and all documents reasonably requested by PainCare to effectuate the foregoing including, without limitation, stock powers with medallion guarantees with respect to the PainCare Share certificates. 
  
 (d) Subject to the complete and full performance of the
Shareholder, the PC and Mr. Graves with respect to Sections 13.2(a)(b) and (c) above, PainCare will deliver to the Shareholder certificates free of any and all Security Interests together with appropriate stock powers evidencing the ownership of all
capital stock of the Subsidiary issued and outstanding. 
  
 (e) Subject to the complete and full performance of the Shareholder, the PC and Mr. Graves with respect to Sections 13.2(a)(b) and (c) above, PainCare will return to Dr. Wright the Wright Pledged Interests free of any
and all Security Interests caused or imposed by PainCare. 
  
 13.3
Addition Covenants 
  
 (a)
Claims Against Merger Consideration. 
  
 1. Claims. PainCare may at any time and from time to time, until all of the Merger Consideration shall have been released hereunder as provided in this Agreement, assert one or more claims (the “Claim(s)”) against the
Merger Consideration with respect to the following: 
  
 (i) PainCare may assert Claim(s) against all or any portion of the Merger Consideration with respect to any matter giving rise to a claim for indemnification against the Company or Shareholder pursuant to Section 10 of this Agreement;
and/or any other obligation of Company or Shareholder arising from this Agreement, or any other agreement delivered in connection with this Agreement; 
  

 48 

 (ii) PainCare may assert Claim(s) up to Three Hundred Sixty Thousand and no/100 Dollars
($360,000) against the Merger Consideration with respect to any inappropriate, improper and/or illegal medical coding and/or billing undertaken by or on behalf of the Company or PC (whether same occurred prior or subsequent to the Merger Closing)
including, without limitation, improper coding patterns, up-coding, over-coding, lack of medical necessity, incident to coding, evaluation and management coding, or any other inappropriate, improper and/or illegal coding or billing (collectively
hereinafter called “Improper Billing”) if such Improper Billing results in (or could result in) the Acquiring Companies, the Company or PC incurring any costs, expenses, penalties, payments and/or refunds with respect thereto; 

 
 (iii) PainCare may assert Claim(s) up to One Million
Three Hundred Thousand and no/100 Dollars ($1,300,000) against the Merger Consideration with respect to any “Cash Deficit” (as defined hereafter) of the PC. For purposes of this Agreement, if at any time prior to the termination of this
Agreement, the PC is unable for whatever reason to pay its expenses, bills, debts and/or claims including, without limitation, the Management Fee to the Subsidiary as and when same shall be due and payable then the PC shall be deemed to have
experienced a Cash Deficit; 
  
 (iv) PainCare
may assert a Claim against all of the Merger Consideration with respect to its right to rescind this Agreement pursuant to this Section 13. 
  
 2. Making a Claim. Such Claim(s) shall be made PainCare by giving written notice of the Claim(s) to Mr. Graves and Shareholder.
Such notice shall (x) identify and describe the nature of the Claim(s) in reasonable detail; (y) identify generally the section(s) of this Agreement or the applicable agreement alleged to have been breached or the event which is alleged to have
occurred giving PainCare a right to a Claim(s); and (z) state the amount of the Claim(s), to the extent known (the “Notice of Claim(s)”). 
  
 Unless, within ten (10) business days after Mr. Graves and Shareholder shall have received the Notice of Claim(s) from PainCare, the
Shareholder shall have given written notice to PainCare, indicating that the Claim(s) described in the applicable Notice of Claim(s) is/are subject to continuing negotiations, or is/are otherwise being appropriately contested, PainCare may keep and
Mr. Graves shall, and is hereby directed to, immediately upon the expiration of such ten (10) business day period, and without further act or consent of Shareholder, deliver to or as directed by PainCare the Merger Consideration in an amount equal
to the full amount of the Claim(s) described in the Notice of Claim(s). 
  
 3. Objection. If PainCare shall have received written notice from the Shareholder within the above-referenced ten (10) business day period indicating that the Claim(s) described in the Notice of Claim(s) is/are
subject to continuing negotiations, is/are otherwise being appropriately contested, or that payment of the Claim(s) has been satisfied in cash or otherwise, then PainCare may not keep and Mr. Graves shall not deliver any of the Merger Consideration
to PainCare until PainCare shall be reasonably satisfied that the Claim(s) has/have been resolved such that all or a portion of the Merger Consideration should be released to PainCare. In making such determination, PainCare shall be entitled to rely
upon: (1) a written notice executed by the Shareholder: (A) stating that all matters in dispute as to the Claim(s) have been settled, or have been resolved, and (B) setting forth the amount of such Claim(s) that PainCare shall be entitled to
receive; (2) a copy of an order confirming any award issued by one 

  

 49 

 
or more arbitrators; or (3) a copy of a court decision and order or a judgment issued by a court of competent jurisdiction which shall not have been appealed
as permitted by applicable laws, rules and regulations confirming the basis and amount of the Claim(s). After PainCare shall have determined that such pending dispute has been resolved, any distribution of Merger Consideration made in accordance
with this Section shall be made by Mr. Graves as promptly as practicable. Any action taken by PainCare in reliance upon information obtained by it pursuant to this Section 6(c), or upon the failure of PainCare or Shareholder to deliver written
notice pursuant to this Section, shall be binding and conclusive as to any claims against PainCare by the Acquiring Companies, Company or Shareholder. 
  
 4. Release and Use of Merger Consideration. 
  
 (i) Release Pursuant to Claim(s) Under Section 13.2(a). With respect to the release of the Merger
Consideration to PainCare regarding Claim(s) made pursuant to Section 13.2(a), PainCare shall have the following rights and/or responsibilities: 
  
 (w) with respect to Claim(s) made pursuant to Section 13.2(a)(i) above, PainCare shall be entitled to use the Merger Consideration as it
deems appropriate, in its sole and absolute discretion, with the understanding that the Merger Consideration (i.e., purchase price for the Company) shall be reduced by the amount of the returned Merger Consideration; 
  
 (x) with respect to Claim(s) made pursuant to Section
13.2(a)(ii) above, PainCare shall be entitled to use the Merger Consideration to (x) pay any and all costs, expenses, penalties, payments and/or refunds that it, the Company and/or PC incurs or could incur with regard to such Improper Billing with
the understanding that the Shareholder will treat such returned Merger Consideration as if he received same and thereby not causing a reduction of the Merger Consideration (i.e., purchase price for the Company); 
  
 (y) with respect to Claim(s) made pursuant to Section
13.2(a)(iii) above, PainCare shall be entitled to use the Merger Consideration pay the PC’s expenses, bills, debts and/or claims including, without limitation, the Management Fee, with the understanding that the Shareholder will treat such
returned Merger Consideration as if he received same and thereby not causing a reduction of the Merger Consideration (i.e., purchase price for the Company); and 
  
 (z) with respect to Claim(s) made pursuant to Section 13.2(a)(iv) above, PainCare shall be entitled to use
the Merger Consideration as it deems appropriate, in its sole and absolute discretion, with the understanding that this Agreement has been rescinded and that the transaction is null and void with no further force or effect saving surviving rights as
provided this Agreement. 
  
 (ii) If by December
15, 2004, Mr. Graves and PainCare shall not have disbursed all of the Merger Consideration as provided in this Agreement either to PainCare or the Shareholder or Claim(s) are not pending as of that date, then in such event all Merger Consideration
then remaining in trust and held by PainCare in excess of the amount required to settle any outstanding and unresolved Claim(s), if any, that have been asserted by 

  

 50 

 
Acquiring Companies prior to such date shall be distributed as promptly as possible thereafter to the Shareholder, as the case may be, in conformity with the
provisions of this Agreement. 
  
 (b) The parties
covenant and agree that, except as otherwise set forth in this Agreement, until all matters with respect to the rescission are completed, the business of the Subsidiary and PC shall be conducted in the ordinary course of business and in a manner
consistent with past practice; and the parties will in good faith using their reasonable best efforts preserve intact such business organizations, to keep available the reasonable services of their present officers, employees and consultants and to
preserve the existing relationships with patients, customers, suppliers and other persons with which they have significant business relations. 
  
 (c) Subject to compliance with applicable law, the parties will (a) cooperate with one another (i) in promptly determining whether any
filings are required to be made or consents, approvals, permits or authorizations are required to be obtained under any federal, state or foreign law or regulation and (ii) in promptly making any such filings, furnishing information required in
connection therewith and seeking timely to obtain any such consents, approvals, permits or authorization and (b) provide one another with copies of all filings made by such party with any governmental authority in connection with this Agreement.

  
 [SIGNATURES APPEAR ON NEXT PAGE] 
  

 51 

 IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the date first above
written. 
  

			
	PAINCARE:
	
	PAINCARE HOLDINGS, INC., a Florida corporation
		
	By:	 	/s/    Randy Lubinsky        
	 	 	

	 Print:
	 	Randy Lubinsky
	 	 	

	 Its:
	 	CEO
	 	 	

  

			
	ACQUISITION:
	
	PAINCARE ACQUISITION COMPANY X, INC., a Florida corporation 
		
	By:	 	/s/    Randy Lubinsky        
	 	 	

	 Print:
	 	Randy Lubinsky
	 	 	

	 Its:
	 	CEO
	 	 	

  

			
	 COMPANY:

	
	 REW MERGER CORP. 

		
	 By:
	 	/s/    Robert E. Wright, M.D.        
	 	 	

	 	 	 Robert E. Wright, M.D.
 President and Secretary

  

 52 

									
	SHAREHOLDERS:	 	 	 	 
				
	/s/    Robert E. Wright, M.D.	 	 	 	 	 	/s/    Kenneth M. Alo, M.D.        
	
	 	 	 	 	 	

	 	 	Robert E. Wright, M.D.	 	 	 	 	 	Kenneth M. Alo, M.D.

  

									
	 R. E. WRIGHT, FLP
 a Nevada Limited Partnership
	 	 	 	 DELTA KMA TWO, FLP,
 a Nevada Limited Partnership

					
	By:	 	/s/    Robert W. Wright        	 	 	 	By:	 	/s/    Kenneth Mark Alo        
	 	 	
	 	 	 	 	 	

	 	 	 Robert W. Wright, Manager
 Of R.E. WRIGHT GROUP, LLC,
 as General Partner
	 	 	 	 	 	 Kenneth Mark Alo, Manager
 Of ALPHA TWO, LLC,
 as General Partner

  

									
	 WRIGHT NONGRANTOR
 TRUST (U/D/T
2004)
	 	 	 	 ALO NONGRANTOR TRUST
 a Non-Grantor’s Trust

					
	By:	 	/s/    Arthur A. Graves, III        	 	 	 	By:	 	/s/    Robert C. San Luis        
	 	 	
	 	 	 	 	 	

	 	 	 Arthur A. Graves, III, President
 First Trustee Fiduciary Services, Inc.,
 As Trustee
	 	 	 	 	 	Robert C. San Luis, as Trustee

  
 With respect to Section 13, the
undersigned agrees to be bond by the provisions set forth therein. 
  

	
	
	/s/    Arthur Graves        
	

	Arthur Graves

  

 53 

 EXHIBITS 
  

			
	 Exhibit 1
	  	Definitions
	 Exhibit 2.3
	  	Articles of Merger
	 	  	DISCLOSURE SCHEDULES
	 2.11(a)
	  	Medical Assets
	 2.11(b)
	  	Non-Medical Assets
	 2.13
	  	Shareholder Consent and Release
	 3.2(c)
	  	Shareholder Allocations
	 3.3(b)
	  	Financial Statements
	 4.1
	  	Officers and Directors
	 4.4(a)
	  	Consents to be Obtained Prior to Closing
	 4.4(b)
	  	Consents to be Obtained After Closing
	 4.5
	  	Broker’s Fees
	 4.6
	  	Assets
	 4.8
	  	Liabilities Not Shown on Financial Statements
	 4.9
	  	Subsequent Events
	 4.10
	  	Liabilities
	 4.11
	  	Tax Returns
	 4.12
	  	Real Property
	 4.15
	  	Material Contracts
	 4.16
	  	Powers of Attorney
	 4.17
	  	Insurance
	 4.18
	  	Litigation
	 4.19
	  	Third Party Payor Agreements
	 4.23
	  	Medical Staff
	 4.24
	  	Employment Matters
	 4.25
	  	Employment Benefits
	 4.26
	  	Physician Matters
	 4.27
	  	Guaranties
	 4.28
	  	Environmental Permits, Licenses and Approvals
	 4.30
	  	Third Party Payors
	 4.31
	  	Bank Accounts
	 4.37
	  	HIPAA
	 4.39
	  	Accounts Receivable
	 5.4
	  	Consents and Approvals
	 5.6(a)
	  	Capitalization
	 5.6(b)
	  	Financing proposed to be raised by PainCare in connection with the transactions contemplated by this Agreement
	 5.7
	  	Litigation
	 5.8
	  	Undisclosed Liabilities of PainCare
	 7.1(f)
	  	Permitted Indebtedness
	 10.2
	  	Indemnification
	 11.6
	  	Conduct of Business

  
  

 EXHIBIT 1 
  

DEFINITIONS 
  
 For purposes of this Agreement, the following terms shall have the meanings set forth below: 
  
 1. “Accounts Receivable” means the accounts receivable of the Company and the PC determined in accordance with GAAP with respect
to the operations of the Company prior to the Closing Date arising from the rendering of services to patients through the Closing Date, including, without limitation, those from private pay patients, private insurance payors, third party payors and
governmental programs. 
  
 1.1 “Adjustment Payment Date” has the meaning
set forth in Section 3.3(c). 
  
 1.2 “Adverse Consequences” means all
actions, suits, proceedings, hearings, investigations, complaints, claims, demands, injunctions, judgments, orders, decrees, rulings, damages, dues, penalties, fines, costs, amounts paid in settlement, Liabilities, obligations, Taxes, liens, losses,
expenses, and fees, including court costs and reasonable attorneys’ fees and expenses. 
  
 1.3 “Affiliate” shall mean, with respect to any Person: (a) any corporation, proprietorship, partnership, limited liability company, or any other business entity whatsoever that, directly or indirectly, owns
or controls, is under common ownership or control with, or is owned or controlled by, such Person; and (b) if the Person is an individual, any other individual who is related to such Person. For the purposes of this definition, the terms
“controls,” “is controlled by” and “is under common control with” shall mean the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through
the ownership of voting securities, by contract, or otherwise. Neither PainCare nor Subsidiary is an Affiliate of the Company or the Shareholder for purposes of this Agreement and neither the Shareholder nor the Company is an Affiliate of PainCare
or Subsidiary for purposes of this Agreement. 
  
 1.4 Intentionally Omitted.

  
 1.5 “Agreement” has the meaning set forth in the Preamble.

  
 1.6 “Articles of Merger” has the meaning set forth in Section 2.3.

  
 1.7 “Closing Cash” has the meaning set forth in Section 3.1.

  
 1.8 “Certificate(s)” has the meaning set forth in Section 2.10.

  
 1.9 “Closing” has the meaning set forth in Section 6. 
  
 1.10 “Closing Date” has the meaning set forth in Section 6. 
  

 2 

 1.11 “Closing Date Balance Sheet” has the meaning set forth in Section 3.3. 
  
 1.12 “Code” means the Internal Revenue Code of 1986, as amended. 
  
 1.13 “Commission” means the U.S. Securities and Exchange Commission. 
  
 1.14 “Company” has the meaning set forth in the Preamble. 
  
 1.15 “Company Shares” means any share of common stock of the Company. 

 
 1.16 “Disclosure Schedule” has the meaning set forth in Section 4. 

 
 1.17 “ Earnings Threshold” has the meaning set forth in Section 3.4. 

 
 1.18 “EBITDA” has the meaning set forth in Section 3.4. 
  
 1.19 Intentionally Omitted. 
  
 1.20 “Employee Benefit Plan” means any: (a) nonqualified deferred compensation or retirement plan or arrangement which is an
Employee Pension Benefit Plan; (b) qualified defined contribution retirement plan or arrangement which is an Employee Pension Benefit Plan; (c) qualified defined benefit retirement plan or arrangement which is an Employee Pension Benefit Plan
(including any Multiemployer Plan); (d) Employee Welfare Benefit Plan; or (e) any bonus, incentive, severance, stock option, stock purchase, short-term disability plan or other material fringe benefit plan, program or arrangement, including policies
concerning holidays, vacations and salary continuation during short absences for illness or otherwise. 
  
 1.21 “Employee Pension Benefit Plan” has the meaning set forth in ERISA Section 3(2). 
  
 1.22 “Employee Welfare Benefit Plan” has the meaning set forth in ERISA Section 3(1). 
  
 1.23 “Environmental, Health, and Safety Requirements” means the Comprehensive Environmental Response, Compensation and Liability
Act of 1980, the Resource Conservation and Recovery Act of 1976, the Clean Air Act, the Federal Water Pollution Control Act, the Safe Drinking Water Act, the Toxic Substance Control Act, the Emergency Planning and Community Right-to-Know Act of
1986, the Hazardous Material Transportation Act, and the Occupational Safety and Health Act of 1970, each as amended, together with all other laws (including rules, regulations, codes, injunctions, judgments, orders, decrees, and rulings) of
federal, state, local, and foreign governments (and all agencies thereof) concerning pollution or protection of the environment, public health and safety, or employee health and safety, including laws relating to emissions, discharges, releases, or
threatened releases of pollutants, contaminants, or chemical, industrial, hazardous, or toxic materials (including petroleum products and asbestos) or wastes into ambient air, surface water, ground water, or lands or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport, or 

  

 3 

 
handling of pollutants, contaminants, or chemical, industrial, hazardous, or toxic materials or wastes. 
  
 1.24 “ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

  
 1.25 “Fair Market Value” has the meaning set forth in Section 3.4.

  
 1.26 “Fiduciary” has the meaning set forth in ERISA Section 3(21).

  
 1.27 “Financial Statements” has the meaning set forth in Section
4.8. 
  
 1.28 “Florida Act” and “Colorado Act” have the
meanings set forth in Section 2.1. 
  
 1.29 “Formula Period” has the
meaning set forth in Section 3.4. 
  
 1.30 “Formula Period Profits
Statement” has the meaning set forth in Section 3.4. 
  
 1.31
“GAAP” means the United States generally accepted accounting principles in effect from time to time. 
  
 1.32 “HIPAA” has the meaning set forth in Section 4.37. 
  
 1.33 “Indemnified Party” has the meaning set forth in Section 10.4. 
  
 1.34 “Indemnifying Party” has the meaning set forth in Section 10.4. 
  
 1.35 “Intended Installment Payment” has the meaning set forth in Section 3.4. 
  
 1.36 “Installment Payment” has the meaning set forth in Section 3.4. 
  
 1.37 “Installment Payment Discount” has the meaning set forth in Section 3.4. 
  
 1.38 “Installment Payment Premium” has the meaning set forth in Section 3.4. 
  
 1.39 “Intellectual Property” means: (a) all trade secrets and confidential business
information (including customer and supplier lists, ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, pricing and cost
information, and business and marketing plans and proposals); (b) all trademarks, service marks, trade dress, logos, trade names, and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including
all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith; (c) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents,
patent applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof; (d) all copyrightable works, all copyrights, and all applications, registrations,
and renewals in connection therewith; (e) all computer software (including data and related documentation); (f) all other proprietary 

  

 4 

 
rights; and (g) all copies and tangible embodiments thereof (in whatever form or medium). 
  
 1.40 “IRS” means the U.S. Internal Revenue Service. 
  
 1.41 “Knowledge” An individual will be deemed to have “Knowledge of a particular fact or other matter if: 
  
 (a) such individual is actually aware of such fact or other matter; or

  
 (b) a prudent individual could be expected to discover or
otherwise become aware of such fact or other matter in the course of conducting a reasonably comprehensive investigation concerning the existence of such fact or other matter. 
  
 A Person (other than an individual) will be deemed to have “Knowledge” of a particular fact or other matter if the
Shareholder or any individual who is a serving, or who has at any time served, as a director, officer, partner, executor, or trustee of such Person (or in any similar capacity) has, or at any time had, Knowledge of such fact or other matter.

  
 1.42 “Liability” means any liability, whether known or unknown,
whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due, including, but not in any way limited to, any liability for Taxes. 
  
 1.43 “Management Agreement” means that certain Management Services Agreement by and
among PainCare Acquisition Company X, Inc., the PC and Drs. Wright and Alo, dated as of the Statutory Merger Time. 
  
 1.44 “Medical and Non-Medical Assets” have the meanings set forth in Section 2.11. 
  
 1.45 “Medical Waste” has the meaning set forth in Section 4.40 
  
 1.46 “Merger” has the meaning set forth in Section 2.1. 
  
 1.47 “Most Recent Year End” has the meaning set forth in Section 4.9. 
  
 1.48 “Multiemployer Plan” has the meaning set forth in ERISA Section 3(37).

  
 1.49 “NASDAQ” has the meaning set forth in Section 3.4. 

 
 1.50 “PC” has the meaning set forth in Paragraph D of the Recitals. 

 
 1.51 “Other Net Equity Adjustment” has the meaning set forth in Section 3.3.

  
 1.52 “PainCare” has the meaning set forth in the Preamble.

  

 5 

 1.53 “PainCare Shares” means any share of common stock, $.0001 par value per share, of PainCare. 
  
 1.54 “Party(ies)” has the meaning set forth in the Preamble. 
  
 1.55 “PBGC” means the Pension Benefit Guaranty Corporation or any entity succeeding
to any or all of its functions under ERISA. 
  
 1.56 “Person” means an
individual, a partnership, a corporation, an association, a joint stock company, a limited liability company or partnership, a trust, a joint venture, an unincorporated organization, any other form of entity whatsoever, or a governmental entity (or
any department, agency, or political subdivision thereof). 
  
 1.57
“Prohibited Transaction” has the meaning set forth in ERISA Section 406 and Code Section 4975. 
  
 1.58 “Reportable Event” has the meaning set forth in ERISA Section 4043. 
  
 1.59 “Securities Act” means the Securities Act of 1933, as amended. 
  
 1.60 “Securities Exchange Act” means the Securities Exchange Act of 1934, as amended. 
  
 1.61 “Security Interest” means any lien, claim, encumbrance, mortgage, hypothecation, pledge, or other security interest,
excluding purchase money security interests arising in the ordinary course of business and liens arising by operation of law for Taxes not yet due and payable. 
  

1.62 “Shareholder” has the meaning set forth in the recitals, and shall further include any individual who acquires shares of the Company stock, PC stock, or
the PainCare Shares, pursuant to the terms of this Agreement. 
  
 1.63
“Subsidiary” has the meaning set forth in the Preamble. 
  
 1.64
“Surviving Corporation” has the meaning set forth in Section 2.1. 
  
 1.65 “Tax” or “Taxes” means any federal, state, local, or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental (including taxes
under Code Section 59A), customs duties, capital stock, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, production, transfer, registration, value added,
alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including interest, penalty, or additions thereto, whether disputed or not, and whether or not accrued on the Financial Statements. 
  
 1.66 “Tax Return” means any return, declaration, report, claim for refund, or
information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof. 
  

 6 

 1.67 “Third Party Claim” has the meaning set forth in Section 10.4. 
  
 1.68 “Trade Secrets” has the meaning set forth in Section 11.5. 
  
 1.69 “Transaction” has the meaning set forth in Section 2.1. 
  
 1.70 “Transaction Consideration” has the meaning set forth in Section 3.1.

  

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]